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Summary
Traumatic brain injury (TBI) remains a significant cause of morbidity and 
mortality, and is one of the commonest causes of disability in young people. 
Increasingly evidence is emerging to suggest that TBI results in long-term 
neurodegeneration and is a risk factor for the subsequent development of Alzheimer’s 
disease (AD) in later life. The mechanisms underlying the association between head 
injury and AD are unknown, although the response to TBI and the pathology of AD 
have some features in common not only in terms of a cellular and protein response but 
also striking parallels in the genetic influences.
Statement of aims: This studied aimed to assess the potential contribution of 
cytoskeletal pathology and neuroinflammation to long-term outcome after head 
injury, and influence of genetic factors in determining outcome.
Methodology: Archived human brain tissue was used for this study. Both 
cytoskeletal pathology and neuroinflammation were assessed by 
immunohistochemistry. Cytoskeletal pathology was assessed semi-quantitatively 
while neuroinflammation was assessed using image analysis. Genotyping of cases 
used a PCR based technique. Standard statistical methods were used to assess the 
data.
Neurofibrillary tangles were not seen in acute fatal TBI cases but they may be 
an important feature o f neurodegeneration in long-term survivors. Cytoskeletal 
neurodegenerative pathology has been demonstrated after repetitive mild head injury 
in humans and a single head injury in animals, and is a major component of the 
neurodegenerative pathology associated with AD. This study assessed tow-associated
cytoskeletal pathology in individuals dying after a single episode of TBI. Subtle 
alterations in tau immunoreactivity, for example in oligodendrocytes, were present in 
some head injury cases but not controls. However, neurofibrillary tangles did not 
appear more prevalent after TBI when compared with age-matched controls.
Although alterations in tau immunoreactivity may occur which warrant further study, 
neurofibrillary tangles were not more prevalent after a single fatal episode of TBI.
Possession o f APOE s4 was associated with more severe vascular related 
pathology after fatal TBI (contusions, global cerebral ischaemia) and this may be 
relevant to the relatively poor outcome from TBI in patients with APOE s4 identified 
in clinical studies. APOE has genetic polymorphisms which may increase 
susceptibility to AD. Possession o f APOE s4 has been shown to increase 
susceptibility to AD. In addition possession of APOE e4 is associated with a worse 
outcome after TBI. This study demonstrated that possession of APOE e4 is associated 
with the greatest incidence of moderate/severe contusional injury and severe 
ischaemic brain damage in fatal cases of TBI.
There does appear to be an increased neuroinflammatory response after TBI 
particularly in cases with diffuse traumatic axonal injury. This increased 
neuroinflammatory response may be associated with greater neurotoxicity. 
Neuroinflammation has been implicated as a potential cause of neurodegeneration 
both in AD and in the response to brain injury. There have been few studies looking at 
the neuroinflammatory response after acute head injury or in long-term survivors.
Possession o f IL-1 A allele 2 is not associated with a greater 
neuroinflammatory response. Interleukin-1 (IL-1) is the main controller of 
neuroinflammation and homozygosity for IL-1 A allele 2 has been shown to increase
xii
susceptibility to AD. This study has demonstrated no association between possession 
of IL-1 A allele 2, either heterozygosity or homozygosity, and an increased 
inflammatory response (identified by expression of MHC class II molecules) after 
TBI. However, the neuroinflammatory response is most pronounced in cases with 
diffuse white matter damage (diffuse traumatic axonal injury).
Conclusion: This study has demonstrated that possession of APOE s4 is 
associated with the greatest incidence of moderate/severe contusional injury and 
severe ischaemic brain damage in fatal cases of TBI and that this may account for the 
over-representation of APOE e4 in severe outcome after head injury. With regard to 
neurodegeneration after head injury there is increased neuroinflammation, particularly 
in cases with diffuse TAI, but this did not appear to be modified by genetic influences 
although the number of cases studied was small. Cytoskeletal pathology was limited 
to subtle glial alterations although the study only looked at a survival of less than 12 
months.
1 Introduction
1.1 The mechanisms of traumatic brain injury and its significance in society
1.1.1 Incidence of traumatic brain injury
Traumatic brain injury remains a significant cause of morbidity and mortality 
throughout the world. In the United Kingdom more than 150 000 patients are admitted 
to hospital each year with a head injury. Of this group more than 80% are classified as 
having a mild head injury, as defined by the Glasgow Coma Scale (GCS). The GCS 
(Teasdale and Jennett 1974, Teasdale and Jennett 1976) provides a means of 
quantifying the level of consciousness after traumatic brain injury based on the 
clinical features of verbal performance, eye opening and motor response. Using this 
scale three levels of severity of head injury are defined; mild (score 13-15), moderate 
(score 9-12), and severe (score 3-8).
1.1.2 Outcome after traumatic brain injury
Approximately 1-2% of patients admitted to hospital after traumatic brain 
injury die as a consequence of their injuries. The majority of fatalities are within the 
severe head injury group, with 40% of the cases resulting in death at 6 months 
(Murray et al 1999). The outcome is modified by the type and severity of injury and 
may be influenced by the pre-morbid state such as age, nutritional status and pre­
existing disease (Vollmer 1993).
Among survivors of traumatic brain injury of all grades chronic disability may 
have a physical component although it is predominantly the cognitive and behavioural 
problems which provide the greatest challenge (Jennett et al 1981). Outcome may be 
assessed by the Glasgow Outcome Scale (GOS) (Jennett and Bond 1975) which 
defines four outcome states; death/ vegetative state, severe disability, moderate 
disability, and good recovery. The GOS is based predominantly on assessment of
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social re-integration after traumatic brain injury involving a structured questionaire- 
based interview. This has recently been modified as the extended GOS (Teasdale et 
al 1998). Predictors of neurobehavioural outcome in adults include age (greater than 
50 years is a poor prognostic factor), the acute GCS, abnormal brain stem reflexes, 
subacute ventricular enlargement, neurological deficit, and the duration of post- 
traumatic amnesia (Capruso and Levin 2000).
Recent studies have indicated that the incidence of moderate and severe 
disability in young people and adults one year after mild head injury is similar to that 
seen in survivors of moderate and severe head injury (Thornhill et al 2000). In 
addition there is evidence (discussed below) that traumatic brain injury may be 
associated with continuing cognitive decline in later years and with an increased 
incidence of Alzheimer’s disease (AD). The mechanisms underlying the association 
between head injury and AD are unknown, although, as shall be discussed, the 
response to traumatic brain injury and the pathology of AD have some features in 
common not only in terms of a cellular and protein response but also striking parallels 
in the genetic influences.
1.1.3 The pathology of traumatic brain injury
In order to attempt to clarify the mechanisms underlying post-traumatic 
cognitive deficit a basic understanding of the pathology of traumatic brain injury is 
helpful.
Blunt force head injury results in both focal and diffuse pathologies involving 
the skull and the underlying brain and its coverings. Focal lesions can take the form of 
skull fractures, cerebral contusions, focal ischaemic lesions secondary to raised 
intracranial pressure, and intracranial haematomas. Diffuse lesions may take the form 
«of cerebral ischaemia or cerebral swelling, or may develop as a consequence of
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rotational forces (diffuse traumatic axonal injury and diffuse vascular injury) (Graham 
et al 1995a). The primary injury is related to mechanical damage, and can be focal or 
diffuse, or a combination of both. It is related to the effects of both the impact and 
inertial forces on the skull and brain. Delayed secondary events such as diffuse 
traumatic axonal injury and cerebral ischaemia develop over a period of hours or days 
after the traumatic episode. The secondary events may be related to neurochemical 
alterations and the associated cellular and molecular alterations induced by trauma 
(Graham et al 2000).
1.2 The effects of head injury on cognitive function
1.2.1 Concussion and vegetative state
Concussion refers to an immediate, usually reversible episode of brain 
dysfunction after traumatic brain injury. A clinical spectrum is recognised ranging 
from mild concussion, in which consciousness is often preserved, to severe diffuse 
axonal injury resulting in the vegetative state (Gennarelli 1993). The anatomical basis 
of concussion syndromes is currently considered to be diffuse traumatic axonal 
pathology and, in particular, axonal disruption resulting in disconnection between 
areas involved in consciousness; cerebral cortex, brainstem reticular activating areas, 
thalamus and hypothalamus (Gennarelli 1993). The vegetative state refers to a group 
of patients who have loss of meaningful cognitive function and awareness, but retain 
spontaneous breathing and periods of wakefulness. The neuropathological basis of the 
vegetative state has been explored in a study that examined 49 patients in the 
vegetative state, 35 o f whom had experienced traumatic brain injury (Adams et al
2000). In the trauma-related cases diffuse traumatic axonal injury of grade 2 or 3 was 
found in 71% of cases, and thalamic pathology in 80% of cases. In cases with minimal 
brainstem and cerebral cortical pathology, thalamic pathology was always present.
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Therefore, damage to the thalamic nuclei and/or the afferent and efferent white matter 
pathways of the thalamus appear to play a major role in the genesis of the vegetative 
state after head injury. White matter (Wallerian) degeneration is a consequence of 
severe diffuse traumatic axonal injury. The axonal loss results in gliosis and 
macrophage activation, which may be under genetic control as discussed later. In 
contrast, the structural basis of moderate disability after traumatic brain injury is more 
likely to be a focal lesion rather than diffuse brain pathology, usually an evacuated 
intracranial haematoma (Adams et al 2001). In a study of 30 severely disabled 
patients 50% had focal brain pathology only. Some severely disabled patients did 
show diffuse brain pathology similar to vegetative state patients, and it may be that 
there is a greater quantitative amount of damage in the vegetative cases (Jennett et al
2001). In assessment of the pathology of moderate and severe disability case selection 
may be important. It must be remembered that autopsy based studies may not be a 
true reflection of the clinical spectrum associated with both moderate and severe 
disability.
1.2.2 Long term outcome from head injury and chronic neurodegeneration
1.2.2.1 Clinical studies
Mild head injury (acute GCS 13-15) is associated with a higher than expected 
incidence of disability (GOS moderate or severe disability) at one year post injury 
(Thornhill et al 2000). Of major interest in the context of this discussion are the 
longer term effects on cognition many years after the injury, and the possible 
relationship between traumatic brain injury and AD.
There is a considerable epidemiological literature examining the relationship 
between traumatic brain injury and the development of AD in later life. Many of these 
take the form of retrospective case-control studies and are therefore subject to recall
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bias. A number have also reported an association between traumatic brain injury and 
AD (French et al 1985, Graves et al 1990, van Duijn et al 1992, Mayeux et al 1993, 
Rasmussen et al 1995, Salib et al 1997, O’Meara et al 1997, Nemetz et al 1999, Guo 
et al 2000) although some do not reach statistical significance (Chandra et al 1987, 
Amaducci et al 1986). In particular, the study by Mayeux et al in 1993 reported an 
almost 4x increased risk of developing AD after traumatic brain injury when 
compared to age matched controls. Guo et al (2000) studied 2233 individuals who 
met the criteria for probable or definite AD, and compared them with 14668 controls 
(first-degree relatives or spouses) as part of the MIRAGE (Multi-Institutional 
Research in Alzheimer Genetic Epidemiology) project. They reported that traumatic 
brain injury was a risk factor for AD and that the risk was proportional to the severity 
of the injury. For example, comparison of probands with unaffected spouses yielded 
odds ratios for AD of 9.9 for head injury with loss of consciousness and 3.1 for head 
injury without loss of consciousness. Comparison of probands with their parents and 
sibs were 4.0 for head injury with loss of consciousness and 2.0 for head injury 
without loss of consciousness. At age 93 years the lifetime risk of developing AD was 
77.2% for those with and 40.1% for those without a history of head injury. Other 
retrospective case-control studies, however, have not confirmed that there is an 
association between traumatic brain injury and AD (Broe et al 1990, Ferini-Strambi et 
al 1990, Li et al 1992, Mendez et al 1992, Fatiglioni et al 1993).
To try and address the problems of recall bias inherent in case-control studies 
a number of prospective studies have been designed. Again, however, there is 
conflicting data. Corkin et al (1989) performed neuropsychological assessment of 57 
World War 2 veterans with a penetrating head injury at two time points 30 years 
apart, and compared their performance with 27 veterans who experienced a peripheral
5
nerve injury only and who were assessed over the same 30 year period. They found 
that a penetrating head injury exacerbated the decline in cognitive performance over 
time when compared with the peripheral injury group. Schofield et al (1997) reported 
a community based longitudinal study of ageing in north Manhattan. 271 participants 
without significant cognitive impairment at the time of enrolment were interviewed in 
relation to previous head injury and associated loss of consciousness. Patients were 
then followed-up for 5 years with annual evaluations. They reported that previous 
traumatic brain injury was a 3x risk factor for AD. Plassman et al (2000) examined 
1776 World War 2 navy and marine veterans, with military medical records. 548 had 
a history of non-penetrating traumatic brain injury, 1228 did not. All individuals were 
assessed for AD. They found in this group that moderate head injury (Frankowski 
scale, Frankowski et al 1985) resulted in 2.3 x increased risk of AD while severe head 
injury resulted in a 4 x increased risk. Against this data, however, there are a number 
of prospective studies which have failed to demonstrate an association between 
traumatic brain injury and AD (Katzman et al 1989, Aronson et al 1990, Williams et 
al 1991, Breteler et al 1995). Launer et al (1999), as part of the European Studies of 
Dementia (EURODEM), analysed four European population-based prospective 
studies, with individuals aged 65 years or older at time of recruitment. This large 
study did not find an association between traumatic brain injury and AD. Mehta et al 
(1999) reported the prospective population-based Rotterdam study, which looked at 
6645 individuals aged 55 years or older and who did not have dementia when 
recruited. This study found that mild traumatic brain injury was not associated with an 
increased risk of AD, although the follow-up period was short being on average 2.1 
years after initial assessment.
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Meta-analysis has been used to review case-control studies. Mortimer et al 
(1991) studied 7 case-control studies and reported a relative risk of developing AD of 
1.82 for head injury with loss of consciousness. The relative risk, however, only 
reached significance for males. Fleminger et al (2003) studied 15 case-control studies 
and showed an odds-ratio (OR) of 1.58. Again, however, this study showed that the 
association between head injury and AD was only significant for males (males OR 
2.26, females OR 0.92).
There are many difficulties in assessing the relationship between traumatic 
brain injury and AD as the conflicting results presented above clearly illustrate. 
Retrospective case-control studies have both recall and selection bias. The prospective 
studies have a lesser degree of recall bias and do not rely on the recollections of 
cognitively impaired individuals. However, some of the prospective studies have only 
a short follow up period, 5 years in many cases, and this may bias the outcome. 
Comparisons between studies are difficult due to differences in definitions of severity 
of brain injury, post injury outcome status, and clinical definitions of AD. Also the 
age at the time of the injury and the age at the time of assessment are likely to be 
important variables.
1.2.2.2 Boxers and dementia pugilistica
While the data relating to long term associations between traumatic brain 
injury and AD is currently conflicting, the association between mild repetitive head 
injury and cognitive impairment has been established in the literature for many years. 
The “punch drunk” state was first described by Martland in 1928 and was renamed 
dementia pugilistica by Millspaugh in 1937. Dementia pugilistica has been 
extensively reviewed (Bruton 1997) and a summarised account will be presented here. 
This condition is described in boxers who have competed in many bouts over a long
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period of time. Clinically, they develop a degree of intellectual deterioration often 
with an associated movement disorder, usually parkinsonism but in some cases 
predominantly ataxia. The largest study of this disorder clinically (Roberts 1969) 
examined 224 ex-boxers using neurological examination, electroencephalogram, and 
simple psychometric testing. He found that 17% had varying degrees of movement 
disorder involving the cerebellar, pyramidal and extrapyramidal systems. Minor 
degrees of intellectual dysfunction were seen in several of the ex-boxers, although 
only two required long term care as a result of their cognitive impairment. Roberts 
(1969) concluded that the occurrence of encephalopathy increased significantly with 
the number of bouts and the length of the boxer’s career. He also concluded, however, 
that the rate of cognitive decline was not greater than that associated with ageing 
alone. More recent studies (Casson et al 1984, McLatchie et al 1987, Brooks et al 
1987, Murelius and Haglund 1991, Heilbronner et al 1991) suggest that full blown 
dementia pugilistica is now rarely seen, although mild cognitive and movement 
disorders are still associated with boxing.
While dementia pugilistica was initially described in relation to boxing, cases 
have been described in National Hunt jockeys (Foster et al 1976). In addition, there is 
a considerable literature relating to the risks of repetitive mild traumatic head injury 
and other sports such as soccer (Matser et al 1999, Kirkendall et al 2001), rugby 
union and Australian rules football (McIntosh et al 2000), American football (Maroon 
et al 2000), and ice hockey (Biasca et al 1993). In the absence of large prospective 
studies the risk of cognitive impairment and movement disorders secondary to 
repetitive mild traumatic brain injury in relation to these contact sports, remains 
uncertain.
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The largest pathological assessment of dementia pugilistica was the 
examination of the brains of 15 boxers, 11 of whom were diagnosed with dementia 
pugilistica in life (Corsellis et al 1973). This followed on from previous case reports 
(Brandenburg and Hallervorden 1954, Grahmann and Ule 1957, Constantinidis and 
Tissot 1967) and the descriptions by Mawdsley and Ferguson (1963,1965) of the 
brains of four ex-boxers. Corsellis et al (1973) reported four principal features of the 
brain in dementia pugilistica ;
(1) abnormalities of the septum pellucidum, (2) cerebellar damage, (3) degeneration 
of the substantia nigra, and (4) cerebral cortex pathology.
(1) A fenestrated cavum septum pellucidum was seen in 77% of ex-boxers but 
in only 3% of non-boxers. One third of the non-boxers who had a fenestrated cavum 
septum pellucidum had evidence of a previous head injury. The degree of separation 
of the two leaflets of the septum pellucidum may be related to repetitive injury being 
most pronounced in the ex-boxers.
(2) Ataxia may be a feature of dementia pugilistica. Corsellis et al (1973) 
described cortical scarring of the inferior aspects of the lateral cerebellar hemispheres 
adjacent to the tonsils in 10 of the 15 ex-boxers brains studied. Histologically there 
was gliosis and loss of both Purkinje cells and granule cells.
(3) Parkinsonism is a common feature of dementia pugilistica and pathology 
of the substantia nigra appears to be the underlying cause. Pigmented cell loss is often 
marked, both within the substantia nigra and the locus coeruleus, and neurofibrillary 
tangles can be seen in some of the remaining neurons. Lewy bodies are not a feature 
(Corsellis et al 1973).
(4) Gross cortical pathology, a common feature of acute traumatic brain injury 
in the form of contusions, does not appear to be a significant feature of dementia
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pugilistica (Corsellis et al 1973, Adams and Bruton 1989). However, diffuse 
microscopic cortical pathology is a feature of dementia pugilistica (see below).
1.3 Pathological mechanisms which may underlie long term neurodegeneration 
after head injury
Over-representation of late cognitive decline in survivors of traumatic brain 
injury may simply reflect the additive effects of the acute damage and later age- 
related functional compromise. From this viewpoint the acute injury acts to decrease 
the “functional reserve” of the brain and subsequent age-related neurodegeneration is 
more likely at an earlier age to result in a breach of the threshold of impairment 
required to manifest as dementia. However, there are remarkable parallels in the 
pathological processes involved both in the response to traumatic brain injury and AD 
(see below). It is possible that a component of the acute response to traumatic brain 
injury acts as a “trigger” to initiate a positive feedback loop that smoulders away to 
become manifest in later years as frank neurodegenerative pathology and dementia 
(Nicoll et al 1995, Griffin et al 1998) (figure 1).
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Figure 1; A graphical representation o f a postulated cognitive reserve and how head 
injury may increase the risk o f cognitive decline. The broken green line [1] represents 
the “normal’1 situation. There is loss o f cognitive function with ageing until a 
threshold point is crossed (broken red line) resulting clinically in dementia. After an 
episode o f traumatic brain injury there is a significant decline in cognitive function 
which recovers, the degree o f recovery being dependent on the severity o f the head 
injury. Recovery is, however, not complete resulting in a loss o f functional reserve. 
After this point cognitive decline may be as for normal ageing (broken blue line [2]) 
with the dementia threshold being crossed earlier due to loss o f functional reserve, or 
there may a continued synergistic effect o f mechanisms initiated by the head injury 
which accelerates cognitive decline (broken purple line [3]).
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Detailed classical neuropathological descriptions of cohorts of long-term 
survivors of traumatic brain injury including immunohistochemical studies are 
lacking. However, some of the processes that are believed to be involved in chronic 
neurodegeneration, including AD, have been explored in the context of both acute 
injury and long term survival after trauma.
1.3.1 Cytoskeletal neurodegenerative pathology
Tau is a microtubule -associated protein (MAP) which is found predominantly 
in axons of the nervous system. Microtubules have a range of important functions 
required for normal neuronal function, including maintenance of cell structure and 
transport of vesicles along axons. MAPs are required for the normal functioning of 
microtubules. Six isoforms of the protein exist in humans, the isoforms being 
produced by alternative splicing of the gene. In neurodegenerative conditions in 
which tau is implicated (tauopathies) the protein is abnormally phosphorylated 
(hyperphosphorylation) resulting in accumulation of the abnormal protein within the 
neuronal cell body (neurofibrillary tangles) and processes (neuropil threads).
Cytoskeletal pathology after diffuse traumatic brain injury has been examined 
experimentally using a pig model with injury induced via controlled head rotational 
acceleration (Smith et al 1999). Head-injured pigs were examined at days 1, 3, 7 and 
10 post-injury, and compared to control animals without head injury. Within the 
experimental group tau and neurofilament accumulations were identified 
immunohistochemically within the white matter, co-localised with damaged axons 
(Ap-PP immunoreactive), and within neuronal perikarya in the cerebral cortex. Smith 
et al (2003) demonstrated neurofilament and Ap accumulations within the white 
matter of patients dying after a single episode of TBI. To date neuronal perikaryal 
inclusions have not been demonstrated in humans after a single episode of traumatic
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brain injury although cleaved forms of tau protein are markedly elevated in the CSF 
of brain-injured patients (Zemlan et al 1999). However, in cases of repetitive head 
injury cytoskeletal pathology is observed. Neurofibrillary tangles were reported in ex­
boxers by Corsellis et al (1973) scattered throughout the cerebral cortex and the 
brainstem, being most prominent in the medial temporal cortex. Recently, Geddes et 
al (1999) examined the brains of four young individuals (age range from 23-28 years) 
with a history of repetitive head injury (two boxers, one footballer, and one mentally 
subnormal patient with a history of self inflicted head banging) and a frontal 
lobectomy specimen from an individual with intractable complex partial seizures with 
recurrent minor head injury. They identified widespread neocortical neurofibrillary 
tangles and neuropil threads not seen in age matched controls which in areas showed a 
perivascular distribution. Schmidt et al (2001) have compared the molecular profiles 
of the neurofibrillary tangles in dementia pugilistica and AD. They found that 
dementia pugilistica and AD had a common tau isoform and phosphorylation profile. 
They concluded that the mechanisms underlying both these conditions might be 
similar.
1.3.2 Amyloid deposition
Diffuse (3-amyloid protein (AP) plaques have been identified in approximately 
30% of individuals who die shortly after a single episode of severe traumatic brain 
injury (Roberts et al 1991, Roberts et al 1994, Graham et al 1995). This is a higher 
proportion than in non-head injury controls. Another group (Adle-Biassette et al 
1996), however, has not confirmed this observation. Most of the deposits consist of 
Ap42 (Gentleman et al 1997, Horsburgh et al 2000a), which is believed to be of 
pathological significance in AD. Smith et al (2003) have demonstrated Ap 
accumulation within damaged axons in human brains after a single episode of fatal
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TBI. They postulate that damaged axons can act as a reservoir of Ap which may then 
be involved in plaque formation.
The distribution of the plaques does not correlate with focal traumatic lesions 
such as contusions but may be an expression of a diffuse acute phase response (e.g. 
hypoxia, acidosis, oedema, reduced cerebral blood flow) (Graham et al 1995b). For 
example, the Ap deposits may be the result of increased production or altered 
distribution of Ap-PP, increased cleavage of Ap-PP in a proteolytic environment to 
produce Ap, an alteration in the balance of production of Ap4o:Ap4 2 , extracellular 
conditions which favour the precipitation of amyloid fibrils, or decreased removal or 
drainage of Ap. Tracer studies in experimental animals and observations on human 
brains suggest that Ap is removed from the brain by passing along the peri-arterial 
interstitial fluid drainage pathways (Weller and Nicoll 2003).
In the study by Corsellis et al (1973) neurofibrillary tangles were found in the 
almost complete absence of senile plaques when examined using silver 
(Bielschowsky) and Congo red stains. However, when this was re-examined using 
immunohistochemistry with formic acid pre-treatment for Ap, extensive 
immunoreactive plaque-like structures were seen in most cases of dementia 
pugilistica (Roberts et al 1990) although the neuritic plaques characteristic of AD 
were absent. In the study by Geddes et al (1999) of repetitive mild head injury Ap 
plaques were not seen despite using both a modified Bielschowsky silver stain and Ap 
immunohistochemistry with formic acid pre-treatment. They concluded that 
neurofibrillary tangle formation in the absence of Ap deposition is an early 
consequence of repetitive head injury and that, because of their striking perivascular 
distribution, neurofibrillary tangle formation may be related to damage to blood 
vessels.
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The relationship between Ap deposition and genetic polymorphisms is 
discussed in a later section.
1.3.3 Neuronal Loss
Neuronal loss after traumatic brain injury has been reported in the neocortex, 
the hippocampus, the cerebellum and the thalamus (Adams et al 1985, Kotapka et al 
1992, Ross et al 1993). In the acute phase, neuronal loss is related to contusions or as 
a consequence of cerebral ischaemia, and bilateral hippocampal neuronal loss has 
been documented in 85% of cases in one study (Adams et al 1985). The mechanisms 
of cell death have been extensively studied and the processes of necrosis and 
programmed cell death have been considered to be separate mechanisms, although 
this view is being increasingly challenged and shared molecular pathways have been 
identified in both processes. The role of programmed cell death after traumatic brain 
injury has been reviewed by Raghupathi et al (2000) and Royo et al (2003). Cell 
death has been identified in situ after traumatic brain injury in both animal models and 
in human material using the terminal deoxynucleotidyl transferase mediated dUTP 
nick end-labelling (TUNEL) technique (Rink et al 1995, Smith et al 1997). This 
technique identifies DNA fragmentation, a feature common to both necrosis and 
programmed cell death. Differentiation between necrosis and programmed cell death 
is possible by assessing other mechanisms seen in programmed cell death such as 
caspase activation, and identification of the morphological expression of programmed 
cell death, apoptosis. TUNEL positive neurons and oligodendroglial cells have been 
reported in human traumatic brain injury; Clark et al (1999) demonstrated elevated 
levels of bcl-2 and caspase 3, increased cleavage of both caspases 1 and 3, and cells 
with the morphological appearances of apoptosis in 8 patients who had contusions 
removed surgically between 1-9 days after an episode of traumatic brain injury. Smith
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et al (2000) and Shaw et al (2001) studied a number of brain areas in human post­
mortem tissue of 18 patients who survived between 6 hours and 10 days after 
traumatic brain injury. TUNEL-positive cells were seen in both grey and white matter, 
peaking between 25 and 48 hours although still identifiable at 10 days post injury. 
There was a mixture of both apoptotic and necrotic morphology in neurons, although 
white matter TUNEL-positive cells more consistently showed an apoptotic 
morphology. They concluded that in human frontal lobe contusions both apoptosis 
and necrosis contributed to post-traumatic pathology, and that multiple cell types, 
including neurons, were involved.
Recent experimental studies suggest that the cellular pathology initiated by an 
episode of acute traumatic brain injury may indeed be progressive. Rats subjected to 
severe lateral fluid-percussion brain injury were studied for up to 12 months and 
showed long term cognitive and neurological motor dysfunction (Pierce et al 1998). 
Bramlett et al (1997) and Smith et al (1997) demonstrated cell loss from neocortex, 
thalamus and hippocampus with associated gliosis and ventriculomegaly in rats after 
fluid-percussion induced injury. Bramlett et al (1997) demonstrated tissue loss up to 8 
weeks while Smith et al (1997) demonstrted continuing tissue loss up to 12 months. 
Recent studies in human cases have demonstrated TUNEL-positive cells up to 12 
months after traumatic brain injury (Williams et al 2001). The majority of the cells 
were present in the white matter and were considered to be closely associated with 
Wallerian degeneration. Long-term DNA fragmentation therefore appears to be a 
feature of traumatic brain injury in man.
1.3.4 Cholinergic brain pathways
The nucleus basalis of Meynert within the basal forebrain provides cholinergic 
innervation of the cerebral cortex and the hippocampus, and damage to this pathway
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can result in attention, memory and emotional dysfunction (Everitt and Robbins 
1997). Abnormalities within the cholinergic projection system have been postulated to 
contribute both to the altered mental state in AD (Geula and Mesulam 1994) and to 
the neurobehavioural sequelae which persist after a head injury (Cardenas et al 1994).
In rats there is a reduction in the number of choline acetyltransferase [ChAT] 
positive neurons after experimentally-induced traumatic brain injury (Schmidt and 
Grady 1995), and alterations of cholinergic innervation of the cerebral cortex and 
hippocampus have been detected (Dixon et al 1995, Dixon et al 1997).
Patients who die acutely as a consequence of traumatic brain injury have 
reduced levels of cortical ChAT when compared to age-matched controls (Dewar and 
Graham 1996, Murdoch et al 1998). Recently, neuronal damage has been 
demonstrated within the nucleus basalis of Meynert in eight of twelve fatally head 
injured patients, with a median survival time of 27 hours (Murdoch et al 2002). 
Neuronal damage was a result of both mechanical distortion (tissue herniation) and 
focal ischaemia. The authors concluded that damage to cholinergic neurons may 
contribute to the dysfunction of memory and cognition in survivors of traumatic brain 
injury, although studies of the nucleus basalis of Meynert in long-term survivors has 
not been undertaken.
1.3.5 Neuroinflammation
Recent studies have focussed attention on “neuroinflammation” as a potential 
underlying mechanism both in AD and in the response to brain injury (Engel et al 
2000, Nicoll et al 2000, Griffin et al 1998). The principal mediator of inflammatory 
processes in the CNS is the microglial cell. Microglia have a variety of functions 
including antigen presentation, synthesis and secretion of cytokines and phagocytosis. 
These cells are a source of several of the proteins upregulated both in AD and after
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traumatic brain injury, including apolipoprotein E, and pro-inflammatory cytokines 
such as interleukin 1 (IL-1), This raises the question that patients who sustain a head 
injury may have a microglial response which plays a role both in influencing their 
outcome following injury and their increased susceptibility to AD later in life.
1.3.5.1 Morphological changes associated with microglial activation
Microglia form an extensive network throughout the brain and spinal cord 
“sensing” the microenvironment, with each cell providing surveillance of a non­
overlapping field. When stimulated they pass through several stages which can be 
distinguished morphologically. In the adult CNS microglia are in a functionally 
quiescent state, and morphologically are ramified. When activated the microglia 
hypertrophy and express several cell surface markers, including the MHC class II 
antigen (Streit et al 1989). The monoclonal antibody CR3/43 is directed against the p- 
chain of the MHC class II antigen and can be used to detect activated microglia 
(Graeber et al 1994). After this phase the microglia may become phagocytic, 
transforming into intrinsic brain macrophages (Streit and Kreutzberg 1988). The 
monoclonal antibody PG-M1 is directed against CD 68, a transmembrane 
glycoprotein involved in lysosomal transport, although the precise function of this 
protein remains uncertain (Holness and Simmons 1993). CD 68 immunoreactivity can 
be used to detect phagocytic microglia and morphologically they have a rounded 
appearance with loss of the extensive ramifying cellular processes. Microglia can 
migrate within the CNS to areas of injury, and a number of chemokines have been 
described which can induce microglial motility (Rezaie and Male 2002), including Ap 
(Davis et al 1992).
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1.3.5.2 The acute response to injury
After brain injury cytokines are released and microglia are activated, the 
degree of activation reflecting the severity of the injury. In animal models of 
ischaemia microglial activation is seen within 20 minutes of reperfusion (Morioka et 
al 1991), and this is associated with the production of both Ap-PP (Banati et al 1993) 
and apolipoprotein E (Uchihara et al 1995). Microglial activation in itself will lead to 
cytokine release, including IL-1, possibly secondary to elevated levels of ATP 
released from damaged cells (Di Virgilio 1995), with activation of purinergic P2X7 
receptors on microglia (Ferrari et al 1997). IL-1 is actually a family of three related 
proteins two of which act as agonists (IL-1 a  and IL-ip) and one as an antagonist (IL- 
lra) at the IL-1 receptors. IL-1 a  is active in both the precursor (pro-IL-la) and 
mature forms while pro-IL-ip is inactive. Activation requires the intracellular enzyme 
IL-lp converting enzyme (ICE) (Mrak and Griffin 2001). Functional differences 
between IL-1 a  and IL-lp in the CNS are poorly defined but IL-1 p is the first to be 
released (Davies et al 1999) and induces expression of other cytokines including IL-6, 
TNFa and TGFp (Allan and Rothwell 2001). IL-1 is thought to orchestrate the 
inflammatory responses within the brain after an injury, resulting in a number of 
responses including; (a) microglial proliferation (Ganter et al 1992), (b) induction of 
neuronal production of Ap-PP (Goldgaber et al 1989), and (c) astrocytic activation 
with upregulation of astrocytic-derived proteins (Das and Potter 1995). The IL-1 
receptor IL-1RI binds both IL-1 a  and IL-lp (Greenfeder et al 1995) although IL-1 
may also bind to other less specific receptors (Rothwell et al 2000). By binding to 
receptors IL-1 has been shown to enhance neurotoxicity in vivo by inducing 
cyclooxygenase 2 (COX2) and inducible nitric oxide synthase (iNOS) (Serou et al 
1999). A recent study of mixed cultures of activated glia and neurons suggested that
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inflammatory neurodegeneration may be mediated by glial nitric oxide (NO) (Bal- 
Price and Brown 2001). They proposed that NO produced by activated microglia or 
astrocytes inhibits the mitochondrial function of surrounding neurons, causing 
glutamate release from neurons (and possibly from astrocytes). Activation of NMD A
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receptors by glutamate triggers massive influx of Ca into neurons, leading to cell 
death. Other potential mechanisms of NO mediated neuronal death include 
mitochondrial damage (Heales et al 1999) and poly(ADP-ribose) synthetase activation 
(Zhang et al 1994).
Further cellular injury may be produced by glial activation and release of 
neurotoxins such as Ap-PP (Allan and Rothwell 2001). Hypothalamic corticotrophin 
releasing factor (CRF) is also released and may be neurotoxic although the 
mechanisms remain uncertain (Roe et al 1998).
1.3.5.3 Chronic microglial activation
IL-1 is expressed in increased quantities in the cerebral cortex within hours of 
traumatic brain injury (Griffin et al 1994), and chronic overexpression of IL-1 is 
found in AD (Griffin et al 1989). Griffin et al (1998) have proposed a “Cytokine 
Cycle” in which traumatic brain injury, or other forms of brain injury, can, in 
susceptible individuals, initiate an overexuberant sustained inflammatory response 
which can result in neurodegeneration. Ap-PP and the astrocyte-produced molecule S- 
100P are upregulated in response to increased IL-1 levels, and the situation is similar 
in AD (Griffin et al 1989, Mrak et al 1996). Ap-PP is not only upregulated in acute 
traumatic brain injury, but there is increased intraneuronal processing of the molecule 
(Buxbaum et al 1992) potentially resulting in Ap production and deposition. The 
relation between IL-1 and Ap-PP is uncertain, but increased levels of IL-1 may result 
in sustained Ap-PP, and therefore Ap, production. Positive feedback of this
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interaction may be provided by soluble fragments of Ap-PP (sAPP) which are 
produced by the processing of Ap-PP. sAPP promotes microglial activation by a 
mechanism that is modulated by apolipoprotein E in an isoform specific fashion 
(Barger and Harmon 1997).
IL-1 positive microglial cells lie in close relation to Ap-PP positive neurons 
and dystrophic neurites in the brains of head-injured patients (Griffin et al 1994) and 
are also found in close apposition to neurofibrillary tangle-containing neurons in AD 
(Sheng et al 1997). IL-1 is known to be trophic to neurons in low concentrations, but 
at higher concentrations IL-1 has a neurotoxic effect, inducing overexpression and 
phosphorylation of both neurofilaments and tau (Sheng et al 2000). The IL-1 
mediated pathological effects of microglia on tau phosphorylation in neurons are 
through a p38-MAPK signalling pathway (Li et al 2003).
1.4 Evidence for genetic influences on outcome after head injury
1.4.1 APOE polymorphisms
The response to brain injury and AD have in common not only a cellular and 
protein response but there are striking parallels in the genetic influences. 
Apolipoprotein E (apoE) is a protein, initially described in 1973 (Shore and Shore, 
1973), which in the circulation plays an important role in the transport of lipids. There 
is a polymorphism of the apolipoprotein E gene {APOE, gene; apoE, protein) of which 
there are 3 common alleles (s2, s3 and s4) resulting in three common protein isoforms 
(E2, E3 and E4). In the human CNS apoE has been demonstrated in both neurons and 
glia (Horsburgh et al 2000b), with marked increases in intraneuronal apoE after brain 
injury (Horsburgh et al 1999a). The function of apoE after brain injury is uncertain 
but apoE may be retained within the parenchyma of the CNS and may have a
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protective role which is isoform dependent. Decreases in cerebrospinal fluid apoE 
concentration have been detected after TBI in humans (Kay et al 2003).
Possession of APOE s4 allele is the major genetic susceptibility factor for 
sporadic AD (Saunders et al 1993). In addition, the APOE polymorphism influences 
neuropathological findings in patients who die from head injuries (Nicoll et al 1995). 
This study examined the brains of 90 cases who died within 2 weeks of a head injury. 
Ap deposits were found in 23 patients and the frequency of the APOE s4 allele within 
this group was significantly greater than that seen in either control populations 
without neurological disease or in AD. In addition all cases homozygous for the 
APOE e4 allele had Ap deposition. Furthermore, the density of these plaques was 
related to APOE genotype, with greater numbers of plaques being associated with the 
APOE e4 allele in an allele dose dependant manner (i.e. homozygotes having greater 
numbers of plaques than heterozygotes) (Horsburgh et al 2000a). The initial 
interpretation of these findings by Nicoll et al (1995) was that in genetically 
susceptible individuals (i.e. those with an APOE s4 allele) traumatic brain injury 
appears to act as a trigger for Ap deposition. However, there are alternative 
explanations for these observations (Roses and Saunders 1995); Ap deposits may pre­
date the injury, and patients with s4, who are more likely to have age-related deposits, 
may have a higher mortality from traumatic brain injury and therefore be selected for 
an autopsy-based study. Until it is possible to image Ap plaques during life it may not 
be possible to resolve this uncertainty. Subsequent clinical studies have indeed shown 
that head-injured patients (and patients with spontaneous intracerebral haemorrhage) 
who possess APOE e4 have a poorer outcome than non-carriers of APOE s4 (Alberts 
et al 1995, Teasdale et al 1997, McCarron et al 1998). Jordan et al (1997) studied 30 
professional boxers and assessed their cognitive status in relation to APOE genotype
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and number of professional bouts. They concluded that possession of an APOE e4 
allele is associated with increased severity of chronic neurological deficits in high- 
exposure boxers. A recent neuropathological study compared Ap deposits in long 
term survivors of traumatic brain injury (survival time up to 20 years) with age- 
matched and APOE genotype matched controls (MacFarlane et al 1999). They found 
Ap deposits were more common in e4 patients in both the long-term survivors and the 
control groups, but were not more common among long term survivors than controls. 
Activated microglial cells are involved in the deposition of Ap, as discussed above, 
and when deposited Ap is bound by apoE in an isoform specific manner (Strittmatter 
et al 1993). In addition, possession of the APOE s4 allele is associated with greater 
Ap deposition (Schmechel et al 1993) and an increase in the number of activated 
microglial cells (Egensperger et al 1998) in the brains of patients with AD.
However, Millar et al (2003) studied the long-term neuropsychological 
outcome after head injury and found no clear differences in individuals who possess 
the e4 allele. This study did provide additional data for a late decline after head injury. 
Comparison using the Glasgow outcome scores demonstrated a neuropsychological 
decline after a 6 month assessment and found that improvement in condition after this 
assessment was uncommon. Therefore, this study suggested that although possession 
of the e4 allele was not related to neuropsychological outcome, there was a late (after 
6 months) decline which may be related to other genetic polymorphisms, such as 
those of IL-1. The cohort was considered too young (mean age 42.1 years) to assess 
the risk of AD.
In AD there is evidence that patients with APOE s4 have increased microglial 
activity compared to patients without APOE s4 (Egensperger et al 1998). Further 
investigations relating APOE genotypes and the neuroinflammatory response have
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shown that response targeted-replacement mice expressing human APOE s4 genes 
express greater levels of systemic and brain pro-inflammatory cytokines (TNFa and 
IL-6) after administration of lipopolysaccharide (LPS) when compared to animals 
expressing APOE e3 genes (Lynch et al 2003). These results suggest that apoE has an 
isoform specific effect on modulation of the neuroinflammatory response after injury. 
Multiple sclerosis is a demyelinating condition in which neuroinflammation is a key 
feature. APOE polymorphisms have been demonstrated to modify disease severity 
with possession of APOE s4 being associated with severe disease (Fazekas et al 2001, 
Schmidt et al 2002) and APOE e2 being associated with less severe disease (Schmidt 
et al 2002), particularly in women (Kantarci et al 2004). While these findings suggest 
that apoE isoforms do modify neuroinflammation in humans the findings are disputed 
by other investigators (Savettieri et al 2003).
1.4.2 IL-1 A and IL-1 B polymorphisms
A further genetic polymorphism has recently been suggested to confer 
susceptibility to AD and this also implicates neuroinflammatory processes.
Interleukin 1 (IL-1) exists in two distinct forms (IL-1 a  and IL-lp with IL-1 A and IL- 
1B genes respectively) and polymorphisms have been identified in each of these genes 
(both have an allele 1 and an allele 2). An association has been demonstrated between 
the IL-1 A 2,2 genotype and AD (Nicoll et al 2000, Grimaldi et al 2000). Nicoll et al 
studied 232 pathologically confirmed cases of Alzheimer’s disease and found the IL­
IA 2,2 genotype in almost 13% of cases as compared to 6.6% of age-matched and 
APOE-matched controls. In addition they found that homozygosity for allele 2 of both 
IL-1 A and IL-1B conferred an even greater risk, although homozygosity for allele 2 of 
IL-1B alone was not significant. A gene dose dependent association of IL-1 A allele 2 
polymorphism and AD has been demonstrated (Combarros et al 2002) with the risk of
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developing AD for a heterozygote having an odds ratio of 1.4 increasing to 3.1 for 
homozygotes. Some studies, however, have not demonstrated an association between 
IL-1 A allele 2 and AD (Bertram et al 2000, Green et al 2002).
1.4.3 Genetic influence overview
Although there is currently a lack of definitive information about APOE 
genotype, IL-1 genotype and microglial activation in traumatic brain injury, the 
observations outlined above raise the possibility that microglial activation 
(“neuroinflammation”) may be under genetic influence. Specifically, they raise the 
question that individuals with the relevant alleles (APOE s4 or IL-1 A  allele 2) who 
sustain a head injury may have a relatively overexuberant microglial response which 
is associated both with a poorer outcome from injury and greater susceptibility to later 
AD. If this were the case it is possible to speculate that simple anti-inflammatory 
medication may have a role in the long-term management of the head-injured patient 
in much the same way that non-steroidal anti-inflammatory drugs (NSAIDs) may be 
useful in protecting against AD (McGeer et al 1990, McGeer et al 1996).
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2 Hypotheses
In light of this background information the present study was designed to test 
potential cellular and genetic mechanisms which may underlie the association 
between head injury and AD. This study tested the hypotheses;
Neurofibrillary pathology
• That tau accumulation occurs in humans in the acute phase after TBI.
N eu roin flamma tion
• That there is a sustained neuroinflammatory response after TBI which may, in 
the long-term, have significant neurodegenerative effects.
Genetic
• That head-injured patients with APOE s4 are selectively predisposed to one or 
more of the different pathological features that constitute the response to TBI, 
and that this underlies the association of APOE e4 with poor clinical outcome.
• That possession of IL-1 A allele 2 (heterozygosity or homozygosity) results in 
an increased neuroinflammatory response.
• The neuroinflammatory response may further be modified by possession of IL- 
1B allele 2 or APOE e4.
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3 Methods
3.1 Case selection
3.1.1 Traumatic brain injury archive
The departments of Neurosurgery and Neuropathology in Glasgow have a 
long standing research interest in TBI. One of the key resources in Glasgow, and 
which has been key to much of the published research in this field, is the extensive 
and probably unique archive of tissue retained in the Neuropathology department, 
accumulated from cases of fatal traumatic brain injury. Tissue was retained for 
diagnostic purposes and subsequently used for research. Detailed examination and 
retention of tissue from the brains of patients dying after an episode of trauma dates 
back to 1968. From 1968 until 1999 approximately 1400 cases were examined. Many 
of these cases were neurosurgical in-patients and as such have detailed clinical 
information. Autopsy information is generally detailed; neuropathologists undertook 
many of the autopsies although, more recently, most of the autopsies were undertaken 
by staff of the University Department of Forensic Medicine and Science who then 
made the brains available for neuropathological examination. In all these cases there 
was a macroscopic examination of the brain; in the great majority they were then 
sampled in a standardised way for microscopic examination. The tissue was processed 
to paraffin blocks, as detailed below, and the paraffin blocks were retained in the 
archive of the Neuropathology department as part of the patient record. Every case 
has a unique identifying code number. Following the diagnostic process the range of 
pathologies seen in each case were entered into a database. Using this database, cases 
could be selected on the range of pathologies present. The database is cross- 
referenced with the unique identifying code for each case and the archived paraffin 
blocks could be retrieved for research purposes.
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3.1.2 Previous cohorts published using cases from the archive
Previous studies have been published analysing the distribution of brain injury 
in fatal non-missile TBI in the West of Scotland using the archive. Adams et al (1980) 
provided detailed neuropathological data on 151 cases of fatal TBI between 1968- 
1972, and this cohort was again assessed along with 112 cases accrued between 1981- 
1982 (Graham et al 1989). A larger cohort of 635 cases, accrued between 1968-1982, 
was used to assess the prevelance of raised intracranial pressure (Adams and Graham, 
1976), ischaemic brain injury (graham et al 1989), contusions (Adams et al 1985), 
and diffuse TAI (Adams et al 1989). As a result of these detailed neuropathological 
studies there has been greater clinico-neuropathological correlation and an 
understanding of the structural basis of clinical outcomes, such as the vegetative state 
(Adams et al 2000), severe disability (Jennett et al 2001), and moderate disability 
(Adams et al 2001).
3.1.3 Identification of cases
The current study utilised cases from the paraffin-embedded tissue archive of 
the Glasgow Neuropathology department. Initially all cases that died from TBI 
during the 13-year period 1987-1999 within the archive were selected. These cases 
were identified from the database as all had been coded as “acute head injury”. The 
unique identifying number allowed all paraffin blocks to be retrieved from the archive 
along with all neuropathological reports. While many of the cases had been managed 
by the Department of Neurosurgery, Institute of Neurological Sciences, some patients 
had died at District General Hospitals or at the scene of the injury. Requirements for 
inclusion into this cohort were;
Coded as acute head injury in the database, allowing cases to be studied “blind” to the 
clinical data.
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Each case had detailed clinico-neuropathological information available.
Each case had a full autopsy examination.
Standardised set of paraffin blocks were available in the archive.
Cases had been reported by Professors DI Graham, JH Adams or JAR Nicoll.
A total of 259 cases were identified and they are detailed in appendix 2.
3.1.3.1 Identification of cases used in the study of cytoskeletal pathology
A total of 45 acute TBI cases with varying survival times ranging from <24 
hours up to one month were included in this study. They were grouped on the basis of 
age and survival times (tables 1-3). In general, the acute TBI cases had all 
experienced a severe head injury (Glasgow Coma Scale [GCS] 8 or less) with only 
one case having a moderate injury (GCS 9-12). Four cases had a mild head injury 
(GCS 13-15) and died of pathology not directly related to the brain injury. In 12 cases 
GCS was not recorded as patients either died rapidly before hospital admission or 
were not formally assessed. In all of these cases the pathology suggested a head injury 
was a major feature of the autopsy findings. The mechanisms of injury varied with 
road traffic accidents (RTA) being more common in the <20 year old group, and falls 
more common in the >50 year old group. 15 cases with no significant neurological 
impairment or neuropathological abnormality were used as controls (table 4). These 
cases were all hospital autopsies which were fully consented. Tissue was retained for 
diagnostic purposes and subsequently used for research after examination.
The issue of consent for these cases is discussed below.
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Table 1; Details of TBI cases aged < 20 years used in the cytoskeletal pathology
study
Age
(years)
Documented
survival
Severity of head 
injury
(admission GCS)
Mechanism 
of head 
injury
Main
pathology
Survival 
<24 hours
8 wks 4 hours Severe (NA) RTA DVI
1.5 22 hours Severe (NA) Fall TAI
3 21 hours Severe (5) RTA TAI, swelling
9 10 hours Severe (3) RTA TAI, swelling
14 7 hours Severe (3) RTA DVI
Survival
24 hours- 1 week
3 48 hours Severe (NA) RTA Brain swelling
5 3 days Severe (NA) RTA TAI, swelling
7 48 hours Severe (6) RTA Brain swelling
12 7 days Severe (5) RTA ICH, TAI
14 48 hours Severe (3) RTA TAI, swelling
Survival 
1 week- 1 month
5 9 days Severe (5) RTA Acute LSDH
15 8 days Severe (4) RTA TAI, swelling
15 8 days Severe (4) RTA TAI, swelling
17 14 days Severe (5) RTA TAI
19 21 days Severe (3) RTA TAI
Legend: NA= Not available
RTA= Road traffic accident 
DVI= Diffuse vascular injury 
TAI= diffuse traumatic axonal injury 
ICH= intracerebral haemorrhage 
R/LSDH= right/left subdural haemorrhage
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Table 2; Details of TBI cases aged 20- 49 years used in the cytoskeletal pathology
study
Age
(years)
Documented
survival
Severity of head 
injury 
(admission 
GCS)
Mechanism of 
head injury
Main pathology
Survival 
<24 hours
23 8 hours Severe (3) RTA TAI
25 20 hours Severe (4) RTA Global ischaemia 
due to raised ICP
30 16 hours Severe (3) RTA Acute LSDH
34 23 hours Severe (3) Fall Acute LSDH
39 12 hours Severe (3) RTA DVI
Survival 
24 hours- 1 
week
23 3 days Mild (15) Assault Extracranial
pathology
26 24 hours Severe (3) Fall Contusions,
swelling
26 4 days Severe (6) Fall Contusions,
swelling
37 24 hours Severe (3) Fall Acute RSDH
40 5 days Severe (4) Assault Acute LSDH
Survival 
1 week- 1 
month
21 9 days Severe (NA) RTA TAI, acute LSDH
23 28 days Severe (3) Assault TAI
27 11 days Moderate (10) Fall TAI, R burst lobe
30 18 days Mild (15) Fall Extracranial
pathology
35 10 days Mild (15) Fall Extracranial
pathology
Legend: NA= Not available
RTA= Road traffic accident 
DVI= Diffuse vascular injury 
TAI= diffuse traumatic axonal injury 
ICH= intracerebral haemorrhage 
R/LSDH= right/left subdural haemorrhage 
ICP= intracranial pressure
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Table 3; Details of TBI cases aged > 50 years used in the cytoskeletal pathology
study
Age
(years)
Documented
survival
Severity of head 
injury
(admission GCS)
Mechanism 
of head 
injury
Main
pathology
Survival 
<24 hours
51 12 hours Severe (3) Fall Acute RSDH
59 20 hours Severe (3) Fall Bilateral acute 
SDH
66 21 hours Severe (4) RTA Acute LSDH
71 12 hours Severe (NA) Fall Acute LSDH
88 7 hours Severe (NA) Fall Acute LSDH
Survival
24 hours- 1 week
53 2.5 days Severe (NA) Fall Acute RSDH
56 4 days Severe (5) Fall Acute RSDH, 
TAI
60 8 days Severe (NA) Fall ICH
68 3 days Severe (4) RTA Acute LSDH, 
TAI
73 7 days Severe (NA) RTA Contusions,
swelling
Survival 
1 week- 1 month
53 11 days Severe (3) Fall Acute LSDH
59 17 days Severe (6) Fall LSDH
60 10 days Mild (14) Fall ICH, TAI
79 8 days Severe (NA) RTA Acute LSDH
83 18 days Severe (NA) RTA ICH, TAI
Legend: NA= Not available
RTA= Road traffic accident 
DVI= Diffuse vascular injury 
TAI= diffuse traumatic axonal injury 
ICH= intracerebral haemorrhage 
R/LSDH= right/left subdural haemorrhage
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Table 4; Details of control cases used in the cytoskeletal pathology study
<20 years 20-50 years >50 years
Age Cause of death Age Cause of death Age Cause of death
Non-head 
injured controls 
with no 
neurological 
disease
4 Congenital heart disease 20 Dmg overdose 50 Metastatic carcinoma
8 Viral infection 21 Septic shock 59 Disseminated 
Langerhan’s histiocytosis
10 Bums 28 Dmg overdose 68 Ruptured aortic 
aneurysm
18 Leukaemia 33 Ischaemic heart 
disease
69 Congestive cardiac 
failure
18 Systemic Hodgkin’s 
disease
38 Congestive cardiac 
failure
71 Pneumonia
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3.1.3.2 Identification of cases used in the study of neuroinflamation
A subset of cases were selected from the main cohort to form a smaller group 
used to study the neuroinflammatory response after TBI. A total of 55 TBI cases with 
varying survival times ranging from <24 hours up to 4 years were included in this 
study (tables 5-7). In general, these cases had all experienced a severe head injury 
(Glasgow Coma Scale [GCS] 8 or less) with only three cases having had a moderate 
injury (GCS 9-12). Three cases had had a mild head injury (GCS 13-15) and died of 
pathology not directly related to the brain injury. In 11 cases GCS was not recorded as 
patients either died rapidly before hospital admission or were not formally assessed.
In all of these cases the pathology suggested a head injury was a major feature of the 
autopsy findings. In four of the longer survivors there was no data relating to the GCS 
at time of admission. The mechanisms of injury varied with road traffic accidents 
(RTA) being more common in the <20 year old group, and falls more common in the 
>50 year old group.
20 cases with no significant neurological impairment or neuropathological 
abnormality were used as controls (table 8). These cases were all hospital autopsies 
which were fully consented. Tissue was retained for diagnostic purposes and 
subsequently used for research.
The issues relating to consent for these cases is discussed below.
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Table 5; Details of TBI cases aged < 20 years used in neuroinflammatory study
Age
(years)
Documented
survival
Severity of head 
injury
(admission GCS)
Mechanism 
of head 
injury
Main
pathology
Survival 
<24 hours
1.5 22 hours Severe (NA) Fall TAI
3 21 hours Severe (5) RTA TAI, swelling
9 10 hours Severe (3) RTA TAI, swelling
14 7 hours Severe (3) RTA DVI
Survival
24 hours- 1 week
3 48 hours Severe (NA) RTA Brain swelling
5 3 days Severe (NA) RTA TAI, swelling
7 48 hours Severe (6) RTA Brain swelling
12 7 days Severe (5) RTA ICH, TAI
Survival 
1 week- 1 month
5 9 days Severe (5) RTA Acute LSDH
15 8 days Severe (4) RTA TAI, swelling
15 8 days Severe (4) RTA TAI, swelling
17 14 days Severe (5) RTA TAI
19 21 days Severe (3) RTA TAI
Survival 
1-3 months
18 2.5 months Severe (4) RTA TAI
Survival 
>3 months
NA Nil Nil Nil NA
Legend: NA= Not available
RTA= Road traffic accident 
DVI= Diffuse vascular injury 
TAI= diffuse traumatic axonal injury 
ICH= intracerebral haemorrhage 
R/LSDH= right/left subdural haemorrhage
35
Table 6; Details of TBI cases aged 20- 49 years used in neuroinflammatory study
Age
(years)
Documented
survival
Severity of head 
injury 
(admission 
GCS)
Mechanism of 
head injury
Main pathology
Survival 
<24 hours
23 8 hours Severe (3) RTA TAI
25 20 hours Severe (4) RTA Global ischaemia 
secondary to
30 16 hours Severe (3) RTA Acute LSDH
34 23 hours Severe (3) Fall Acute LSDH
Survival 
24 hours- 1 
week
23 3 days Mild (15) Assault Extracranial
pathology
26 24 hours Severe (3) Fall Contusions,
swelling
26 4 days Severe (6) Fall Contusions,
swelling
37 24 hours Severe (3) Fall Acute RSDH
40 5 days Severe (4) Assault Acute LSDH
Survival 
1 week- 1 
month
21 9 days Severe (NA) RTA TAI, acute LSDH
23 28 days Severe (3) Assault TAI
27 11 days Moderate (10) Fall TAI, R burst lobe
35 10 days Mild (15) Fall Extracranial
pathology
Survival 
1-3 months
45 30 days Severe (5) RTA Global ischaemia 
secondary to
Survival 43 10 months Severe (6) Assault TAI
>3 months 38 4 years NA Fall Extracranial
pathology
28 9 months Severe (5) RTA TAI
Legend: NA= Not available
RTA= Road traffic accident 
DVI= Diffuse vascular injury 
TAI= diffuse traumatic axonal injury 
ICH= intracerebral haemorrhage 
R/LSDH= right/left subdural haemorrhage 
EDH= extradural haematoma 
MI= myocardial infarct
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Table 7; Details of TBI cases aged >50 years used in neuroinflammatory study
Age
(years)
Documented
survival
Severity of head 
injury
(admission GCS)
Mechanism 
of head 
injury
Main
pathology
Survival 
<24 hours
51 12 hours Severe (3) Fall Acute RSDH
59 20 hours Severe (3) Fall Bilateral acute 
SDH
66 21 hours Severe (4) RTA Acute LSDH
71 12 hours Severe (NA) Fall Acute LSDH
88 7 hours Severe (NA) Fall Acute LSDH
Survival
24 hours- 1 week
53 2.5 days Severe (NA) Fall Acute RSDH
56 4 days Severe (5) Fall Acute RSDH, 
TAI
68 3 days Severe (4) RTA Acute LSDH, 
TAI
73 7 days Severe (NA) RTA Contusions,
swelling
Survival 
1 week- 1 month
53 11 days Severe (3) Fall Acute LSDH
59 17 days Severe (6) Fall LSDH
60 10 days Mild (14) Fall ICH, TAI
79 8 days Severe (NA) RTA Acute LSDH
Survival 
1-3 months
50 7 weeks Severe (4) Fall pneumonia
RSDH
51 2 months Severe (NA) Fall LSDH
Global
ischaemia
76 6 weeks Moderate (9) Assault RSDH
76 5 weeks NA Fall RICH
TAI
Survival 
>3 months
56 4 months NA NA AD
65 5 months Severe (6) Assault Pneumonia
TAI
67 12 months Severe (6) RTA Pneumonia
Cerebral
swelling
70 6 months NA Assault PTE
eEDH
75 11 months Severe(5) Assault Pneumonia
TAI
78 4 months Moderate (10) RTA LSDH
79 4 months Severe (NA) RTA eLSDH
Legend: NA= Not available
RTA= Road traffic accident 
DVI= Diffuse vascular injury 
TAI= diffuse traumatic axonal injury 
ICH= intracerebral haemorrhage
(e)R/LSDH= (evacuated) right/left subdural haemorrhage
RICH= right intracerebral haematoma
AD= Alzheimer’s disease
eEDH= evacuated extradural haematoma
PTE= pulmonary thrombo-embolus
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Table 8; Details of control cases used in the neuroinflammatory study
<20 years 20-50 years >50 years
Age Cause of death Age Cause of death Age Cause of death
Non-head 
injured controls 
with no 
neurological 
disease
18 Leukaemia 20 Drug overdose 50 Metastatic carcinoma
18 Systemic Hodgkin’s 
disease
21 Septic shock 55 Gastric lymphoma 
PTE
24 Drug overdose 59 Disseminated 
Langerhan’s histiocytosis
28 Drug overdose 60 Bronchial carcinoma
33 Ischaemic heart 
disease
64 Sarcoidosis
35 Malignant teratoma 69 Acute pyelonephritis
43 Hodgkin’s
lymphoma
69 Congestive cardiac 
failure
44 Myocardial infarct 70 Breast carcinoma
47 T cell lymphoma 71 Pneumonia
Legend: PTE= pulmonary thrombo-embolus
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3.1.4 Issues related to organ retention
The retention of organs at post-mortem examination and the use of retained 
tissues in medical research has been the focus of much public and political attention 
over the past five years. The practise of removing and retaining organs at autopsy 
examination had been widespread and long-standing in the United Kingdom. While 
this was considered to be part of the normal autopsy examination by many health care 
professionals it became clear that many relatives who consented to autopsy 
examination after a death were unaware of the possibility of organ retention for 
diagnostic purposes and, in some cases, use of the retained tissues in research. The 
issue came to light during an inquiry into paediatric heart surgery at Bristol Royal 
Infirmary (Kennedy 2001). At this inquiry it was disclosed that organs (malformed 
hearts) had been retained as part of the diagnostic process. Subsequent investigations 
focussed on Liverpool (Alder Hey Children’s Hospital) where the practises of an 
individual paediatric pathologist were scrutinised (Redfem 2001). It became apparent 
that there was inadequate information being provided to relatives and that the whole 
process of consent for autopsy examination had to be addressed. In Scotland Professor 
Shelia McLean headed the inquiry, the findings being published in 2001 (McLean 
2001). The medical profession responded to the recommendations made by these 
various reports and have improved the process of seeking and documenting informed 
consent such that relatives are fully aware of any retained tissues and give specific 
consent allowing the use of any retained tissues in medical research and education.
Much of the discussion relating to retained organs focussed on autopsies that 
had been performed in cases outwith the authority of the Procurator Fiscal (or Coroner 
in England, Wales and Northern Ireland). There was, however, considerable concern 
relating to retention of organs in cases which had been instructed by the Procurator
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Fiscal (or Coroner) and the subsequent use of tissues for medical research and 
education. A particularly high profile case resulted in a review of the practises by Her 
Majesty’s Inspector of Anatomy (Metters 2003) which coincided with a review of the 
Coroners system in England and Wales (Luce 2003). There remains uncertainty in 
Scotland with regard to the use in medical research of tissue retained for diagnostic 
purposes under the authority of the Procurator Fiscal. In particular archived material 
which was retained in good faith using the appropriate mechanisms available at the 
time was problematic. There is a clear willingness that research which will benefit the 
general public should continue and as such, following a 12 month moratorium on 
research using human tissues during which time relatives could reclaim retained tissue 
if they so wished, research continues. The Metters report makes the following points; 
prior to 1991 Research Ethical Committee (REC) approval was not required for 
research using human material. After 1991 and up to the late 1990’s REC approval 
was required for research using tissues from the recently dead, although this was not 
clearly defined. The current situation is that all research using human materials 
requires REC approval. This normally requires anonymisation of the tissues recruited 
to the studies. Clearly in many situations, such as this current study, reference to 
clinical data is imperative and complete anonymisation would negate any value of the 
research. Therefore the concept of coded anonymised studies exists, whereby the 
cases are all coded with only the principal investigator having access to clinical details 
for each coded case. This current study was submitted to, and approved by, the 
Southern General Hospital Research Ethics Committee (SGHREC). All future studies 
related to this archived material require separate submissions to be made to the 
SGHREC.
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3.2 Processing of tissues 
3.2.1 Fixation and sampling of brains
The brains had been fixed in 4% formal saline for a minimum of 3 weeks prior 
to dissection after which a standardised brain cut and histological sampling was 
undertaken. The brains were cut at a standardised 1-cm thickness in the coronal plane. 
Full macroscopic and microscopic examination was undertaken in each case. Blocks 
for histology were taken from the cerebral hemispheres at the level of the lateral 
geniculate bodies (bilateral parasagittal including corpus callosum, bilateral parietal 
convexities including watershed regions, bilateral thalami including internal capsules, 
bilateral hippocampi), cerebellar hemispheres including dentate nucleus, midbrain, 
pons at the level of the nucleus coeruleus, and medulla.
3.2.2 Processing and staining of histology sections
The tissue was processed in a VIP tissue processor (Bayer Diagnostics, 
Newbury, UK) using a 60-hour cycle and embedded in paraffin wax. Eight 
micrometre thick sections of the paraffin blocks were cut and stained with 
haematoxylin and eosin (H&E) and luxol fast blue/ cresyl violet (LFB/CV).
3.3 Generation of pathological data
Archival data which had been gathered prospectively during the years 1987- 
1999 inclusive according to a uniform protocol (see appendix 1) was logged into a 
database for each case. The data included age and length of survival after the episode 
of TBI. Pathological data included both focal and diffuse pathologies. The focal 
pathologies were skull fractures, intracranial haemorrhages, raised intracranial 
pressure and associated infarcts, contusions and cerebral infection; the diffuse 
pathologies were diffuse traumatic axonal injury (TAI), ischaemic brain damage and 
brain swelling. In addition information was available relating to systemic injuries and
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to the post- mortem interval (PMI) for each case. The data was gathered from the
neuropathological reports and from microscopic examination of cases where required.
3.3.1 Skull fractures and intracranial haemorrhages
Skull fractures were documented as being either present or absent, and 
intracranial haemorrhages were recorded in relation to the anatomical compartment 
involved (extradural, subdural, intracerebral). If known the size of the intracranial 
haematomas was documented and whether there had been neurosurgical intervention 
resulting in evacuation of the haematoma. The criteria for coding are outlined in 
appendix 1.
3.3.2 Traumatic axonal injury
Traumatic axonal injury (TAI) was documented as being absent or present, 
and if present was graded as grade 1, 2 or 3 (Adams et al 1989). Grade 1 lesions had 
widespread axonal damage in the corpus callosum and the cerebral hemispheres.
Grade 2 lesions, in addition, had focal haemorrhagic lesions in the corpus callosum, 
and in grade 3 there was in addition a haemorrhagic lesion in the rostral brain stem. 
The term diffuse axonal injury (DAI) was originally applied to traumatic damage 
exclusively. However, as immunohistochemical studies using p-APP as a marker of 
axonal damage have demonstrated, many brain insults can result in axonal damage. 
Therefore, it has been proposed that the aetiology of any axonal damage should 
always be indicated, and that DAI (as originally defined) should now be referred to as 
TAI (Geddes et al 2000).
Diffuse vascular injury (DVI) is a diffuse injury in which haemorrhages, 
which are often microscopic, are present throughout the brain. The condition is 
usually fatal and is thought to be due to rotational forces applied to the brain. DVI was 
assessed as being either absent or present.
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3.3.3 Ischaemic brain damage
Ischaemic brain damage was assessed as mild, moderate or severe using a 
grading system developed by Graham et al 1989;
1. severe comprised those cases in which the lesions were diffuse, multifocal 
and large within arterial territories.
2. moderate when the lesions were limited to the arterial boundary zones, 
singly or in combination with subtotal infarction in the distribution of the 
cerebral arteries, or if  there were 6-10 subcortical lesions.
3. mild if  there were five or less subcortical lesions in the brain.
3.3.4 Raised intracranial pressure
Raised intracranial pressure was considered to be present if there were 
tentorial hernias (either macroscopic or microscopic), often with associated vascular 
complications within the distributions of the anterior choroidal artery, the pericallosal 
artery, the posterior cerebral artery, and the arterial supply to the cerebellum and 
brainstem (Adams and Graham, 1976).
3.3.5 Contusions
Contusions were graded using the total contusion index (TCI) developed by 
Adams et al (1980) and subsequently modified (Adams et al 1985). This assesses the 
extent (0-3) and depth (0-4) of contusions in a variety of anatomical locators, 
producing a numerical score for each hemisphere which is then combined and 
interpreted as absent, mild, moderate, or severe. The anatomical locators are the 
frontal, temporal, parietal and occipital lobes, the cortex above and below the Sylvian 
fissure, and the cerebellum. The maximum score for an anatomical locator is 12 
(4x3=12), and the TCI has a maximum value of 144 (each side 6x12=72, 2x72=144). 
For this study contusional injury was mild if the TCI was less than 20, moderate if the
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TCI was between 20 and 37, and severe if the TCI was greater than 37 (Graham et al
1988).
3.4 Genotyping
3.4.1 Polymerase Chain Reaction
Polymerase chain reaction (PCR) was introduced in 1985 (Saiki et al 1985) 
and has since revolutionised molecular analysis of tissues. PCR is a technique which 
allows the rapid amplification of a relatively small quantity of DNA from a tissue 
sample. The main principles are as follows; DNA is extracted from the tissue of 
interest and denatured to a single-stranded form (ssDNA). Primers are then introduced 
to specifically bind to a selected region of the ssDNA, the primers usually being no 
more than about 100 base pairs (bp) long. When the primers have bound to the 
ssDNA (annealed) a polymerase enzyme is activated in the presence of excess 
nucleotides, resulting in extension of primer to produce a new double-stranded 
molecule of DNA. The process is then repeated many times (usually between 30 and 
40 times) resulting in the production of many copies of the section of DNA of interest. 
The DNA is then digested in a specific way to produce shorter segments (restriction 
enzyme digestion) and the fragments are separated on an electrophoresis gel.
The PCR technique can be used to examine polymorphisms of specific genes. 
Each gene polymorphism will have a different nucleotide structure which will result 
in segments of differing length after restriction enzyme digestion. These nucleotide 
fragments of different molecular weights will separate out in a specific way on the gel 
dependent on the polymorphism present.
3.4.2 Technical Difficulties
PCR requires the initial DNA sample to be in a reasonable good state of 
preservation. If there is DNA degradation as is often the case where there has been a
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long post-mortem interval (PMI) the yield of nucleic acid after the PCR process can 
be unpredictable and may be of poor quality. PCR analysis in this study was 
complicated by the technical difficulties associated with extracting viable DNA from 
formalin-fixed paraffin-embedded tissues (Greer et al 1991). The DNA extraction 
method is detailed in appendix 2. Briefly, sections (10pm), had to be dewaxed using 
xylene and ethanol prior to digestion. Digestion is required as formalin fixation will 
result in increased cross-linkage between nucleotides in the DNA molecule.
Proteinase K treatment is used to extract (digest) DNA from formalin-fixed material, 
although often the DNA can be very fragmented and there may be a low yield (Palmer 
1995).
In this study successful APOE genotyping was one of the inclusion criteria for 
case selection. Genotyping was considered to be unsuccessful if no interpretable gels 
were produced after four attempts including extended Proteinase K digestion and use 
of different blocks of tissue to extract DNA. In many cases there was only access to 
archived brain material for each case, there being no other tissue blocks available to 
attempt DNA extraction.
3.4.3 APOE genotyping
APOE genotype was determined using a previously described PCR method 
(Nicoll et al 1997). The protocol is outlined in appendix 3. The digested amplified 
fragments had lengths of 91 base pairs (bp), 81bp, 72bp, 48bp and 33bp. All 
genotypes shared fragments of 16bp and 21 bp (figure 2).
3.4.4 IL-1A and IL-1B genotyping
IL-1A and IL-1B genotyping used a previously described technique (Nicoll et 
al 2000) described in appendix 3. A number of common polymorphisms have been 
described for both the IL-1A and IL-IB genes. This study looked at the
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polymorphisms which have been suggested to confer an increased risk for AD and 
have been associated with inflammatory disease (Nicoll et al 2000): for IL-1A this is a 
C-to-T transition at position -889  (relative to the start site for transcription); for IL-1B 
this is at position +3953. The IL-1A polymorphism is a promoter polymorphism and 
may alter the rate and quantity o f gene transcription. The IL-IB  polymorphism is a 
coding polymorphism which may alter the conformation o f the protein thereby 
potentially altering function. For 1L-1A the digested amplified fragments had lengths 
o f 104bp and 83 bp (figure 3a). For 1L-1B the digested amplified fragments had 
lengths o f 182bp, 97bp and 85 bp (figure 3b).
2/2 2/3 2/4 3/3 3/4 4/4 
Figure 2; a gel demonstrating the digested amplified fragments seen in APOE  
genotyping. 2/2 has bands at 91 and 81 base pairs (bp); 2/3 at 91, 81 and 48 bp; 2/4 at 
91, 81 72 and 48 bp; 3/3 at 91 and 48 bp; 3/4 at 91, 72 and 48 bp; and 4/4 at 72, 48 
and 33 bp. The right hand column is a molecular weight ladder.
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[IL-1A] 2/2 1/2 1/1 2/2 1/2 1/1 [IL-lBj
Figure 3; a gel demonstrating the digested amplified fragments seen in IL-1A and IL- 
1B genotyping. The IL-1A genotypes are seen on the left, the IL-1B genotypes on the 
right. For IL-1A\ 2/2 has a band at 104 base pairs (bp); 1/2 at 104 and 83 bp; 1/1 at 83 
bp. For IL-1B; 2/2 has a band at 182 bp; 1/2 at 182, 97 and 85 bp; 1/1 at 97 and 85 bp. 
The right hand column is a molecular weight ladder.
3.5 Immunohistochemistry
Immunohistochemistry is a frequently used technique in which proteins can be 
identified by their specific binding to an antibody labelled with a marker. The 
antibodies used in this study were all monoclonal and therefore o f  greater specificity 
than polyclonal antibodies. Briefly immunohistochemistry involves the application o f 
an antibody labelled with a marker to a paraffin section, with the antibody being 
localised by a second chemical reaction, resulting in a colour change on the paraffin 
section. In this study counterstaining with haematoxylin was weak to allow greater 
sensitivity o f image analysis as discussed below (3.6).
3.5.1 Tau immunohistochemistry
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Immunohistochemistry was undertaken for tau (monoclonal antibody, Dako 1: 
15000). No pre-treatment was required and the primary antibody was applied 
overnight at 4°C. This antibody reacts with both the phosphorylated and non- 
phosphorylated forms of tau protein, and labels the tau protein of neurofibrillary 
tangles. The antibody was detected using the ABC kit (Vecta Stain, Vector 
Laboratories, Peterborough, UK) and developed with diaminobenzidine (DAB).
3.5.2 Neuroinflammation immunohistochemistry
Immunohistochemistry was undertaken for markers of microglial activation. 
Sections were immunostained with anti-CD68 to identify microglia with phagocytic 
functions (mouse monoclonal antibody to a macrophage-specific 110 kDa 
glycoprotein - Dako, 1:1000) and CR3/43 which labels activated microglia (mouse 
monoclonal antibody to class IIMHC: HLA-DR, -DQ and -DP p chains - Dako,
1:800). The antibodies were detected using the ABC kit (Vecta Stain, Vector 
Laboratories, Peterborough, UK) and developed with diaminobenzidine (DAB).
3.6 Image analysis
Image analysis is a technique which allows capture and manipulation of digital 
images. Image analysis was undertaken to assess the immunostaining load within 
defined anatomical regions in cases of TBI and to compare these with control cases. 
The regions of interest were the hippocampus including the alveus, the inferior 
temporal gyrus including both grey and white matter, the corpus callosum at the level 
of the lateral geniculate body, and the grey and white matter of the cingulate gyrus 
again at the level of the lateral geniculate body.
3.6.1 Image capture and generation of tiled images
The morphometric study used an image analysis system consisting of a digital 
CCD-Camera (CoolSnap-Pro®) linking an Olympus BX 40 Light Microscope to a PC
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with the image analysis software ( Image-Pro® Plus, Media Cybernetics) (figure 4).
Figure 4; The image analysis system used to analyse the immunohistochemistry. The 
microscope is connected to the computer and converts histological slides to digital 
images.
Immunostained sections were placed on an automated stage (Prior®) which 
could move in both the X- and Y- axis. Multiple non-overlapping colour images o f the 
area o f interest were captured using x 10 stage objective lens and the images were 
tiled together automatically to give a large composite image (figure 5). Images were 
stored using the RGB 24 (red, green, blue) colour model. This system allows the 
production o f colour images as every colour can be produced by varying levels o f red, 
green and blue. The bitmaps (digital grids o f  which each individual element is called a 
pixel) have pixels which contain varying brightness values for each o f red, green and
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blue. The brightness values range from 0 to 255 for each colour and allow detailed 
colour images to be created digitally.
Figure 5; This is a composite tiled image o f  a section o f hippocampus including the 
alveus. Non-overlapping images are captured at xlO and tiled together automatically 
to produce a composite image. This example is produced by tiling 63 separate images; 
rows o f  9 images in the x-axis and 7 images in the y-axis. The image is stored as a 
jpeg file and can be magnified to x40 for segmentation. Areas o f interest (AOI) can 
then be defined manually for assessment o f  immunoload.
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Each image had a field 0.32 mm (width 0.66 mm, height 0.49 mm) and 
contained 1447690 pixels (width 1392 pixels, height 1040 pixels). The number of 
images taken for each anatomical area was variable due to anatomical variation 
between cases, but generally in the region of 50-60 images were taken for each 
composite image. The composite image was stored as a data file in jpeg format. Lamp 
intensity, digital camera set-up and calibration parameters were kept constant 
throughout the capture of images.
3.6.2 Area of interest function
Using the stored image an “area of interest” (AOI) could be defined for data 
generation. The AOI tool allowed a freehand or geometric area to be defined; the area 
defined was dependent on the anatomical area being studied. For example, zones of 
the hippocampus required freehand areas to be defined whereas corpus callosum was 
more suited to a defined geometric area for analysis. Each AOI was defined in terms 
of pixels such that the number of pixels forming the X- and Y- axes of the shape were 
known. The system was calibrated such that this figure could be converted to 
microns (pm) or millimetres (mm).
3.6.3 Assessment of immunostaining load
The image analysis software (Image-Pro® Plus, Media Cybernetics) used in 
this study allowed the definition of immunoreactive profiles based on a defined 
threshold (segmentation). Segmentation is a process which allows the isolation of 
certain colours from an image as a whole. In this study the immunoreaction was 
developed by diaminobenzidine (DAB) which produces a brown precipitate. A 
manual segmentation technique was used to isolate the brown immunoreaction in the 
captured images. The sections were all weakly counterstained with haematoxylin to 
allow greater differentiation between the brown immunostaining reaction and the
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bluish background. The stored images were magnified to allow greater sensitivity 
during the segmentation process. The colour cube-based model was used for these 
images. This allows a square measuring 3x3 pixels to be assessed for segmentation; 
this produces great sensitivity in differentiating between an area of brown 
immunostaining and adjacent haematoxylin counterstaining.
While this programme did allow the threshold setting to be applied as a constant 
to all images this was not done due to immunostaining intensity variation between 
batches of immunostaining. Therefore each slide had unique parameters set for 
segmentation based on the intensity of immunostaining. While this was more labour 
intensive it allowed greater sensitivity in the segmentation process. All results were 
generated by one analyst to remove any inter-observer variation. To assess intra­
observer variation, the same field of the same slide was analysed at the start of each 
session, and the load scores checked to see if they were similar. This showed less 
than 5% variation over a ten day period.
Immunostaining load within a given AOI was determined using the “Per 
Area” function found in the measurements tools. This gave information regarding the 
ratio between the area of the counted object (the immunostained area) to that of the 
entire area of the pre-defined AOI.
3.7 Statistical analysis
The study was designed as an observational study. Statistical analysis varied 
dependent on the variables being assessed and the spread of data. The statistical 
assessment of each study is presented in the results section and statistical data is 
presented in appendix 4.
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4 Results
4.1 Genotyping
Of the initial 259 cases 239 were successfully genotyped (92% success rate) 
for APOE. IL-1A and IL-1B genotyping was attempted on all of the cases which had 
been successfully genotyped for APOE (239 cases in total). YoxIL-lA  228 (95%) 
cases were successfully genotyped; for IL-1B 207 (87%) cases were successfully 
genotyped. Cases were considered to have been unsuccessful after four failed attempts 
including extended proteinase K digestion and DNA extraction from different blocks.
4.2 Association of APOE e4 and cerebrovascular pathology in traumatic brain 
injury
Of the total number of 239 cases of fatal TBI examined there were 83 APOE 
s4 carriers (35%) and 156 were non-carriers of APOE s4 (65%). The pathological 
features for each case documented on the database were assessed in relation to APOE 
s4 allele carriage presence or absence. The power of a study refers to the chance of 
detecting a specified effect if it exists, in this case that possession of s4 was associated 
with specific pathological features. The study had 70% power to detect differences of 
approximately 15-19% in patterns of response between s4 carriers and non-carriers. 
Comparison of the prevalence of the features was made using confidence intervals 
(Cl) for the differences in proportions. Calculations were performed using Minitab 
(Version 12). The Cl is presented for each feature in table 9.
Differences were noted between APOE s4 carriers and non-carriers of APOE 
s4 in relation to contusions and ischaemic brain damage (table 9). 42% of s4 carriers 
had moderate or severe contusions {i.e. a total contusion index of >20) compared with 
29% of non-carriers of s4 (p=0.05). With regard to ischaemic brain damage a trend
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was noted between the possession of APOE e4 and severe ischaemic brain damage 
which was present in 54% of APOE s4 carriers and 42% of non-carriers of s4 
(p=0.08). No significant associations were demonstrated between possession of 
APOE s4 and the presence of extradural haematoma, subdural haematoma, 
intracerebral haematoma, skull fracture, traumatic axonal injury or evidence of raised 
intracranial pressure.
Table 9; The incidence of specific pathological features in relation to the presence 
and absence of APOE s4. There is a significant association between the possession of 
e4 and moderate/severe contusions in fatal TBI, and a greater incidence of severe 
ischaemic brain damage.
Pathological Feature APOE e4 
carriers 
n=83 (35%)
APOE e4  
non-carriers 
n=156 (65%)
95% Confidence 
Interval for 
difference
p-value
Moderate/severe
contusions
35 (42%) 46 (29%) 0 to25% 0.05
Severe ischaemic brain 
damage
45 (54%) 66 (42%) -1 to25% 0.08
Skull fracture 61 (73%) 105 (67%) - 6 tol8% 0.31
Traumatic axonal injury 31 (37%) 68 (44%) - 19 to 7% 0.35
Extradural haemorrhage 13 (16%) 13 (8%) -4 to 14% 0.31
Subdural haemorrhage 52 (60%) 98 (63%) -13 to 13% 0.98
Intracerebral haemorrhage 31 (37%) 47 (30%) -5 to 20% 0.26
Raised intracranial 
pressure
58 (70%) 98 (63%) -5 to 20% 0.27
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4.3 Cytoskeletal pathology
Four patterns of tau immunoreactivity were seen (figure 6);
1/ neuronal perikaryal immunoreactivity.
2/ neuropil threads with a pattern similar to that seen of the dendritic neuropil threads 
seen in AD.
3/ glial cell immunoreactivity with associated punctate staining in white matter.
4/ diffuse neuropil staining although thte cell processes involved could not be 
established by immunohistochemistry.
55
Figure 6a; Photomicrograph from the medial temporal cortex demonstrating both 
neuronal perikaryal immunoreactivity and neuropil threads. Tau immunoreactive 
fibrillary structures (neurofibrillary tangles) are seen in 4 neuronal cell bodies, and 
neuropil threads are numerous. Tau immunostaining x20.
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Figure 6b; Photomicrograph from cerebral white matter showing tau 
immunoreactivity within glial cell bodies. In addition there is a punctate pattern o f 
staining within the white matter. Tau immunostaining x20.
57
Figure 6c; Photomicrograph from the hippocampus showing diffuse tau 
immunoreactivity in the stratum pyramidalis o f the cornu ammonis. Tau 
immunostaining x20.
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Neuronal perikaryal immunoreactivity was seen in the form of fibrillary 
structures (neurofibrillary tangles). These were identified by anatomical region and 
analysed semi-quantitatively as total number per xlO field. Neuronal perikaryal 
immunoreactivity was seen in both TBI and control cases and, in both groups, 
increased with age (table 10).
Neuropil threads were assessed as being either present or absent. Neuropil 
threads, like neuronal perikaryal immunoreactivity, were seen in both TBI and control 
cases and, in both groups, increased with age.
Glial cell immunoreactivity was assessed as either present or absent. Glial tau 
immunoreactivity was seen in 9 of 45 (20%) TBI cases and in only 1 of 15 (6.7%) 
control cases.
Diffuse neuropil staining was assessed as either present or absent. This pattern 
of immunoreactivity was seen at all ages in both TBI and control cases.
The number of cases examined in this part of the study was small so no formal 
statistical analysis was carried out. If the trend is maintained with an increased sample 
size then this may indicate increased glial tau immunoreactivity with ageing.
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4.4 Neuroinflammation
4.4.1 Immunohistochemistry
CD 68 and CR3/43 immunohistochemistry was undertaken on all 55 pre­
selected cases for the neuroinflammation study. Microglial cells were seen with 
differing morphological appearances; these ranged from resting ramified cells through 
to rounded phagocytosing amoeboid cells (figure 7). There was considerable variation 
in CD 68 and CR3/43 immunoreactivity within cases and a range o f staining 
intensities is presented in figure 8.
Figure 7a; ramified microglial cells. CR3/43 immunostaining x40
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Figure 7b; amoeboid (phagocytosing) microglial cells. CD 68 immunostaining x40.
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Figure 8e- high intensity Figure 8f- high intensity
Figure 8; Examples o f the variation o f immunostaining seen between cases. The left 
column (figures 8 a, c and e) was stained with CD 68; the right column (figures 8 b, d 
and f) was stained with CR3/43. All figures are xlO.
4.4.2 Control cases
An average of the CR3/43 immunoload in the control cases for each 
anatomical region is shown in table 11 and for CD 68 in table 12. For statistical 
analysis the immunoloads were summarised for each case by averaging the individual 
values of each anatomical region. Statistical analysis compared all control cases under 
the age of 50 (n=l 1) against all control cases over the age of 50 (n=9). Median values 
for each group were analysed using a non-parametric test (Mann-Whitney test). There 
was no significant difference observed between the two groups for CR3/43 (p=0.29). 
For CD 68, however, there was a reduction in the immunoload with ageing and this 
reached statistical significance (p=0.05) [see appendix 9.4.1].
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Table 11; CR3/43 immunoreactivity in selected anatomical areas in the control group. 
There is an increase with ageing seen in the temporal lobe and hippocampus, sites 
commonly involved in Alzheimer’s disease. Comparison of the overall immunoloads 
between those less than 50 years old and those greater than 50 years old, however, 
showed no significant difference. The numbers refer to the immunostaining intensity 
presented as a percentage of the total area. The values presented are the median values 
of the dataset. Mean values were not used due to the small number of cases studied
and the skewed distribution of values.
cc eg cw tg tw alveus hippo
0-19 5.86 1.07 2.70 0.46 1.00 0.69 0.52
20-49 2.35 0.48 1.70 0.17 0.60 1.84 1.01
50+ 5.35 1.15 2.05 1.01 2.94 2.19 2.18
Legend: cc= corpus callosum cg= cingulate grey matter
cw= cingulate white matter tg= temporal grey matter 
tw= temporal white matter hippo= hippocampus
Table 12; CD68 immunoreactivity in selected anatomical areas in the control group. 
Comparison of the overall immunoloads between those less than 50 years old and 
those greater than 50 years old showed a significant reduction in the immunoload in 
the older age group. The numbers refer to the immunostaining intensity presented as a 
percentage of the total area. The values presented are the median values of the dataset. 
Mean values were not used due to the small number of cases studied and the skewed 
distribution of values.
cc eg cw tg tw alveus hippo
0-19 0.08 0.24 0.46 0.63 1.23 3.80 2.58
20-49 1.15 0.27 0.57 0.06 0.18 0.09 0.08
50+ 0.68 0.34 0.98 0.10 0.29 0.19 0.20
Legend: cc= corpus callosum cg= cingulate grey matter
cw= cingulate white matter tg= temporal grey matter 
tw= temporal white matter hippo= hippocampus
4.4.3 Control v TBI cases
The next part of the study looked to see if there was a difference in the 
neuroinflammatory response between the control group and the TBI group. For 
statistical analysis the immunoloads were summarised for each case by averaging the 
individual values of each anatomical region. Statistical analysis compared all control 
cases (n=20) against all TBI cases (n=55). Cases were not separated by age. Median 
values for each group were analysed using a non-parametric test (Mann-Whitney test). 
A significant difference was seen with CD 68 there being a significant increase in CD 
68 immunoload in the TBI cases (p= 0.03). There was no significant difference in 
CR3/43 immunoload between TBI and control cases (p= 0.42) [see appendix 9.4.2].
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4.4.4 Traumatic axonal injury
Within the group of 55 TBI cases 30 had a pathological diagnosis of diffuse 
TAI. Image analysis of CR3/43 of diffuse TAI cases when compared to non-TAI 
cases showed an increased immunoload in regions related to the central white matter; 
corpus callosum (p=0.01) and cingulate white matter (parasagittal white matter) 
(p=0.02) (table 13). In addition there was a significant increase in immunoload in the 
cingulate grey matter (p=0.02). These include white matter regions which consistently 
show significantly more axonal damage in diffuse TAI. CD 68 did show a similar 
increase in cases of diffuse TAI although these were less pronounced than those seen 
for CR3/43 (table 14). The increased CD 68 immunoreactivity was significant in the 
cingulate grey (p=0.05) and white matter (p=0.04). The statistical methods appear in 
the appendix in sections 9.4.3 and 9.4.4.
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Table 13; CR3/43 immunostaining. Comparison between cases diagnosed with and 
without diffuse traumatic axonal injury (TAI). The numbers refer to the 
immunostaining intensity presented as a percentage of the total area. The values 
presented are the median values of the dataset. Mean values were not used due to the 
small number of cases studied and the skewed distribution of values.
cc eg cw tg tw alveus hippo
+TAI
(n=30)
4.76 1.11 3.38 0.34 2.35 2.16 0.70
-TAI
(n=25)
1.00 0.10 0.24 0.13 0.84 1.15 0.30
p-values 0.01 0.02 0.02 0.11 0.11 0.45 0.50
Legend: cc= corpus callosum
cg= cingulate grey matter 
cw= cingulate white matter 
tg= temporal grey matter 
tw= temporal white matter 
hippo= hippocampus 
TAI= traumatic axonal injury
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Graph 1: The average neuroinflammatoiy response is charted against age for each 
case, with cases of TAI being separated from cases of non-TAI.
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Table 14; CD68 immunostaining. Comparison between cases diagnosed with and 
without diffuse traumatic axonal injury (TAI). The numbers refer to the 
immunostaining intensity presented as a percentage of the total area. The values 
presented are the median values of the dataset. Mean values were not used due to the 
small number of cases studied and the skewed distribution of values.
cc eg cw tg tw alveus hippo
+TAI
(n=30)
1.46 0.52 0.93 0.24 0.74 0.61 0.21
-TAI
(n=25)
0.93 0.22 0.58 0.10 0.27 0.45 0.21
p-value 0.08 0.05 0.04 0.23 0.09 0.29 0.47
Legend: cc= corpus callosum
cg= cingulate grey matter 
cw= cingulate white matter 
tg= temporal grey matter 
tw= temporal white matter 
hippo= hippocampus 
TAI= traumatic axonal injury
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case, with cases of TAI being separated from cases of non-TAI.
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4.4.5 Genotype data
4.4.5.1IL-1A and IL-1B genotypes
For IL-1A the results were as follows;
Controls Trauma cases
1.1 9 (47.5%) 30 (56%)
1.2 9 (47.5%) 20 (35%)
2.2 1 (5%) 5 (9%)
This gave an allele frequency of 0.71 and 0.29 for alleles 1 and 2 respectively 
in the control cases and 0.73 and 0.27 for the trauma cases. A chi-squared test 
demonstrated no significant difference between the control group and the TBI group 
regarding possession of IL-1A allele 2 (p= 0.59) [see appendix 9.4.5]. For assessment 
of the neuroinflammatory response the immunoloads were summarised for each case 
by averaging the individual values of each anatomical region. Median values of the 
immunoloads for each polymorphism in the control and TBI groups are shown in 
table 15. The neuroinflammatory response was assessed in individuals who possessed 
any copies of IL-1A allele 2 and in individuals who were II-1A allele 2 homozygotes. 
There was no significant difference in the median neuroinflammatory response in 
individuals who possessed any copies oilL -lA  allele 2 and those who had no copies 
when control and TBI cases were considered together and when TBI cases were 
considered against other TBI cases (see table 16). The statistical methods appear in 
the appendix in sections 9.4.6 (any copy of allele 2) and 9.4.7 (homozygotes).
For IL-1B the results were as follows;
Controls Trauma cases
1.1 10(67%) 30(69%)
1.2 3 (20%) 11(26%)
71
2,2 2 (13%) 2 (5%)
This gave an allele frequency of 0.77 and 0.23 for alleles 1 and 2 respectively 
in the control cases and 0.83 and 0.17 for the trauma cases. A chi-squared test 
demonstrated no significant difference between the control group and the TBI group 
regarding possession o ilL -lB  allele 2 (p= 0.82) [see appendix 9.4.5]. For assessment 
of the neuroinflammatory response the immunoloads were summarised for each case 
by averaging the individual values of each anatomical region. Median values of the 
immunoloads for each polymorphism in the control and TBI groups are shown in 
table 15. The neuroinflammatory response was assessed in individuals who possessed 
any copies of IL-1B allele 2 and in individuals who were IL-1B allele 2 homozygotes. 
There was no significant difference in the median neuroinflammatory response in 
individuals who possessed any copies of IL-1B allele 2 and those who had no copies 
when control and TBI cases were considered together and when TBI cases were 
considered against non-TBI cases (see table 16). The statistical methods appear in the 
appendix in sections 9.4.6 (any copy of allele 2) and 9.4.7 (homozygotes).
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Table 16; Statistical analysis could not demonstrate any significant difference in 
median intensity of the neuroinflammatory response between IL-1A and IL-1B allele 2 
homozygotes and heterozygotes. Statistical analysis was carried out on all cases (TBI 
and control 2,2 cases against TBI and control non-2,2 cases) and on TBI only cases 
(TBI 2,2 cases against TBI non-2,2 cases).
CD 6 8 CR3/43
IL-1A 2,2 All cases
(n=6 vs 68)
II © o p=0 . 2 1
TBI cases
(n=5 vs 50)
p=0 . 2 1 p=0.24
IL-1B 2,2 All cases
(n=4 vs 54)
p=0.53 II p
TBI cases
(n=2 vs 41)
p=0.19 p=0.16
IL-1A allele 2 
any copy
All cases
(n=35 vs 39)
p=0.75 p=0.72
TBI cases
(n=25 vs 30)
p=0.25 p=0.24
IL-1B allele 2 
any copy
All cases
(n=18 vs 40)
p=0.19 p=0.40
TBI cases 
(n=13 vs 30)
p=0 . 2 2 p=0.25
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4.4.5.2 APOE genotypes
For APOE the results were as follows;
Controls Trauma c
2 , 2 1 (5%) 0
2,3 1 (5%) 9 (16%)
2,4 0 1 (2 %)
3,3 13 (65%) 32 (58%)
3,4 3 (15%) 1 2  (2 2 %)
4,4 2  (1 0 %) 1 (2 %)
This gave an allele frequency of 0.08, 0.75 and 0.17 for alleles 2, 3 and 4 
respectively in the control cases and 0.09, 0.77 and 0.14 for the trauma cases. The 
neuroinflammatory response was assessed in individuals who possessed any copy of 
APOEe4 or any copy of APOEzl in the control and TBI groups. Possession of 
APOEz4 was not associated with any statistically significant difference in the median 
neuroinflammatory response in either control or TBI groups. In addition there was no 
significant difference in the neuroinflammatory response between TAI and non-TAI 
cases. Similar results were obtained for APOEzl. The statistical methods appear in the 
appendix in sections 9.4.8 and 9.4.9.
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Table 17; No significant differences in the neuroinflammatory response could be 
demonstrated based on possession of any copy of either APOEs4 or APOEzl. 
Statistical analysis was performed on control cases, TBI cases and TAI cases,
comparing the neuroinflammatory response in those cases with any copy of either 
APOEs4 or APOEsl against that in those cases which did not possess a copy.
Control TBI TAI
Any copy of 
APOE&4
CR343 p=0 . 1 2 p=0.14 p=0.34
CD6 8 p=0 . 1 2 p=0.47 p=0.27
Any copy of 
APOE&2
CR343 p=0.41 p=0.75 p=1 . 0 0
CD6 8 p=0.34 p=0.37 p=0.53
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5 Discussion
A limitation of this study relates to the fact that the pathology of only the most severe 
outcome from TBI group could be assessed (i.e. a fatal outcome). A United Kingdom 
based study found a fatal outcome occurs in only 5-10% of the total hospitalised TBI 
population, although approximately 50% of TBI related deaths occur before the 
patient can be transferred to hospital (Jennett and MacMillan 1981). Many of these 
initial deaths are due to very severe injuries and occur almost instantaneously while 
improvements in trauma care have reduced the numbers of deaths occuring several 
hours after the injury (Wyatt et al 1995). A USA based report found that annually 1.5 
million people sustained a head injury of which 230000 were hospitalised and 
survived (15%) and 50000 (3%) died from their injuries (CDC report 1999).
Therefore this autopsy-based study is only addressing a small proportion of the head 
injured population. An important question is whether the association identified in this 
study is of relevance to survivors of TBI.
5.1 Cytoskeletal pathology in acute brain injury
This study has assessed tau immunoreactivity in the hippocampus and adjacent 
temporal lobe in cases of fatal TBI with survival times ranging from <24 hours up to 
one month. In humans, unlike the previously reported animal studies, tau 
immunoreactivity is a feature of control brains, that is brains with neither clinical nor 
gross neuropathological abnormalities. The control brains demonstrated perikaryal, 
neuropil thread and diffuse neuropil tau immunoreactivity. Tau perikaryal and 
neuropil thread immunoreactivity increased with age, while diffuse tau neuropil 
immunoreactivity was seen at all ages. Tau glial immunoreactivity, however, did 
appear to be associated with acute TBI and immunoreactivity could be detected in 
cases with a survival of <24 hours. There was no demonstrable perikaryal
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accumulation of phosphorylated tau after acute TBI in these human studies, a finding 
reported in the pig model (Smith et al 1999). Smith et al (1999) used controlled head 
rotational acceleration to induce injury, resulting in diffuse traumatic axonal 
pathology. A range of antibodies was used to assess tau pathology (Tau-2, PHF-1, 
PHF-6 , PHF-13.5). These antibodies recognised different epitopes of tau;
Tau-2 recognises 52-68 kDa phosphorylated and non phosphorylated tau. The 
antibody stains neurofibrillary tangles, neuropil threads and neuritic plaques, 
astrocytes and ribosomes.
PHF-1 recognises an epitope in phosphorylated tau at position serine 396 in human 
tau and serine 387 in rodent tau.
PHF- 6  and PHF-13.5 have not been fully characterised.
The current study has examined human material derived from cases of fatal TBI due 
to different causes of primary insults (road traffic accident, fall, assault) producing 
mixed focal and diffuse pathologies, including diffuse TAI. It is probable that the 
loading conditions determine the brain response, and that the highly controlled 
laboratory situation accentuates a specific brain response. The current study used only 
a single antibody to detect tau (Dako monoclonal antibody); this antibody identifies 
an epitope in the C-terminus region of human tau which contains the four repeated 
sequences involved in microtubule binding. This antibody will react with both 
phosphorylated and non-phosphorylated forms. It may be that a wider panel of 
antibodies, such as that used by Smith et al (1999) may be required to detect specific 
cytoskeletal abnormalities. There are difficulties in replicating the study by Smith et 
al (1999) in that the antibodies used in that study do not work on formalin-fixed 
paraffin-embedded human material. In addition, there may be species differences, 
such that cytoskeletal disruption, if  present in man, may develop over a different time
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course. Smith et al (1999) demonstrated axonal tau immunoreactivity at 3 days post­
trauma, and consistently found expression up to 1 0  days post-trauma (latest time-point 
examined) in animals. The current study included up to one month post-trauma, but 
longer survival times may need to be examined to fully assess the possibility of tau 
expression after TBI.
The study by Newman et al (1995), although looking at TBI in man, utilised a 
different antibody against tau from this study. While the current study utilised an 
antibody that reacts with both phosphorylated and non-phosphorylated forms of tau, 
Newman et al (1995) used Alz50, an antibody which selectively binds specific 
conformations of the tau protein (Carmel et al 1996). The different antibodies may 
identify different stages in the temporal evolution of neurofibrillary pathology.
The cases of mild TBI reported by Geddes et al (1999) were all subjected to 
repetitive relatively mild blows to the head. These cases clearly differ from the mixed 
neuropathologies seen in most cases of human TBI, but demonstrate that in this rather 
specific type of insult TBI is associated with tau pathology. In cases of fatal TBI after 
a single blow to the head structural cytoskeletal disturbances involving tau may be 
initiated. The pathological response to human TAI is known to develop over a period 
of time (Gentleman et al 1995), and the cytoskeletal response may be modified by co­
existent primary and secondary pathologies. Future studies may have to look at 
survival times beyond one month to fully assess the role of tau in the response to TBI, 
and the relationship between a single episode of TBI and the development of 
Alzheimer-type pathology.
In man, genetic influences may play an important role in modifying the 
outcome after TBI. Possession of APO s4 is associated with a worse outcome after 
TBI (Teasdale et al 1997), and with an increased severity of chronic neurological
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deficits in high-exposure boxers (Jordan et al 1997), with high-exposure being 
defined as participation in at least 12 professional bouts. The role of APOE 
polymorphisms in modifying cytoskeletal responses after TBI was not addressed in 
the current study but may be an area of future research.
5.2 Association of APOE e4 and cerebrovascular pathology in traumatic brain 
injury
Among the pathological features which are present in fatal cases of TBI this 
study has identified an association between possession of APOE s4 and the severity of 
contusions and a trend for an association with severe ischaemic brain damage. These 
findings suggest that cerebrovascular and haematological mechanisms may underlie, 
at least in part, the association of APOE s4 with poor outcome after TBI. A recent 
study, performed in the same institute, of CT scans of survivors of TBI (Liaquat et al
2002) showed that although patients with APOE s4 were no more likely to have 
intracranial haemorrhages than-non carriers of APOE s4, if  haemorrhages were 
present then they were of greater volume in those patients with APOE s4. This study, 
therefore, provides a degree of clinical correlation with our autopsy based work, and 
suggests that our findings may well be relevant to survivors of TBI.
Although prospective clinical studies of outcome after TBI have identified 
APOE s4 carriers as more likely to fall into poor outcome or poor recovery groups 
(Teasdale et al 1997, Sorbi et al 1995), they have not yet specifically addressed the 
question of whether APOE s4 carriers are more likely to have a fatal outcome. The 
previous clinical studies have looked at the prevalence of e4 carriers in poor outcome 
(severe, vegetative, or fatal) after TBI (Teasdale et al 1997) or in the vegetative state 
patients only (Sorbi et al 1995). The present study, looking at only the fatal
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outcome group, did not find an over-representation of s4 carriers, the APOE s4 
carriage rate (35%) being similar to that of all head-injured patients admitted to the 
same institution (33%, n=984, Teasdale et al, unpublished observations). Therefore, 
although APOE ^-associated vascular pathology may influence the outcome in 
survivors it seems unlikely to significantly increase the probability of a fatal outcome 
after TBI. However, the situation after spontaneous intracerebral haemorrhage appears 
to be different; there is evidence that among patients with stroke due to spontaneous 
intracerebral haemorrhage APOE £4 carriers are substantially more likely to die in 
hospital (McCarron et al 1999, McCarron et al 2003).
These findings point towards an important role for apoE in cerebrovascular 
and haematological mechanisms which are of relevance in the response to an episode 
of brain injury. More specifically, existing evidence indicates that apoE may play an 
important role in relation to both blood vessel wall integrity and coagulation of blood.
One role of apoE is as a lipid transport protein and apoE is therefore involved 
in the transport of the fat soluble vitamins together with lipids, from the small 
intestine to the liver. This mechanism is suggested to underlie the relatively low 
levels of plasma vitamin K in APOE s4 carriers (Shearer 1995). Vitamin K is required 
by the liver for the synthesis of clotting factors and prothrombin times have been 
reported to vary with APOE genotype (Giraud et al 1998). Prolonged clotting times 
were also identified in APOE s4 carriers after stroke (Weir et al 2001) providing 
further evidence that APOE genotype is of relevance to the coagulation cascade. The 
possibility that contusions in head-injured patients with APOE s4 are more severe as a 
result of relatively deficient clotting mechanisms provides the basis for a testable 
hypothesis.
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A further mechanism of possible relevance to the findings of this study relates 
to the increased prevalence of atherosclerosis and cerebral amyloid angiopathy in 
carriers of APOE e4 (Horsburgh et al 2000b). Such vascular pathology might pre­
date the head injury and promote contusional haemorrhage by increasing vascular 
fragility and decreasing the capacity for reactive vasoconstriction. Post mortem 
studies have confirmed the association of APOE s4 with cerebral amyloid angiopathy 
in patients who died from TBI and have suggested that this is associated with 
increased severity of contusions (Leclercq et al 2002).
Animal models, using APOE knockout and transgenic mice, have provided 
further information about apoE mechanisms and the response of the brain to injury 
(Horsburgh et al 2000b). ApoE deficient mice were found to have larger infarcts than 
wild-type mice (Laskowitz et al 1997) and a greater extent of neuronal damage after 
controlled ischaemia (Horsburgh et al 1999b), which can be ameliorated by 
continuous intracerebral infusion of apoE (Horsburgh et al 2000c). Using transgenic 
mice differences have been demonstrated between the response to ischaemia and 
excitotoxicity in mice with human APOEs3 and APOE£4 genes, such that the 
APOEs4 mice have larger lesions (Horsburgh et al 2000d, Buttini et al 1999) than 
APOEe3 mice (Buttini et al 2000). These animal studies correlate with the findings of 
this study that there is a trend for greater ischaemic damage after fatal TBI in 
individuals who possess APOEs4.
Further elucidation of potential vascular and haematological mechanisms 
which may underlie the role of apoE in response to brain injury could result in the 
development of new therapeutic interventions which may modify the outcome after 
TBI.
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5.3 Neuroinflammation
This study has shown that there is a significant up-regulation of the 
neuroinflammatory response as identified with CD 6 8  immunoreactivity after TBI 
when compared to non-trauma controls. Within the group of TBI cases a difference 
was seen between TAI cases and non-TAI cases with both CD 6 8  and CR3/43 being 
up-regulated in TAI cases.
After TBI the increase in CD 6 8  immunoreactivity signifies increased 
phagocytic activity. This phagocytic activity may be a function of both microglia and 
macrophages and is a response to damaged tissue. The tissue damage may be diffuse 
(ischaemia or TAI) or may be focal in response to lesions such as contusions or other 
focal infarcts. In TAI cases, however, the neuroinflammatory response was not due to 
phagocytic activity alone. Indeed, the dominant response was increased expression of 
MHC class II, as assessed by CR3/43 immunoreactivity. The increased 
neuroinflammatory response was seen within one week of injury and persisted for 
many months after the injury.
MHC class II molecules are used to present a processed antigen to T- 
lymphocytes resulting in lymphocyte activation, acting as a form of 
immunosurveillance. The majority of cells expressing MHC class II in the central 
nervous system are microglia although increasingly evidence is being generated 
supporting the view that astrocytes can express these molecules in some situations 
(Dong and Benveniste 2001). Assessing the resting levels of MHC class II expression 
in human brains is difficult as even control (non-trauma) brains will have been 
subjected to some form of agonal event which may have resulted in microglial 
activation. A further confounding factor is the increasing realisation that inflammation 
within the CNS can be modified by systemic inflammatory responses (Perry et al
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2003). Clinical studies of AD patients have demonstrated further impairment of 
cognitive function after systemic infection that persists for up to 2  months and is 
associated with elevated serum levels of IL-ip (Holmes et al 2003). The cases used as 
controls in this study were defined as having no neurological disease during life and 
no significant neuropathology demonstrated at autopsy. However, on review some of 
these cases died after pneumonia and others had systemic haematological 
malignancies or inflammatory conditions. It is possible, therefore, that some of the 
control cases had a significant neuroinflammatory response to systemic disorders such 
as infection and malignancy. Systemic disorders did not appear to affect the CNS in a 
predictable fashion such that some cases of systemic haematological malignancy were 
associated with increased microglial reaction while others were not. Future studies 
assessing the neuroinflammatory response may need to apply more stringent 
definitions to their control tissue.
Despite these limitations the age matched control cases used in this study have 
results which suggest that MHC class II expression is normally low in the human 
brain and that while there is an age-related increase in MHC class II expression in 
temporal and hippocampal regions this did not reach statistical significance. These are 
regions frequently affected in AD and MHC class II expressing microglia have been 
described in relation to neuritic plaques (Haga et al 1989, McGeer et al 1988) in AD, 
a condition predominantly associated with ageing.
Activation of microglial cells can be produced by a variety of mechanisms. In 
a study of patients with a severe head injury IL- 8  was noted to be markedly 
upregulated acutely, with a xlOOO increase in CSF when compared to peripheral blood 
levels (Kushi et al 2003). The authors, therefore, postulated a role of this cytokine in 
initiating the neuroinflammatory response. S100B activation of microglia and other
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glial cells after ischaemia was investigated in S100B transgenic, knockout and wild- 
type mice (Wainwright et al 2004). The transgenic mice showed significantly 
increased mortality compared with knockout and wild-type mice, and also exhibited 
greater cerebral injury and volume loss in the ischaemic hemisphere after an 8 -day 
recovery period. The neuroinflammatory response was greatest in the transgenic mice.
Cultured microglial cells have been shown to express alpha 7 nicotinic 
acetylcholinergic receptors (Shytle et al 2004) and acetyl choline and nicotine pre­
treatment can inhibit the lipopolysaccharide induced microglial response. An alpha 7 
selective nicotinic antagonist can attenuate this inhibitory effect. Therefore, the 
intrinsic cholinergic system within the CNS may modulate the neuroinflammatory 
response. As discussed earlier, this system is frequently damaged in severe TBI and 
may result in loss of inhibition of the neuroinflammatory response. A second receptor 
system which may modulate the microglial response is the purinergic receptor group 
P2X. Activation of the ionotrophic P2 X7 microglial receptor by extracellular ATP 
increases diacylglycerol lipase activity and inhibits monoacyl glycerol lipase (Witting 
et al 2004). This results in increased levels of 2-arachidonoylglycerol being produced 
by microglia. This molecule is currently thought to be instrumental in co-ordinating 
the neuroinflammatory response. 2 -arachidonoylglycerol, via cannabinoid receptors, 
can reduce excitotoxicity damage by reducing glutamate release (Marsicano et al
2003), reduce cerebral oedema by reducing cerebral blood flow (Parmentier-Batteur et 
al 2002), and inhibiting the production of neurotoxic agents by microglia (Klegeris et 
al 2003).
As discussed, microglia may act in a phagocytic capacity or as antigen 
presenting cells (APC). Both of these functions may be beneficial in the response to 
TBI. In the peripheral nervous system (PNS) macrophages mount a phagocytic
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response post-injury. The phagocytosis of damaged tissue is considered to be a 
prerequisite prior to any attempt at axonal regeneration. Within the CNS microglia 
perform a phagocytic function but appear to be unable to mount a response sufficient 
to allow axonal regeneration. The optic nerve crush model in the rat has been used to 
study microglial responses. After crush injury in both PNS and CNS there is a 
significant increase in IL-18, a cytokine involved in microglial activation (Menge et al 
2001). Although the response in the CNS was similar to that seen in the PNS the 
phagocytic response in the CNS was considered to be insufficient to allow successful 
CNS regeneration. Other processes have been described which may underlie the 
difference in axonal recovery between the CNS and PNS. In the adult CNS axonal 
growth is inhibited by the interaction between myelin-associated proteins, such as the 
extracellular domain of Nogo-A (Nogo-6 6 ), oligodendrocyte myelin glycoprotein 
(OMgp) and myelin-associated glycoprotein (MAG), and an axonal membrane 
receptor, Nogo receptor (NgR) (Prinjha et al 2000). An additional transducing factor 
p75, a neurotrophin receptor, is required for this inhibitory effect to be active. p75 
knockout mice are no longer responsive to myelin and blocking the p75-NgR 
interaction also reduces the activities of these inhibitors (Wang et al 2002). Similar 
mechanisms are not found in the peripheral nervous system and may account for the 
differences between central and peripheral axonal responses to injury. It is currently 
uncertain how, after injury to the central nervous system, microglial function may 
interact with this intrinsic inhibitory mechanism such that axonal growth is inhibited. 
In addition there may be further inhibitory signals from the surrounding 
microenvironment.
The most pronounced increase in MHC class II expression after TBI was seen 
in the central white matter regions (corpus callosum and cingulate gyrus) of cases
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which were diagnosed pathologically as having diffuse traumatic axonal injury. As 
expected, given that there would be Wallerian degeneration secondary to axonal 
disruption there was an increase in phagocytic capacity in these regions, although the 
phagocytic response was less pronounced than the MHC class II expression. These 
findings again focus interest on the white matter as a region of great importance in the 
long-term response to TBI. TUNEL positive cells, both oligodendrocytes (Williams et 
al 2001) and macrophages/microglia (Wilson et al 2004), have been detected in the 
white matter of TBI cases many months after the injury.
One interpretation of these findings is that axonal disruption may continue for 
many months after the initially forces associated with TBI have been applied and that 
there is little, if any, axonal recovery; the neuroinflammatory response may contribute 
to or be secondary to this. There has been speculation in the medical literature for 
many years that multiple sclerosis can be initiated or exacerbated by trauma (reviewed 
in Compston et al 1998). Multiple sclerosis is presumed to be an auto-immune 
condition with myelin degradation resulting in axonal degeneration. Inflammation is a 
prominent feature with both overexpression of microglial MHC class II and an influx 
of T lymphocytes, with antigen being presented to the infiltrating lymphocytes by 
MHC class II expressing microglia. Early expression of MHC class II after crush 
injury in rat optic nerve has been correlated with a less severe injury (Shaked et al
2004). Different strains of rats with known variation in response to crush injury were 
studied. Sprague-Dawley (SPD) rats (a strain relatively resistant to CNS injury) were 
compared with Lewis rats (a strain susceptible to injury) at different time points post­
injury. SPD rats had an early transient activation of MHC class II expression in 
microglia which was not seen in the Lewis rats. The authors postulate that the less 
severe injury in the strain with early MHC class II expression is related to T-
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lymphocyte responses which have been described to be protective in some instances 
(Yoles et al 2001 a,b). Auto-immune T-lymphocyte responses underlie the 
demyelination associated with MS. While the finding of over-expression of MHC 
class II after diffuse TAI is of interest in relation to the debate regarding trauma and 
subsequent initiation/exacerbation of multiple sclerosis it is uncertain if  this increased 
expression does predispose to auto-immune myelin destruction.
Other potential functions of MHC class II up-regulation secondary to brain 
injury are speculative. Microglia are usually activated prior to astrocyte activation and 
gliosis although both cellular responses are commonly seen in response to brain 
injury. Microglia may act to control the astrocyte response and to limit the degree of 
gliosis (Lindholm et al 1992) and may be involved in regulating synaptogenesis 
(Nagata et al 1993). Microglia are important to the long-term re-organisation of 
neuronal synptic connections after TBI. TBI results in primary neuronal loss 
(ischaemia, excitotoxicity) with substantial re-organisation of the residual tissue 
including synaptic sprouting and synaptogenesis. Eyupoglu et al (2004) studied 
microglial roles in synaptogenesis in both in vivo entorhinal cortex lesion and 
complex organotypic entorhino-hippocampal slice cultures. Pharmacological blocking 
of microglial activation protected neurones from microglial induced secondary 
dendritic modification and promoted useful re-innervation.
Microglia may also be activated to secrete cytokines which may be neurotoxic. 
Further studies are required to elucidate if the up-regulation of microglia after TBI is a 
protective response or if is ultimately harmful to the brain.
5.3.1 Genetic factors influencing the neuroinflammatory response
IL-1A genotypes were present in frequencies consistent with those described in 
Western European control populations (Rebeck 2000). Therefore, there was no over­
representation oilL -lA  allele 2 in fatal TBI. In addition possession of allele 2, either 
one or two copies, was not associated with an increased neuroinflammatory response 
as assessed by CD 6 8  and MHC class II expression.
As discussed above APOE genotypes may influence the neuroinflammatory 
response with possession of APOE&4 being associated with an over-exuberant 
response and possession of APOE&2 being associated with a less pronounced 
response. ApoE can modulate Ap induced microglial activation. Studies using 
cultured rat glia demonstrated that exogenous apoE suppressed the Ap induced 
production of inducible nitric oxide synthase and cyclo-oxygenase-2 (Guo et al 2004). 
In the absence of Ap, however, exogenous apoE could induce IL-ip expression, with 
apoE4 producing a significantly greater response than apoE3. The authors postulate 
that while Ap stimulation of glial apoE limits the neuroinflammatory response, 
overproduction of apoE by glial cells may ultimately be pro-inflammatory.
This study, however, found no APOE genotype related differences in the 
neuroinflammatory response in the TBI cases. It should be noted that the numbers of 
cases studied were however small and the power of the study was insufficient to 
exclude a potential role of APOE genotypes in modifying the neuroinflammatory 
response.
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6 Conclusions
This study has highlighted a number of potential mechanisms, both cellular 
and genetic, which may modify the response of a patient to an episode of TBI and 
may help to explain the possible association between TBI and AD in later life. 
Possession of APOE e4, although not over-represented in fatal outcome after TBI, 
results in more significant vascular based pathology (contusions, global cerebral 
ischaemia) which may account for the association with a more severe outcome after 
TBI. However, possession of IL-1A allele 2 does not appear to be associated with a 
greater acute neuroinflammatory response after TBI.
There is an increased neuroinflammatory response after TBI which develops 
within the first week after TBI and persists for many months. The response is 
particularly pronounced in the white matter in cases with diffuse TAI, a region in 
which continuing cell death has been demonstrated up to 12 months after an episode 
of TBI. Studies looking at long-term survivors of TBI (many years) are under way to 
assess the time scale of the neuroinflammatory response and to assess any influences 
that IL-1A allele 2 may have in the long-term. In addition studies of the long-term 
survivors will also look for tau-related pathology. Although the present study did not 
find any neurofibrillary tangles related to acute TBI (death within one month) it is 
important to see if Alzheimer-type pathology develops at a younger age in survivors 
of TBI. In addition it will be of interest to follow the glial-related tau pathology 
identified in the acute group in survivors of many years.
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Neurofibrillary pathology
• Neuronal neurofibrillary tangles were not seen after fatal TBI. The 
cases examined included survival up to 1 month after TBI. A longer 
survival period may be required.
• Glial tau inclusions were seen in TBI cases but were not a feature of 
age-matched controls.
N euromflammation
• There was no significant increase in neuroinflammation with ageing in 
control cases.
• Increased phagocytic activity was seen after TBI.
• There was increased expression of MHC class II and increased 
phagocytic activity in TAI cases.
Genetic
• APOE e4 possession does not make vascular based pathology more 
likely after TBI, but if present the lesion is likely to be larger.
• IL-1A allele 2 possession does not appear to modify the 
neuroinflammatory response to TBI.
• APOE polymorphisms do not appear to modify the neuroinflammatory 
response to TBI.
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7 Future Studies
This study has addressed a number of points, outlined in the 
conclusions section, relating to potential shared genetic and protein responses 
in the response to TBI and AD.
Neurofibrillary tangles were not seen in this study. This study assessed 
cases with a survival of up to one month only. Currently studies are underway 
to assess cytoskeletal pathology in individuals who have survived many 
months to years after an episode of TBI. In addition the neuroinflammatory 
response is being assessed in these cases to investigate the timescale of the 
inflammatory response after TBI. This inflammatory response will again be 
correlated with the genetic polymorphisms discussed in this thesis.
A limitation of the interpretation of the genetic polymorphism findings 
relates to the number of cases studied. While analysis of the pathological 
features associated with APOEs4 was based on a large number of cases, the 
analysis of the role of polymorphisms in the neuroinflammatory response was 
based on a small number of cases. Therefore there is potential for recruitment 
o f greater numbers of cases to fully investigate the role of genetic 
polymorphisms in modulating the neuroinflammatory response. As discussed 
in the material and methods section there is increasing difficulty associated 
with consent for research using human tissues. This will limit the availability 
o f tissue for study in post mortem based research. A potential solution to the 
problems of long-term recruitment include multi-centre research with fully 
consented tissue being recruited from a number of centres. Development of a 
consented prospective archive could allow genotyping of all cases from blood 
removed at autopsy, the genotype success rate being considerably higher when
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fresh tissue is used rather than formalin fixed paraffin-embedded tissue as used 
in this study. However, the generation of such a prospective multi-centre 
trauma archive would require willingness and collaboration with the 
medicolegal profession, and in particular with the Coroners and Procurators 
Fiscal, to ensure that such an archive was fully consented.
To supplement any pathological data clinical studies could look at 
long-term outcome after head injury of variable severity correlated with IL-1A 
and IL-1B genotypes. As stated previously autopsy based studies look at only 
the most severe outcome after head injury, death. By incorporating clinical 
studies, particularly long-term neuropsychological studies, with pathological 
studies a clearer picture of the significance of genetic polymorphisms to long­
term outcome after TBI may begin to emerge. The pathological studies are 
beginning to suggest mechanisms that may be important in determining long­
term outcome and possibly areas of pharmacological intervention which may 
improve outcome.
Any future studies looking at the neuroinflammatory response will 
need to define control material carefully. From the studies undertaken in this 
thesis it has become clear that the inflammatory response within the CNS can 
be modified by systemic inflammation/ cytokine release. Therefore control 
cases may have to take into consideration systemic disease such as pneumonia, 
haematological malignancy, sepsis etc. as well any neurological disease during 
life. This will considerably reduce the control material available for studies of 
neuroinflammation. However, careful selection of age-matched controls 
should allow for greater accuracy in the assessment of genetic factors involved 
in the neuroinflammatory response to head injury.
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Study No.
BRAIN DAMAGE IN NON-MISSILE HEAD INJURY
University Department of Neuropathology, 
Institute of Neurological Sciences, 
Southern General Hospital,
Glasgow, G51 4TF.
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20.Diffuse axonal injury
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DAI grade 1 : 2
DAI grade 2m : 3
DAI grade 2M : 4
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Other intracranial complications
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9.3 Appendix 3
PCR protocols
9.3.1 DNA extraction
[1] Microtomy-
17 Clean the knife with analar xylene followed by ethanol before cutting and between 
blocks.
2/ Use sterile forceps for each sample.
3/ Wear gloves and change them every few samples or if you feel they have become 
contaminated.
4/ Cut paraffin sections 10-20 pm thick.
5/ Place section a sterile pre-labelled eppendorf.
[2] De-waxing-
1/ Wear gloves and change them every few samples or if you feel they have become 
contaminated.
2/ Use dedicated pipettes and autoclaved tips.
3/ Add 1ml of analar xylene to each tube and vortex for 1 minute.
4/ Centrifuge at 13000 rpm for 5 minutes.
5/ Decant xylene, add 1ml of ethanol and vortex for 1 minute.
6/ Centrifuge at 13000 rpm for 5 minutes.
7/ Decant ethanol, add 1ml fresh ethanol and vortex for 1 minute.
8/ Centrifuge at 13000 rpm for 3 minutes.
9/ Decant the ethanol, cover with parafilm (pierced) and dry on a heat block at 55- 
60°C for approximately 1 hour.
[3] Proteinase K digestion-
17 Resuspend dried pellet of de-waxed tissue in Proteinase K mix to a final 
concentration of 200 pg/ml.
Mix (per sample); Water 176 pi
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Buffer 20 pi
Proteinase K (lOmg/ml) 4 pi
2/ Pipette a layer of mineral oil (5-6 drops) into eppendorf.
3/ Incubate at 56°C overnight.
4/ Inactivate Proteinase K at 95°C for 10 minutes.
9.3.2 Common steps in PCR process
When setting up a PCR the reagents are made up as a master mix. A master mix 
includes the appropriate volumes of PCR reagents times the number (n) of target 
samples being amplified. When making up a master mix always allow extra to ensure 
that there is sufficient for all your samples i.e. if  you are amplifying 9 samples make 
the master mix (x 10).
For a 15 pi reaction the standard volume of target DNA added is 0.8pl making the 
I total volume up to 15 pi.
I Adjust the water content of the reaction to allow for any variation which may have to
j
| be made to target sample volumes, primer concentrations, or any other constituent of
i
i
the reaction you may wish to alter. All racks used for handling eppendorfs are stored 
at -20°C. It is also helpful if the PCR is set up on ice or chill blocks. This procedure 
will help to minimize the amount of primer artefact produced.
Procedure; Wear gloves and change them if you feel they have become contaminated. 
All tips and tubes used in setting up a PCR must be autoclaved prior to use.
[1] Label a 1.5ml Eppendorf (autoclaved), pre- chilled (see above).
[2] Remove the PCR reagents (listed above) from the PCR freezer, allow to thaw. 
Add in order.
When pipetting the amplitaq gold polymerase use a plugged sterile tip.
[3] Pipette 14.2pl master mix into each 0.5ml or 0.2ml Eppendorf.
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[4] Overlay each reaction volume with one drop of mineral oil.
(NB This step is required only when the genieE thermal cycler is being used).
[5] Pipette 0.8pi target DNA into each. Use dedicated pipettemans and plugged tips, a 
unique tip for each sample.
Change gloves every few samples. Ensure the target DNA is taken from beneath 
the mineral oil layer. For no target sample use aliquoted water (the same aliquot that 
was used for the master mix).
[6] Transfer to thermal cycler APOE programmes. The AmpliTaq Gold Polymerase 
is provided in an inactive state. Heat activates the enzyme and therefore it is necessary 
to include an additional heat step at the beginning of the thermal cycle programmes of 
7-12 mins. This can be included in the first denaturing step of the thermal cycle 
programmes.
[7] Store the PCR product in the PCR product freezer in the gel room or proceed to 
the restriction enzyme digestion.
9.3.3 APOE reactions
APOE PCR mastermix; 15pl reaction
Analar Water 9.025pl
Amplitaq Buffer (xlO cone) 1.5 pi
dNTPs (2mM cone) 1.5 pi
Primer L3, (10pm cone) 0.3 pi
Primer R3+ (10pm cone) 0.3 pi
Amplitaq Gold Polymerase 0.075pl
Total 14.2pl
Restriction enzyme digestion (Hhal); 15pl reaction
[1] To the 15pl PCR product add 1.2pl of Hhal.
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[2] Incubate samples at 37°C for a minimum of 3hrs up to overnight.
[3] Store Hhal digested samples in the PCR product freezer (-20°C) or proceed to gel 
electrophoresis.
Thermal cycle; Techne Genius (with heated lid)
APOE Thermal Cycling Programmes - Prog 1 - 35.5°C - to preheat lid
Prog 2 - 94.0°C -12 mins to denature target/activate Hhal 
Prog 3 - 94.0°C - lmin
65.0°C - lmin x 40 cycles 
72.0°C - 2mins 
Prog 4 - 4°C Hold
9.3.4 IL-1A reactions
IL-1A PCR mastermix; 15pl reaction
Analar Water
Amplitaq Buffer 
dNTPs
Primer IL-1AR 
Primer IL-1AL
(xlO cone) 
(2mM cone) 
(10pm cone) 
(10pm cone)
Amplitaq Gold Polymerase 
Total
8.7pl
1.5 pi
1.5 pi 
1.2pl 
1.2 pi 
0.1 pi 
14.2ul
Restriction enzyme digestion (Ncol); 15pl reaction
[1] To the 15 pi PCR product add 3 units of Ncol.
[2] Incubate samples at 37°C for a minimum of 3hrs up to overnight.
[3] Store Ncol digested samples in the PCR product freezer (-20°C) or proceed to gel 
electrophoresis.
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Reagents Sigma Molecular Biology Grade Water 
Sigma dNTPs
Perkin Elmer Amplitaq Gold and Buffer 
Primer Sequences IL-1A (-899) IL-1AR TTACATATGAGCCTTCCATG
IL-1AL AAGCTT GTT CT ACC ACCT G AACT AGGC 
Supplier Sigma Genosys 
Restriction Endonuclease: - Nco 1
Supplier - Promega
Fragment Length (after digestion) Allele 1 88bp, 16bp
Allele 2 104bp 
Thermal cycle; Techne GENIUS (with heated lid)
IL-1A Thermal Cycling Programmes - Prog 10- 35.5°C - to preheat lid
Prog 11- 94.0°C -10 mins to denature target/activate Taq 
Prog 7 - 95.0°C - lmin
65.0°C - lmin x 35 cycles 
74.0°C - 2mins 
Prog 8 - 95.0°C - lmin
65.0°C - lmin x 3 cycles 
74.0°C - 2mins 
Prog 9 - 4°C Hold
9.3.5 IL-1B reactions
IL-1B PCR mastermix; 15pl reaction
AnalarW ater 9.3 pi
Amplitaq Buffer (x 10 cone) 1.5 pi
dNTPs (2mM cone) 1.5 pi
Primer L3, (10pm cone) 0.9pl
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Primer R3+ (10pm cone) 0.9pl
Amplitaq Gold Polymerase 0.1 pi
Total 14.2pl
Restriction enzyme digestion (Taql); 15pl reaction
[1] To the 15pl PCR product add 4.5units of Taql.
[2] Incubate samples at 65°C for a minimum of 3hrs up to overnight.
[3] Store Taql digested samples in the PCR product freezer (-20°C) or proceed to gel 
electrophoresis.
Reagents Sigma Molecular Biology Grade Water 
Sigma dNTPs 
Sigma DMSO
Perkin Elmer Amplitaq Gold and Buffer 
Primer Sequences IL-IB (+3953) IL-1BR GCTTTTTTGCTGTGAGTCCCG
IL-1BL CTCAGGTGTCCTCGAAGAAATCAAA 
Supplier Sigma Genosys 
Restriction Endonuclease: - Taq 1
Supplier - Promega 
Fragment Length (after digestion) Allele 1 97bp, 85bp,12bp
Allele 2 182bp,12bp 
Thermal cycle; Techne GENIUS (with heated lid)
IL-IB Thermal Cycling Programmes - Prog 5 - 35.5°C - to preheat lid
Prog 6 - 94.0°C -10 mins to denature target/activate Taq 
Prog 7 - 95.0°C - lmin
65.0°C - lmin x 35 cycles 
74.0°C - 2mins 
Prog 8 - 95.0°C - lmin
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65.0°C - lmin x 3 cycles 
74.0°C - 2mins 
Prog 9 - 4°C Hold
9.3.6 Polyacrylamide gel electrophoresis
[1] Preparing polyacrylamide gel solution 
For a 10% gel add the following in order;
17ml distilled water
6ml 5x Tris borate EDTA buffer
7ml 19:1 acrylamide/bis acrylamide (40%)
230 pi ammonium persulphate 0.5g/5ml 
23 pi TEMED 
This is sufficient for six 0.75 mm thickness gels.
[2] Pouring polyacrylamide gels
1/ Glass plates are cleaned with ethanol and dried.
2/ Spacers (15 well) are placed between plates which are then screwed into the clamp 
assembly and then into the gel stand.
3/ Gel solution is poured between the glass plates and allowed to polymerise for 30 
minutes.
4/ Assembly is clamped into gel running apparatus which is then filled with 
approximately 500ml EDTA buffer.
5/ The spacers are removed from the gels and the wells are rinsed with buffer.
[3] Loading of DNA samples
1/ 3 pi of gel loading solution (Sigma) is added to each 15pl sample of PCR product. 
2/ Samples are loaded into wells using round gel loading tips, a unique tip being used 
for each sample.
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3/ A DNA ladder is prepared by adding 0.5 pi Hinfl to 24pi distilled water and 3pi of 
gel loading solution.
•4/ Gels are run at 200 volts/0.06 amps per gel.
5/ When completed gels are removed and stained with ethidium bromide solution 
(1.25pg/ml). Gloves must be worn and changed immediately after being in staining 
solution.
6/ Gels are viewed on ultraviolet (UV) viewing box using protective glasses and 
photographed.
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9.4 Appendix 4
Statistical Methods
9.4.1 Assessment of age-related increase in neuroinflammation in the
control group 
CR 3/43
Variable conage N N* Mean Median TrMean
avcc-hip 11 11 4 1.641 1.406 1.549
12 9 1 2.908 2.065 2.908
Variable conage StDev SE Mean Minimum Maximum Qi
avcc-hip 11 0.983 0.296 0.557 3.555 0.890
12 2.867 0.956 0.958 10.170 1.183
Variable conage Q3
avcc-hip 11 2.157
12 3.232
Mann-Whitney Confidence Interval and Test 
C2S N =  11 Median = 1.406
C29 N = 9 Median = 2.065
Point estimate for ETA1-ETA2 is -0.473
95.2 Percent Cl for ETA1-ETA2 is (-1.874,0.377)
W = 101.0
Test of ETA1 = ETA2 vs ETA1 not = ETA2 is significant at 0.2875 
CD68
Variable conage N N* Mean Median TrMean
avcc-hip 11 11 4 0.834 0.363 0.569
12 9 1 0.375 0.185 0.375
Variable conage StDev SE Mean Minimum Maximum Ql
avcc-hip 11 1.083 0.327 0.243 3.810 0.288
12 0.361 0.120 0.110 1.040 0.162
Variable conage Q3
avcc-hip 11 0.930
12 0.632
Mann-Whitney Confidence Interval and Test 
C28 N =  11 Median = 0.363
C29 N = 9 Median = 0.185
Point estimate for ETA1-ETA2 is 0.142
95.2 Percent Cl for ETA1-ETA2 is (0.005,0.647)
W = 142.0
Test of ETA1 = ETA2 vs ETA1 not = ETA2 is significant at 0.0482
9.4.2 Assessment of the difference of the neuroinflammatory response
between TBI and control groups 
CR3/43
Variable lcon2TBI N N* Mean Median TrMean
avcc-hip 1 20 5 2.211 1.512 1.861
2 55 8 3.390 2.223 3.050
Variable lcon2TBI StDev SEMean Minimum Maximum Q1 
avcc-hip 1 2.095 0.468 0.557 10.170 1.052
2 3.435 0.463 0.010 13.043 0.368
Variable lcon2TBI Q3 
avcc-hip 1 2.954
2 4.879
Mamn-Whitney Confidence Interval and Test 
avh-ccco N =  20 Median = 1.512
avh-cctb N = 55 Median = 2.223
Point estimate for ETA1-ETA2 is -0.541
95.1 Percent Cl for ETA1-ETA2 is (-1.985,0.630)
W =  692.0
Test of ETA1 = ETA2 vs ETA1 not = ETA2 is significant at 0.4187 
CD68
Variable lcon2TBI N N* Mean Median TrMean
avcc-hip 1 20 5 0.627 0.300 0.479
2 55 8 0.8887 0.6871 0.8169
Variable lcon2TBI StDev SE Mean Minimum Maximum
avcc-hip 1 0.853 0.191 0.110 3.810
2 0.7231 0.0975 0.0286 3.6929
Variable lcon2TBI Q3
avcc-hip 1 0.808
2 1.3714
Mann-Whitney Confidence Interval and Test 
C23 N =  20 Median = 0.3000
C24 N =  55 Median = 0.6871
Point estimate for ETA1-ETA2 is -0.2643 
95.11 Percent Cl for ETA1-ETA2 is (-0.5614,-0.0299)
W =  572.5
Test of ETA1 = ETA2 vs ETA1 not = ETA2 is significant at 0.0251
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9.4.3 CR3/43 staining in TBI cases, comparing TAI cases with non-TAI
cases.
For TAI; 1 = no, 2 = yes 
Corpus callosum
Mann-Whitney Test and Cl: cc_l, cc_2 
cc_l N =  19 Median = 1.000
cc_2 N =  28 Median = 4.755
Point estimate for ETA1-ETA2 is -3.810 
95-0 Percent Cl for ETA1-ETA2 is (-7.501,-0.770)
W = 336.0
Test ofET A l = ETA2 vs ETA1 not = ETA2 is significant at 0.0096 
The test is significant at 0.0094 (adjusted for ties)
Cing;ulate grey matter
Mann-Whitney Test and Cl: cg_l, cg_2
cg__l N = 18 Median = 0.095
cg_2 N =  26 Median = 1.105
Point estimate for ETA1-ETA2 is -0.570
95-1 Percent Cl for ETA1-ETA2 is (-2.410,-0.090)
W = 308.0
Test ofET A l = ETA2 vs ETA1 not = ETA2 is significant at 0.0213 
The test is significant at 0.0210 (adjusted for ties)
Cingulate white matter
Mann-Whitney Test and Cl: cw_l, cw_2 
cw_ll N = 18 Median = 0.240
cw_2 N = 26 Median = 3.375
Point estimate for ETA1-ETA2 is -1.560
95-1 Percent Cl for ETA1-ETA2 is (-4.810,-0.470)
W = 303.5
Test ofET A l = ETA2 vs ETA1 not = ETA2 is significant at 0.0159 
The test is significant at 0.0157 (adjusted for ties)
Temporal grey matter
Mann-Whitney Test and Cl: tg_l, tg_2
tg 1 N = 23 Median = 0.130
tg_2 N = 29 Median = 0.340
Point estimate for ETA1-ETA2 is -0.080
95.1 Percent Cl for ETA1-ETA2 is (-0.350,0.030)
W = 521.5
Test ofETA l = ETA2 vs ETA1 not = ETA2 is significant at 0.1069 
The test is significant at 0.1066 (adjusted for ties)
Temporal white matter
Mann-Whitney Test and Cl: tw_l, tw_2 
tw_l N = 22 Median = 0.840
tw 2 N =  29 Median = 2.350
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Point estimate for ETA1-ETA2 is -0.625
95.1 Percent Cl for ETA1-ETA2 is (-2.321,0.170)
W = 487.5
Test ofETA l = ETA2 vs ETA1 not = ETA2 is significant at 0.1101 
The test is significant at 0.1101 (adjusted for ties)
Afveus
Mann-Whitney Test and Cl: alveus_l, alveus_2 
alv/eiLis_l N =  22 Median = 1.150
alv/euis_2 N = 28 Median = 2.155
Point estimate for ETA1-ETA2 is -0.290
95.0 Percent Cl for ETA1-ETA2 is (-1.959,0.921)
W = 522.0
Test ofETA l = ETA2 vs ETA1 not = ETA2 is significant at 0.4518 
The test is significant at 0.4516 (adjusted for ties)
Hippocampus
Mann-Whitney Test and Cl: hippo_l, hippo_2 
hippo_l N = 22 Median = 0.300
hippo_2 N = 28 Median = 0.700
Point estimate for ETA1-ETA2 is -0.075 
95..0 Percent Cl for ETA1-ETA2 is (-0.750,0.221)
W = 526.0
Test ofE T A l = ETA2 vs ETA1 not = ETA2 is significant at 0.5001
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9 .4 .4 CD 68 staining in TBI cases, comparing TAI cases with non-TAI
castes-.
For TAI; 1 = no, 2 = yes 
C orpus callosum
Mann-Whitney Test and Cl: cc_l, cc_2 
cc_l N = 19 Median = 0.930
cc_2 N = 28 Median = 1.455
Point estimate for ETA1-ETA2 is -0.675 
95.(0 Percent Cl for ETA1-ETA2 is (-1.430,0.041)
W = 375.0
Test ofE T A l = ETA2 vs ETA1 not = ETA2 is significant at 0.0810
Ciugiulate grey matter
Mann-Whitney Test and Cl: cg_l, cg_2 
cg_l N = 18 Median = 0.2150
cg_2 N =  26 Median = 0.5200
Point estimate for ETA1-ETA2 is -0.1900
95.1 Percent Cl for ETA1-ETA2 is (-0.4397,0.0099)
W = 323.0
Test ofE T A l = ETA2 vs ETA1 not = ETA2 is significant at 0.0517
Cing^ilate white matter
Mann-Whitney Test and Cl: cw_l, cw_2
cw 1 N =  18 Median = 0.575
cw_2 N =  26 Median = 0.930
Point estimate for ETA1-ETA2 is -0.400
95.1 Percent Cl for ETA1-ETA2 is (-0.770,-0.030)
W = 317.5
Test ofE T A l = ETA2 vs ETA1 not = ETA2 is significant at 0.0378
Temporal grey matter
Mann-Whitney Test and Cl: tg_l, tg_2 
tg_l N =  23 Median = 0.1000
tg_2 N =  30 Median = 0.2350
Point estimate for ETA1-ETA2 is -0.0700
95.1 Percent Cl for ETA1-ETA2 is (-0.1702,0.0398)
W = 553.5
Test ofE T A l = ETA2 vs ETA1 not = ETA2 is significant at 0.2292
Temporal white matter
Mann-Whitney Test and Cl: tw_l, tw_2 
tw_l N =  23 Median = 0.2700
tw_2 N =  30 Median = 0.7400
Point estimate for ETA1-ETA2 is -0.3600
95.1 Percent Cl for ETA1-ETA2 is (-0.5899,0.0500)
W = 526.5
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Te:st ofE T A l = ETA2 vs ETA1 not = ETA2 is significant at 0.0916 
Alveus
Mann-Whitney Test and Cl: a lv e u s l, alveus_2 
alveus_l N =  22 Median = 0.4450
alveus_2 N =  29 Median = 0.6100
Point estimate for ETA1-ETA2 is -0.1450 
95-1 Percent Cl for ETA1-ETA2 is (-0.7703,0.1201)
W = 515.5
Test ofE T A l = ETA2 vs ETA1 not = ETA2 is significant at 0.2869 
Hippocampus
Mann-Whitney Test and Cl: hippo_l, hippo_2 
hippo_l N =  22 Median = 0.2050
hippo_2 N = 29 Median = 0.2100
Point estimate for ETA1-ETA2 is -0.0600 
95-1 Percent Cl for ETA1-ETA2 is (-0.2798,0.0799)
W = 533.5
Test ofE T A l = ETA2 vs ETA1 not = ETA2 is significant at 0.4699
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9.4..5 Distribution of IL-1A and IL-1B alleles between TBI and control
castes
Asssessment of IL-1A
Chii-Square Test
C24 C25 Total
11 9 30 39
10.01 28.99
21 10 25 35
8.99 26.01
Tottal 19 55 74
Chii-Sq = 0.103+ 0.035 + 
0.114+ 0.039 = 0.292 
DF = 1, P-Value = 0.589
Asssessment of IL-1B
Chii-Square Test
C28 C29 Total
11 10 30 40
10.34 29.66
22 5 13 18
4.66 13.34
Tottal 15 43 58
Chii-Sq = 0.011 + 0.004 + 
0.026+ 0.009 = 0.050 
DF = 1, P-Value = 0.823
C24= controls, C25=TBI 
1= 1,1; 2= any 2
C28= controls, C29= TBI 
1= 1,1; 2= any 2
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9.4.6 Assessment of the possession of any copy of IL-1A or IL-1B allele 2
and the neuroinflammatory response.
CR3/43
IL-1A
All cases (TBI and control cases)
Variable illaany2 N N* Mean Median TrMea
avcc-hip 1 39 3 3.050 2.065 2.689
2 34 0 3.258 1.828 2.923
* 2 10 0.472 0.472 0.472
Variable illaany2 StDev SE Mean Minimum Maximum
avcc-hip 1 3.274 0.524 0.010 13.043
2 3.108 0.533 0.017 12.161
Variable
avcc-hip
*
illaany2
1
2
*
0.592
Q3
3.694
4.744
0.418 0.053 0.890
Mann-Whitney Confidence Interval and Test 
C50 N =  39 Median = 2.065
C51 N =  34 Median = 1.828
Point estimate for ETA1-ETA2 is -0.181
95.0 Percent Cl for ETA1-ETA2 is (-1.237,0.833)
W = 1410.0
Test of ETA1 = ETA2 vs ETA1 not = ETA2 is significant at 0.7193
CR3/43 - ill A
10  -
Q .
■o
o
>ro 5 -
♦ ♦
11 12 22 11 12 22
Qi
0.557
1.040
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TBI cases only
Variable tbila any N N* Mean Median TrMean
avcc-hip 1 30 3 3.018 1.982 2.527
2 24 0 3.995 4.022 3.804
Variable tbila any StDev SE Mean Minimum Maximum Q1
avcc-hip 1 3.442 0.628 0.010 13.043 0.337
2 3.424 0.699 0.017 12.161 1.106
Variable tbila any Q3
avcc-hip 1 4.012
2 6.468
Mann-Whitney Confidence Interval and Test 
C33 N =  30 Median = 1.982
C34 N = 24 Median = 4.022
Point estimate for ETA1-ETA2 is -1.018
95.2 Percent Cl for ETA1-ETA2 is (-2.793,0.446)
W = 757.0
Test of ETA1 = ETA2 vs ETA1 not = ETA2 is significant at 0.2400 
IL-1B
All cases (TBI and controls!
Variable illbany2 N N* Mean Median TrMean
avcc-hip 1 39 2 3.215 2.047 2.873
2 19 0 3.551 2.838 3.250
* 17 11 2.225 1.335 1.855
Variable illbany2 StDev SE Mean Minimum Maximum Qi
avcc-hip 1 3.445 0.552 0.010 13.043 0.652
2 3.054 0.701 0.053 12.161 1.294
* 2.560 0.621 0.033 9.966 0.380
Variable illbany2 Q3
avcc-hip 1 3.861
2 4.753
* 2.982
Mann-Whitney Confidence Interval and Test 
C50 N =  39 Median = 2.047
C51 N =  19 Median = 2.838
Point estimate for ETA1-ETA2 is -0.540
95.1 Percent Cl for ETA1-ETA2 is (-1.902,0.792)
W = 1099.0
Test of ETA1 = ETA2 vs ETA1 not = ETA2 is significant at 0.3981
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cr3/43 - IL1B
10 -
o .Jz
a
o
>ro 5 -
0 -
11 12 22 12 2211
TBI cases only
Variable tbilb any N N* Mean Median TrMean
avcc-hip 1 29 2 3.323 2.047 3.086
2 14 0 4.172 4.447 3.849
Variable tbilb any StDev SE Mean Minimum Maximum Qi
avcc-hip 1 3.691 0.685 0.010 13.043 0.309
2 3.325 0.889 0.053 12.161 1.231
Variable tbilb any Q3
avcc-hip 1 4.914
2 5.958
Mann-Whitney Confidence Interval and Test 
C33 N = 29 Median = 2.047
C34 N =  14 Median = 4.447
Point estimate for ETA1-ETA2 is -1.012
95.3 Percent Cl for ETA1-ETA2 is (-3.164,0.841)
W = 593.0
Test of ETA1 = ETA2 vs ETA1 not = ETA2 is significant at 0.2488 
The test is significant at 0.2487 (adjusted for ties)
CD68
IL-1A
All cases (TBI and control cases)
Variable illaany2 N N* Mean Median TrMean
avcc-hip 1 39 3 0.770 0.581 0.682
2 34 0 0.900 0.579 0.799
* 2 10 0.4000 0.4000 0.4000
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Variable
avcc-hip
il 1 aany2 StDev SE Mean 
0.706 0.113
0.843 0.145
0.0525 0.0371
Minimum
0.030
0.029
0.3629
Maximum Q1
3.693 0.288
3.810 0.276
0.4371 *
Variable
avcc-hip
illaany2
1
2
Q3
0.995
1.487
C50 N =  39 Median = 0.5814
C51 N =  34 Median = 0.5793
Point estimate for ETA1-ETA2 is -0.0300
95.0 Percent Cl for ETA1-ETA2 is (-0.3315,0.1717)
W = 1414.0
Test of ETA1 = ETA2 vs ETA1 not = ETA2 is significant at 0.7526
CD68 - IL IA
4
3
2
1
0
11 12 22 1 12 22
TBI cases only
Variable tbila any N N* Mean Median TrMean
avcc-hip 1 30 3 0.816 0.641 0.705
2 24 0 0.999 0.899 0.967
Variable tbila any StDev SE Mean Minimum Maximum Qi
avcc-hip 1 0.753 0.138 0.030 3.693 0.372
2 0.695 0.142 0.029 2.671 0.379
Variable tbila any Q3
avcc-hip 1 1.021
2 1.607
Mann-Whitney Confidence Interval and Test 
C33 N =  30 Median = 0.6414
C34 N =  24 Median = 0.8986
Point estimate for ETA1-ETA2 is -0.1914
95.2 Percent Cl for ETA1-ETA2 is (-0.6013,0.1216)
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W = 759.0
Test of ETA1 = ETA2 vs ETA1 not = ETA2 is significant at 0.2542
IL-1B
All cases (TBI and control cases)
Variable illbany2 N N* Mean Median TrMean
avcc-hip 1 39 2 0.774 0.687 0.718
2 19 0 1.093 0.891 0.988
* 17 11 0.617 0.407 0.446
Variable illbany2 StDev SE Mean Minimum Maximum Q
avcc-hip 1 0.626 0.100 0.029 2.671 0.288
2 0.895 0.205 0.152 3.810 0.437
* 0.850 0.206 0.104 3.693 0.219
Variable illbany2 Q3
avcc-hip 1 1.040
2 1.674
* 0.581
C50 N =  39 Median = 0.6871
C51 N =  19 Median = 0.8914
Point estimate for ETA1-ETA2 is -0.2143
95.1 Percent Cl for ETA1-ETA2 is (-0.6341,0.0944)
W = 1071.0
Test of ETA1 = ETA2 vs ETA1 not = ETA2 is significant at 0.1906
CD68 - IL1B
4 H
3 -
CL
_c
6  2 -  o 
>
(0 ♦  ♦
1211 22 11 12 22
TBI cases only
Variable tbilb any N N* Mean Median TrMean
avcc-hip 1 29 2 0.848 0.754 0.810
2 14 0 1.081 1.166 1.093
Variable tbilb any StDev SEMean Minimum Maximum Q1
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avcc-hip 1 0.649 0.121 0.029 2.671 0.385
2 0.624 0.167 0.152 1.864 0.521
Variable tbilb any Q3
avcc-hip 1 1.181
2 1.682
Mann-Whitney Confidence Interval and Test 
C33 N =  29 Median = 0.7543
C34 N =  14 Median = 1.1657
Point estimate for ETA1-ETA2 is -0.2654
95.3 Percent Cl for ETA1-ETA2 is (-0.7472,0.1615)
W = 590.0
Test of ETA1 = ETA2 vs ETA1 not = ETA2 is significant at 0.2183
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9.4.7 Assessment of the possession of IL-1A 2,2 and the
neuroinflammatory response.
CR3/43
IL-1A
All cases (TBI and control cases)
Variable a22nly2 N N* Mean Median TrMean
avcc-hip 1 67 3 3.081 1.940 2.777
2 6 0 3.883 4.286 3.883
* 2 10 0.472 0.472 0.472
Variable a22nly2 StDev SE Mean Minimum Maximum Q1
avcc-hip 1 3.256 0.398 0.010 13.043 0.667
2 2.177 0.889 1.294 7.096 1.518
* 0.592 0.418 0.053 0.890 *
Variable a22nly2 Q3
avcc-hip 1 4.183
2 5.330
C32 N =  67 Median = 1.940
C33 N = 6 Median = 4.286
Point estimate for ETA1-ETA2 is -1.278
95.2 Percent Cl for ETA1-ETA2 is (-3.583,0.930)
W = 2416.0
Test of ETA1 = ETA2 vs ETA1 not = ETA2 is significant at 0.2094
TBI cases only
Variable tbia22 N N* Mean Median TrMean
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avcc-hip 1 49 3 3.361 2.047 3.099
2 5 0 4.341 4.711 4.341
* 21 10 2.108 1.430 1.792
Variable tbia22 StDev SE Mean Minimum Maximum Q
avcc-hip 1 3.548 0.507 0.010 13.043 0.367
2 2.086 0.933 1.294 7.096 2.578
* 2.095 0.457 0.053 10.170 0.994
Variable tbia22 Q3
avcc-hip 1 4.914
2 5.919
* 2.876
C36 N =  49 Median = 2.047
C37 N = 5 Median = 4.711
Point estimate for ETA1-ETA2 is -1.727
95.1 Percent Cl for ETA1-ETA2 is (-4.115,1.344)
W = 1308.0
Test of ETA1 = ETA2 vs ETA1 not = ETA2 is significant at 0.2445 
IL-1B
All cases (TBI and controls)
Variable b22nly2 N N* Mean Median TrMean
avcc-hip 1 54 2 3.477 2.622 3.140
2 4 0 1.275 1.444 1.275
* 17 11 2.225 1.335 1.855
Variable b22nly2 StDev SE Mean Minimum Maximum Q1
avcc-hip 1 3.364 0.458 0.010 13.043 0.941
2 0.889 0.445 0.053 2.157 0.364
* 2.560 0.621 0.033 9.966 0.380
Variable b22nly2 Q3
avcc-hip 1 4.784
2 2.016
* 2.982
C32 N =  54 Median = 2.622
C33 N =  4 Median = 1.444
Point estimate for ETA1-ETA2 is 1.387
95.2 Percent Cl for ETA1-ETA2 is (-0.635,4.646)
W = 1636.0
Test of ETA1 = ETA2 vs ETA1 not = ETA2 is significant at 0.1922
TBI cases only
Variable tbib22 N N* Mean Median TrMean
avcc-hip 1 41 2 3.742 2.838 3.465
2 2 0 0.674 0.674 0.674
* 32 11 2.372 1.655 1.985
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Variable tbib22 StDev SE Mean Minimum Maximum Qi
avcc-hip 1 3.582 0.559 0.010 13.043 0.565
2 0.877 0.620 0.053 1.294 *
* 2.419 0.428 0.033 10.170 0.976
Variable tbib22 Q3
avcc-hip 1 5.326
2 *
* 3.020
C36 N =  41 Median = 2.838
C37 N = 2 Median = 0.674
Point estimate for ETA1-ETA2 is 2.285
95.3 Percent Cl for ETA1-ETA2 is (-1.043,10.463)
W = 927.0
Test of ETA1 = ETA2 vs ETA1 not = ETA2 is significant at 0.1577
CD68
IL-1A
All cases (TBI and control cases!
Variable a22nly2 N N* Mean Median TrMean
avcc-hip 1 67 3 0.8037 0.5483 0.7133
2 6 0 1.130 1.201 1.130
* 2 10 0.4000 0.4000 0.4000
Variable a22nly2 StDev SE Mean Minimum ]Maximum
avcc-hip 1 0.7863 0.0961 0.0286 3.8100
2 0.510 0.208 0.306 1.633
* 0.0525 0.0371 0.3629 0.4371
Variable a22nly2 Q3
avcc-hip 1 1.0400
2 1.556
C32 N =  67 Median = 0.5483
C33 N = 6 Median = 1.2014
Point estimate for ETA1-ETA2 is -0.5195
95.2 Percent Cl for ETA1-ETA2 is (-1.0303,0.1029)
W = 2396.0
Test of ETA1 = ETA2 vs ETA1 not = ETA2 is significant at 0.0975
TBI cases only
Variable tbia22 N N* Mean Median TrMean
avcc-hip 1 49 3 0.869 0.640 0.804
2 5 0 1.169 1.473 1.169
* 21 10 0.618 0.303 0.477
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Variable tbia22 StDev SE Mean Minimum Maximum
avcc-hip 1 0.741 0.106 0.029 3.693
2 0.560 0.250 0.306 1.633
* 0.832 0.182 0.110 3.810
Variable tbia22 Q3
avcc-hip 1 1.287
2 1.581
* 0.686
C36 N = ■49 Median = 0.6400
C37 N = 5 Median:= 1.4729
Point estimate for ETA1-ETA2 is -0.4778
95.1 Percent Cl for ETA1-ETA2 is (-1.0512,0.2426)
W =  1305.0
Test of ETA1 = ETA2 vs ETA1 not = ETA2 is significant at 0.2101
IL-1B
All cases (TBI and control cases')
Variable b22nly2 N N* Mean Median TrMean
avcc-hip 1 54 2 0.904 0.740 0.830
2 4 0 0.529 0.440 0.529
* 17 11 0.617 0.407 0.446
Variable b22nly2 StDev SE Mean Minimum Maximum
avcc-hip 1 0.750 0.102 0.029 3.810
2 0.275 0.137 0.306 0.930
* 0.850 0.206 0.104 3.693
Variable b22nly2 Q3
avcc-hip 1 1.446
2
0.581
0.808
C32 N =  54 Median = 0.7400
C33 N = 4 Median = 0.4398
Point estimate for ETA1-ETA2 is 0.2002
95.2 Percent Cl for ETA1-ETA2 is (-0.2445,1.0062)
W = 1614.0
Test of ETA1 = ETA2 vs ETA1 not = ETA2 is significant at 0.5293
TBI cases only
Variable tbib22 N N* Mean Median TrMean
avcc-hip 1 41 2 0.950 0.891 0.917
2 2 0 0.3714 0.3714 0.3714
* 32 11 0.678 0.350 0.500
Qi
0.385
0.606
0.214
Qi
0.295
0.339
0.219
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Variable tbib22 StDev SE Mean Minimum Maximum Qi
avcc-hip 1 0.647 0.101 0.029 2.671 0.417
2 0.0929 0.0657 0.3057 0.4371 *
* 0.891 0.157 0.104 3.810 0.250
Variable tbib22 Q3
avcc-hip 1 1.469
2 *
* 0.774
C36 N =  41 Median = 0.8914
C37 N = 2 Median = 0.3714
Point estimate for ETA1-ETA2 is 0.4647
95.3 Percent Cl for ETA1-ETA2 is (-0.2756,1.4328)
W = 925.0
Test of ETA1 = ETA2 vs ETA1 not = ETA2 is significant at 0.1944
9.4.8 Assessment of the possession of any copy of APOEs4 and the
neuroinflammatory response.
CD68; Control cases
Variable con e4-4 N
avcc-hip 1 15
2 5
Variable con e4-4 StDev
avcc-hip 1 0.958
2 0.0764
N* Mean
0 0.752
1 0.2520
Median
0.363
0.2825
TrMean
0.567
0.2520
Variable
avcc-hip
con e4-4 
1 
2
SE Mean
0.247
0.0342
Q3
0.961
0.3169
Minimum Maximum QI 
0.110 3.810 0.243
0.1586 0.3367 0.1718
Mann-Whitney Confidence Interval and Test 
C40 N =  15 Median = 0.3629
C41 N = 5 Median = 0.2825
Point estimate for ETA1-ETA2 is 0.1272
95.5 Percent Cl for ETA1-ETA2 is (-0.0487,0.7716)
W = 174.0
Test of ETA1 = ETA2 vs ETA1 not = ETA2 is significant at 0.1625 
CR343; Control cases
Variable con e4-4 N N* Mean Median TrMean
avcc-hip 1 15 0 2.540 1.737 2.097
2 5 1 1.226 1.119 1.226
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Variable con e4-4 StDev SE Mean Minimum Maximum QI
avcc-hip 1 2.324 0.600 0.667 10.170 1.157
2 0.565 0.253 0.557 2.065 0.757
Variable con e4-4 Q3
avcc-hip 1 3.210
2 1.747
Mann-Whitney Confidence Interval and Test 
C42 N =  15 Median = 1.737
C43 N = 5 Median = 1.119
Point estimate for ETA1-ETA2 is 0.727
95.5 Percent Cl for ETA1-ETA2 is (-0.228,2.165)
W = 176.0
Test of ETA1 = ETA2 vs ETA1 not = ETA2 is significant at 0.1161
CD68; TBI cases
Variable tbie4-4 N N* Mean Median TrMean
avcc-hip 1 42 3 0.926 0.740 0.854
2 13 2 0.770 0.437 0.739
Variable tbie4-4 StDev SE Mean Minimum Maximum Qi
avcc-hip 1 0.752 0.116 0.029 3.693 0.405
2 0.633 0.176 0.104 1.777 0.252
Variable tbie4-4 Q3
avcc-hip 1 1.327
2 1.536
Mann-Whitney Confidence Interval and Test
C40 N =  42 Median = 0.7400
C41 N = 13 Median = 0.4371
Point estimate for ETA1-ETA2 is 0.1302
95.1 Percent Cl for ETA1-ETA2 is (-0.2535,0.4891)
W = 1213.0
Test of ETA1 = ETA2 vs ETA1 not = ETA2 is significant at 0.4696 
CR343; TBI cases
Variable tbie4-4 N N* Mean Median TrMean
avcc-hip 1 42 3 3.657 2.909 3.389
2 13 2 2.53 0.48 1.88
Variable tbie4-4 StDev SE Mean Minimum Maximum Qi
avcc-hip 1 3.377 0.521 0.010 13.043 1.107
2 3.62 1.00 0.03 12.16 0.13
Variable tbie4-4 Q3 
avcc-hip 1 5.138
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2 4.46
Mann-Whitney Confidence Interval and Test 
C42 N = 42 Median = 2.909
C43 N =  13 Median = 0.479
Point estimate for ETA1-ETA2 is 1.221
95.1 Percent Cl for ETA1-ETA2 is (-0.228,2.948)
W =  1251.0
Test of ETA1 = ETA2 vs ETA1 not = ETA2 is significant at 0.1400
CD68; TAI cases
Variable tai e4-4 N n * :Mean Median TrMean
avcc-hip 11 17 0 0.669 0.596 0.602
12 8 0 0.618 0.431 0.618
21 25 0 1.100 0.891 1.023
22 5 0 1.013 0.898 1.013
Variable tai e4-4 StDev SE Mean Minimum Maximum Qi
avcc-hip 11 0.589 0.143 0.029 2.320 0.154
12 0.590 0.208 0.104 1.633 0.166
21 0.810 0.162 0.272 3.693 0.448
22 0.689 0.308 0.306 1.777 0.357
Variable tai e4--4 Q3
avcc-hip 11 0.927
12 1.217
21 1.498
22 1.726
Mann-Whitney Confidence Interval and Test 
C43 N = 8 Median = 0.431
C45 N = 5 Median = 0.898
Point estimate for ETA1-ETA2 is -0.279
95.2 Percent Cl for ETA1-ETA2 is (-1.351,0.243)
W = 48.0
Test of ETA1 = ETA2 vs ETA1 not = ETA2 is significant at 0.2723 
CR343; TAI cases
Variable tai e4-4 N N* Mean Median TrMean
avcc-hip 11 17 0 2.773 2.523 2.273
12 8 0 1.621 0.367 1.621
21 25 0 4.258 3.694 4.111
22 5 0 3.98 2.22 3.98
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Variable tai e4-4 StDev SE Mean Minimum Maximum Ql
avcc-hip 11 3.200 0.776 0.010 13.043 0.167
12 2.597 0.918 0.033 6.723 0.090
21 3.424 0.685 0.147 11.757 1.449
22 4.82 2.15 0.04 12.16 0.67
Variable tai e4--4 Q3
avcc-hip 11 4.286
12 3.676
21 6.668
22 8.17
Mann-Whitney Confidence Interval and Test 
C43 N = 8 Median = 0.367
C45 N = 5 Median = 2.223
Point estimate for ETA1 -ETA2 is -1.5 03
95.2 Percent Cl for ETA1-ETA2 is (-7.419,2.522)
W = 49.0
Test of ETA1 = ETA2 vs ETA1 not = ETA2 is significant at 0.3413
9.4.9 Assessment of the possession of any copy of APOEel and the
neuroinflammatory response.
CD68; Control cases
Variable con e4-2 N N* Mean Median TrMean
avcc-hip 1 18 0 0.469 0.300 0.412
2 2 1 2.05 2.05 2.05
Variable con e4-2 StDev SE Mean Minimum Maximum
avcc-hip 1 0.429 0.101 0.110 1.753
2 2.49 1.76 0.29 3.81
Variable con e4-2 Q3
avcc-hip 1 0.564
2 *
Mann-Whitney Confidence Interval and Test
C40 N = 18 Median = 0.300
C41 N = 2 :Median = 2.049
Ql
0.181
*
Point estimate for ET A1 -ET A2 is -1.118 
96.2 Percent Cl for ETA1-ETA2 is (-3.652,0.751)
W = 181.0
Test of ETA1 = ETA2 vs ETA1 not = ETA2 is significant at 0.3447
CR343;Control cases
Variable con e4-2 N N* 
avcc-hip 1 18 0
2 2 1
Mean Median 
2.323 1.512
1.202 1.202
TrMean
1.943
1.202
Variable con e4-2 StDev SE Mean Minimum Maximum Ql
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avcc-hip 1 2.177 0.513 0.557 10.170 1.096
2 0.757 0.535 0.667 1.737 *
Variable con e4-2 Q3
avcc-hip 1 3.076
2 *
Mann-Whitney Confidence Interval and Test 
C42 N =  18 Median = 1.512
C43 N =  2 Median = 1.202
Point estimate for ETA1-ETA2 is 0.579
96.2 Percent Cl for ETA1-ETA2 is (-0.847,8.433)
W = 196.0
Test of ETA1 = ETA2 vs ETA1 not = ETA2 is significant at 0.4128 
CD68; TBI cases
Variable tbi e4-2 N N* Mean Median TrMean
avcc-hip 1 45 5 0.853 0.596 0.779
2 10 0 1.050 0.950 1.008
Variable tbi e4-2 StDev SE Mean Minimum Maximum Ql
avcc-hip 1 0.722 0.108 0.029 3.693 0.389
2 0.745 0.236 0.116 2.320 0.339
Variable tbi e4-2 Q3
avcc-hip 1 1.317
2 1.744
Mann-Whitney Confidence Interval and Test
C40 N =  45 Median = 0.5957
C41 N =  10 Median = 0.9504
Point estimate for ETA1-ETA2 is -0.2314 
95.2 Percent Cl for ETA1-ETA2 is (-0.7464,0.2676)
W = 1218.0
Test of ETA1 = ETA2 vs ETA1 not = ETA2 is significant at 0.3651
CR343; TBI cases
Variable tbi e4-2 N N* Mean Median TrMean
avcc-hip 1 45 5 3.309 2.223 3.048
2 10 0 3.76 2.65 3.06
Variable tbi e4-2 StDev SE Mean Minimum Maximum
avcc-hip 1 3.327 0.496 0.010 12.161
2 4.07 1.29 0.03 13.04
Variable tbi e4-2 Q3
avcc-hip 1 4.816
2 5.69
Mann-Whitney Confidence Interval and Test
Ql
0.367
0.55
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C42 N = 45 Median = 2.223
C43 N =  10 Median = 2.648
Point estimate for ETA1-ETA2 is -0.198
95.2 Percent Cl for ETA1-ETA2 is (-2.173,1.797)
W = 1245.0
Test of ETA1 = ETA2 vs ETA1 not = ETA2 is significant at 0.7517
CD68; TAI cases
Variable tai e4-2 N N* Mean Median TrMean
avcc-hip 11 20 0 0.592 0.493 0.565
12 5 0 0.898 0.906 0.898
21 25 0 1.062 0.891 0.982
22 5 0 1.201 1.312 1.201
Variable tai e4-2 StDev SE Mean Minimum Maximum Ql
avcc-hip 11 0.483 0.108 0.029 1.633 0.166
12 0.894 0.400 0.116 2.320 0.136
21 0.817 0.163 0.272 3.693 0.424
22 0.627 0.280 0.400 1.864 0.563
Variable tai e4-2 Q3
avcc-hip 11 0.854
12 1.657
21 1.498
22 1.784
Mann-Whitney Confidence Interval and Test
C43 N = 5 Median = 0.906
C45 N = 5 Median = 1.312
Point estimate for ETA1-ETA2 is -0.406 
96.3 Percent Cl for ETA1-ETA2 is (-1.588,1.008)
W = 24.0
Test of ETA1 = ETA2 vs ETA1 not = ETA2 is significant at 0.5309 
CR343; TAI cases
Variable tai e4-2 N N* Mean Median TrMean
avcc-hip 11 20 0 1.898 1.118 1.735
12 5 0 4.43 3.86 4.43
21 25 0 4.437 3.723 4.293
22 5 0 3.08 1.94 3.08
Variable tai e4-2 StDev ISE Mean Minimum Maximum Ql
avcc-hip 11 2.067 0.462 0.010 6.723 0.153
12 5.28 2.36 0.03 13.04 0.14
21 3.731 0.746 0.037 12.161 1.307
176
22 2.86 1.28 0.65 7.89 1.12
Variable tai e4-2 Q3
avcc-hip 11 2.983
12 9.00
21 6.668
22 5.62
Mann-Whitney Confidence Interval and Test 
C43 N = 5 Median = 3.861
C45 N = 5 Median = 1.940
Point estimate for ETA1-ETA2 is 0.506
96.3 Percent Cl for ETA1-ETA2 is (-4.031,11.105)
W = 28.0
Test of ETA1 = ETA2 vs ETA1 not = ETA2 is significant at 1.0000
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Tau immunostaining and Image analysis data
Tau data
Semi-quantitative analysis of tau perikaryal immunoreactivity. 
Control cases
Age CA1 CA 2 CA 3 CA 4 Sub EC Neo
33 8
50 1
59 2 1
69 1 1 4
71 2 1 1 3 16
Survival <24 hours
Age CA 1 CA 2 CA 3 CA 4 Sub EC Neo
66 5 6 2
71 1 2 2 1 3
88 15 35
Survival 24 hours- 1 week
Age CA 1 CA 2 CA 3 CA 4 Sub EC Neo
37 1
73 1 2 5 3
60 1
Survival 1 week- 1 month
Age CA 1 CA 2 CA 3 CA 4 Sub EC Neo
53 3 1
79 2 6 3 1
83 4 15 4
j
I Legend: CA1-CA4= regions of hippocampus
! Sub= subiculum
EC= entorhinnal cortex 
Neo= neocortex
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Neuroinflammation data
0-19 years____________ CD 68
Controls
cc eg cw tg tw alveus hippo
418/84 X X X 1.22 2.38 6.98 4.66
960608 0.08 0.24 0.46 0.03 0.09 0.61 0.50
960051
980309
960934
<24 hours
cc eg cw tg tw alveus hippo
688/87
262/89 X X X 0.13 0.18 X X
553/89 X X X 0.23 0.34 0.22 0.36
254/90 0.34 0.09 0.23 0.08 0.19 0.08 0.08
980328 0.71 0.34 0.52 0.03 0.12 0.24 0.18
1 day-1 week
cc eg cw tg tw alveus hippo
338/90 1.40 0.38 0.60 0.45 0.81 0.66 0.51
649/93 0.40 X X 0.21 0.17 0.17 0.04
960640
980389 2.47 0.80 1.05 3.02 0.83 1.50 2.26
990143 2.14 4.94 3.02 0.28 4.33 1.53 2.46
1 w eek-1 month
cc eg cw tg tw alveus hippo
452/90 0.76 0.55 1.00 0.17 0.61 0.61 0.45
960017 3.77 1.10 2.77 0.25 1.02 0.98 0.37
960523 1.45 0.47 0.67 0.17 0.44 X X
961002 0.18 0.78 1.00 1.28 1.36 0.36 0.12
990234 1.24 0.74 0.72 0.07 0.06 0.01 0.01
20-49 years CD68
Controls
cc eg cw tg tw alveus hippo
469/90 0.88 0.15 0.50 0.03 0.12 0.01 0.01
55/92 1.10 0.71 1.00 0.01 0.06 0.07 0.02
165/94 1.2 0.16 0.39 0.06 0.18 0.05 0.04
960280 1.2 X 0.63 0.02 0.05 0.11 0.01
960545
<24 hours
cc eg cw tg tw alveus hippo
489/88 X X X 0.25 0.72 0.18 0.10
96/91 0.24 0.04 0.12 0.44 1.10 0.60 0.32
875/93 0.03 0.06 0.02 0.02 0.02 0.40 0.26
990051 0.33 0.15 0.36 0.55 1.10 0.31 0.18
990219
1 day- 1 week
cc eg cw tg tw alveus hippo
980465 X 0.63 1.25 0.06 0.23 0.73 0.39
152/89 0.02 0.01 0.01 0.01 0.01 0.09 0.05
960228 0.48 X X 0.31 0.26 1.40 2.04
970202 1.96 0.59 1.39 0.15 0.57 3.04 1.90
970696 1.50 0.28 1.00 0.40 1.80 0.84 0.21
1 week- 1 month
cc eg cw tg tw alveus hippo
717/94 1.71 0.70 0.72 1.02 1.70 0.31 0.08
390/95 X X X 0.38 1.74 1.32 0.35
960118
961000 5.60 1.22 2.94 0.31 0.91 1.13 0.94
990451 2.86 1.21 2.32 0.05 0.16 0.68 3.03
50+ years CD68
Controls
cc eg cw tg tw alveus hippo
335/84
488/86 X X X 0.10 0.19 0.08 0.07
675/87 X X X 0.06 0.29 0.41 0.37
08/94 0.18 0.23 0.53 0.02 0.02 0.04 0.09
288/95 0.17 0.21 0.63 0.22 0.58 0.11 0.20
<24 hours
cc eg cw tg tw alveus hippo
825/87 0.04 0.01 0.06 0.02 0.06 0.01 0.01
432/90 0.02 0.03 0.03 0.05 0.40 0.02 0.18
432/93 0.60 X X 0.02 0.09 0.03 0.02
960340 1.46 0.42 0.62 X X X X
960462 X X X 0.17 0.69 0.49 0.30
1 day- 1 week
cc eg cw tg tw alveus hippo
487/91 0.57 0.50 0.60 1.30 3.00 3.35 3.12
209/93 X X X 0.22 0.60 0.14 0.13
960339 1.45 0.11 0.43 0.07 0.96 0.05 0.01
960351
980543 0.44 X X 0.62 1.23 2.34 1.93
1 week- 1 month
cc eg cw tg tw alveus hippo
215/93 1.46 0.52 0.93 0.01 0.01 0.05 0.21
741/95
970787 1.37 0.58 1.51 0.19 1.00 2.70 0.34
980067 0.71 2.76 4.34 1.27 1.55 0.61 0.19
980104 1.6 2.57 3.64 1.86 2.52 1.80 2.25
0-19 years CD68
Controls 
1-3 months
cc eg cw tg tw alveus hippo
960997 2.22 0.80 2.84 0.03 0.63 0.10 0.03
3-12 months
20-49 years CD68
Controls
cc eg cw tg tw alveus hippo
860477 X X X 0.36 1.09 0.20 0.12
860640 X X X 0.98 1.89 1.55 2.59
940083 1.02 0.33 0.81 0.05 0.18 0.03 0.12
940433 X X X 0.25 0.40 0.20 0.30
940634 2.27 0.27 0.25 X X X X
1-3 months
cc eg cw tg tw alveus hippo
950513 19.45 0.50 3.64 0.16 0.76 1.14 0.20
3-12 months
cc eg cw tg tw alveus hippo
880532 X X X 0.71 1.86 1.15 0.26
960312 0.93 0.14 0.55 0.05 0.19 1.54 0.77
960534
980290 5.88 0.21 1.25 0.07 1.08 1.59 0.63
50 + years CD68
Controls
cc eg cw tg tw alveus hippo
850595 1.18 1.09 1.52 0.46 1.36 0.94 0.73
860617 X X X 0.12 0.37 0.09 0.08
880377 X X X 0.09 0.19 0.19 0.27
900041 X X X 0.03 0.09 0.37 0.18
950597 2.00 0.45 1.34 0.63 1.32 0.30 0.69
1-3 months
cc eg cw tg tw alveus hippo
960175 4.04 0.27 0.93 0.01 0.01 0.01 0.01
950336 3.14 0.54 0.64 X X X X
950716 6.26 0.65 1.75 0.37 0.79 1.72 0.63
960518 1.37 0.52 0.72 0.26 0.69 3.79 1.49
3-12 months
cc eg cw tg tw alveus hippo
980230 3.78 0.36 0.82 0.10 0.26 0.82 0.20
980512 2.18 0.06 0.32 0.08 0.35 0.03 0.04
980228 3.20 0.06 0.16 0.07 0.27 0.27 0.04
990339 1.18 0.11 0.27 0.28 0.60 0.09 0.06
960008 0.68 0.11 0.56 0.25 0.96 0.09 0.15
970442 2.39 0.19 0.59 0.12 0.46 0.11 0.10
980072 8.97 0.25 0.83 0.18 0.69 0.61 0.19
0-19 years CR343
Controls
cc eg cw tg tw alveus hippo
418/84 X X X 0.46 1.00 0.69 0.52
960608 5.86 1.07 2.70 X X X X
960051
980309
960934
<24 hours
cc eg cw tg tw alveus hippo
688/87
262/89 X X X 0.06 0.33 X X
553/89 X X X 0.01 0.06 0.20 0.08
254/90 0.01 0.08 0.10 0.01 0.01 0.01 0.01
980328 4.10 X X 0.09 0.78 1.24 0.26
1 day- 1 week
cc eg cw tg tw alveus hippo
338/90 0.11 0.03 0.04 0.01 0.02 0.62 0.14
649/93 1.00 X X 0.07 0.13 0.50 0.13
960640
980389 10.93 0.68 1.57 0.20 0.14 0.05 0.01
990143 4.96 4.15 6.02 1.88 15.3 9.45 11.18
1 week- 1 month
cc eg cw tg tw alveus hippo
452/90 4.21 1.10 3.25 6.33 10.66 1.87 5.85
960017 12.65 6.94 11.13 1.47 6.67 3.79 1.03
960523 2.99 0.18 1.56 0.06 0.43 X X
961002 4.54 1.27 4.08 0.12 0.72 0.23 0.09
990234 3.05 0.20 1.20 1.02 2.22 2.61 1.71
20-49 years CR343
Controls
cc eg cw tg tw alveus hippo
469/90 3.60 0.44 1.14 0.44 1.30 2.32 0.60
55/92 5.60 0.52 1.93 0.01 0.02 0.01 0.01
165/94 2.50 0.38 1.70 0.31 1.20 1.40 0.34
960280 1.10 X 1.60 0.12 0.18 0.18 0.16
960545
<24 hours
cc eg cw tg tw alveus hippo
489/88 X X X 0.07 0.10 0.49 0.15
96/91 0.01 0.01 0.01 0.02 0.06 0.09 0.06
875/93 0.35 0.04 0.15 0.12 0.16 0.62 0.32
990051 1.01 0.04 0.18 0.13 0.89 0.92 0.18
990219
1 day-1 week
cc eg cw tg tw alveus hippo
980465 X 0.11 0.25 0.13 0.29 1.15 0.28
152/89 0.02 0.01 0.01 0.01 0.01 0.01 0.05
960228 0.78 0.60 0.47 0.68 0.69 11.80 0.54
970202 0.01 0.14 0.63 0.03 0.17 0.02 0.03
970696 4.80 1.10 4.04 1.93 3.21 1.15 1.43
1 week- 1 month
cc Cg cw tg tw alveus hippo
717/94 4.55 7.17 9.15 1.12 4.62 8.12 5.19
390/95 X X X 0.16 1.06 5.05 1.40
960118
961000 15.83 3.30 8.47 0.95 12.25 9.07 5.38
990451 7.42 1.48 5.35 0.90 2.73 11.87 3.23
50+ years CR343
Controls
cc eg cw tg tw alveus Hippo
335/84
488/86 X X X 0.04 0.25 3.27 0.56
675/87 X X X X X 1.95 2.18
08/94 3.75 0.42 1.17 0.03 0.44 1.46 2.74
288/95 4.87 0.55 1.62 1.15 6.23 4.13 2.67
<24 hours
cc eg cw tg tw alveus hippo
825/87 0.01 0.01 0.01 0.01 0.01 0.01 0.01
432/90 0.05 0.04 0.23 0.03 0.79 0.22 0.05
432/93 0.01 X X 0.45 3.69 5.06 4.98
960340 2.48 1.15 1.64 X X X X
960462 X X X 2.20 4.58 2.76 2.38
1 day- 1 week
cc eg cw tg tw alveus hippo
487/91 0.47 0.54 0.74 1.14 3.58 11.00 11.81
209/93 X X X 6.06 14.47 2.80 0.89
960339 3.43 0.08 0.74 0.14 3.74 1.06 0.05
960351
980543 0.89 X X 0.49 1.28 0.30 0.30
1 week- 1 month
cc eg cw tg tw alveus hippo
215/93 4.18 0.32 1.24 0.36 0.92 0.65 0.23
741/95
970787 9.55 4.45 7.84 0.09 2.91 0.97 0.05
980067 9.89 4.20 12.80 0.06 1.53 3.62 1.09
980104 7.11 1.78 1.55 0.98 4.17 11.34 7.72
0-19 years CR343
Controls 
1-3 months
cc eg cw tg tw alveus hippo
960997 41.07 6.42 22.45 0.05 0.63 5.38 0.12
3-12 months
20-49 years CR343
Controls
cc eg cw tg tw alveus hippo
860477 X X X 0.03 0.14 7.04 1.42
860640 X X X 3.08 5.47 1.92 3.75
940083 0.40 X X 0.06 0.36 1.76 1.87
940433 X X X 0.21 0.84 3.62 2.28
940634 2.20 0.58 2.00 X X X X
1-3 months
cc eg cw tg tw alveus hippo
950513 39.84 6.79 18.28 0.23 2.18 1.97 0.47
3-12 months
cc eg cw tg tw alveus hippo
880532 X X X 4.25 15.05 26.63 6.24
960312 7.28 1.97 6.60 0.14 0.23 4.53 0.14
960534
980290 30.56 0.26 5.82 0.05 4.67 7.17 1.14
50 + years CR343
Controls
cc eg cw tg tw alveus hippo
850595 5.83 1.75 2.48 1.95 4.18 2.17 0.69
860617 X X X 0.11 1.99 2.94 0.30
880377 X X X 0.87 2.49 0.28 0.19
900041 X X X 4.26 11.05 8.56 16.81
950597 8.14 2.12 4.40 1.45 3.38 2.19 2.35
1-3 months
cc eg cw tg tw alveus hippo
960175 2.74 0.22 1.09 0.57 6.72 2.13 0.86
950336 6.71 4.01 9.45 X X X X
950716 16.69 3.64 14.94 X X X X
960518 7.55 1.69 3.25 0.16 0.38 11.39 1.64
3-12 months
cc eg cw tg tw alveus hippo
980230 0.01 0.05 0.01 5.36 16.31 4.31 0.98
980512 0.18 0.02 0.09 0.01 0,04 0.01 0.01
980228 11.97 1.17 4.82 0.63 10.30 4.71 0.55
990339 5.72 1.00 2.20 0.30 2.35 0.14 0.12
960008 10.90 1.11 3.50 0.79 3.01 2.36 1.82
970442 11.08 3.27 5.04 0.34 2.38 2.18 5.94
980072 23.95 7.17 35.4 1.04 10.56 6.03 0.98
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Abstract
Head injury is commonly encountered in autopsies 
related to trauma. While many o f the macroscopicfeatures o f 
head injury do not provide difficulty in interpretation, the 
microscopical pathology has generated a confusing literature. 
The interpretation o f the microscopical pathology can be o f 
importance to the forensic pathologist. This article aims to 
offer a guide to the pathologist who may undertake an 
autopsy with a clinical history o f and/or macroscopic 
evidence o f a head injury. Further details o f the autopsy 
examination may be found in the guideline section o f the 
British Neuropathological Society website 
(www.bns.org.uk)
Keywords
Trauma, diffuse brain injury.
Introduction
Pathologists undertaking coronial/ procurator 
fiscal autopsies frequently encounter non-missile 
traumatic head injury, the neuropathology o f which 
can be divided into two principal categories: 1) 
focal; and 2) diffuse. Focal injuries include 
lacerations o f  the scalp, fracture o f  the skull, 
lacerations and contusions o f  the brain, raised 
intracranial pressure lesions, and intracranial 
haemorrhages. Diffuse injuries are ischaemia, brain 
swelling and diffuse traumatic axonal injury.
In this article we shall try to illustrate the 
com ponents o f  adult traumatic brain injury, and 
relate these to the clinical history.
Scalp lacerations and skull fractures should be 
accurately docum ented. This should be routine 
practise in any autopsy examination and will not be 
detailed further.
Haematomas
Intracranial haemorrhage is the most com m on 
cause o f clinical deterioration and death in patients 
w ho experience a lucid interval after head injury.1 
Haematomas may act as a mass lesion and produce 
secondary effects (as detailed below). Extradural, 
subdural, subarachnoid, and in tracerebral 
haematomas can all be associated w ith traumatic 
brain injury.
Figure 1. Extradural haematoma at autopsy.
Subdural haematomas (Figure 2) tend to be more 
extensive than extradural lesions as blood can spread 
more freely w ithin the subdural space. The majority 
are due to disruption o f parasagittal bridging veins 
and these can be detected by careful reflection o f the 
dura at autopsy. T he volum e o f the subdural 
haematoma should be estimated; this can be done by 
pouring the haematoma into a measuring cylinder. 
Ageing o f subdural haematomas can be difficult both 
macroscopically and microscopically, although some 
attem pt has been made.3 In cases o f unilateral 
subdural haematoma there is often accentuation o f 
the gyral pattern ipsilateral to the haematoma, with 
flattening o f the contralateral gyri.
Subarachnoid blood is com m only associated 
w ith contusions, but is rarely significant.
Intracerebral haemorrhages (Figure 3) may be 
superficial, usually associated w ith contusions, or 
they may be more deeply seated, usually within the 
basal ganglia (Table 1). W hen an intracerebral lesion 
is in continuity w ith a subdural haematoma the term  
“burst lobe” is used.
Contusions
Contusions are superficial lesions in which the 
pia is intact, whereas in lacerations the pia is
Extradural haematomas (Figure 1) are seen in 
some 10% o f severely head injured patients, 80% 
being associated w ith skull fractures. The majority 
involve the middle meningeal artery w ith fractures o f 
the temporal bone, but 20-30%  occur at other sites.2
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figure 2. Subdural haematoma at autopsy. F igure 3 Traumatic intracerebral haemorrhage.
Aetiology Site
Hypertension Usually putamen, thalamus, cerebellum, or pons.
iTrauma Deep-basal ganglia and thalamus. Superficial-generally related to overlying contusions.
Cerebral amyloid angiopathy Superficial lobar haemorrhage,associated with Alzheimer's disease.
.fiaccular aneurysms MCA aneurysm- Sylvian fissure IntCA- medial temporal lobe AcomA aneurysm- frontal lobe.
Vascular malformation May occur at any site.
Neoplasms Particularly seen with oligodendrogliomas and metastatic tumours.
lOther causes such as iatrogenic bleeding (eg warfarin therapy), vasculitis, infection, recreational drugs. 
'MCA= middle cerbral artery. AcomA= anterior communicating artery. lntCA= internal carotid artery.
Table 1. Causes o f intracerebral haematoma.
I / ruptured. These are seen in approximately 90%  o f fatal 
:^ses o f  traum atic brain injury, although they may be 
absent in  some 6%  o f  fatal cases.4 T hey  are m ore 
tom m only seen at the crests o f  the frontal and temporal 
:: 5yri than w ith in  sulci and occur principally at sites where 
the brain comes in  contact w ith  the uneven bony surfaces 
of the base o f  the skull. W hen contusions occur on the 
lateral aspect o f the cerebral hemispheres they are usually 
in association w ith localised impact injury w ith  or w ithout 
^  skull fracture. T hey  are initially haem orrhagic and 
J swollen, bu t w ith  tim e they become brown and shrunken 
i as a result o f  haem osiderin pigm entation and gliosis 
■ respectively.
|  Complications o f  mass lesions
'  A supracallosal hernia may obstuct flow w ithin the
■  | >ericallosal artery (anterior cerebral circulation) resulting 
h infarction w ith in  the corpus callosum and cingulate 
jyrus (Figure 4). A tentorial hernia may obstruct flow 
vithin the posterior cerebral artery resulting in medial 
Occipital cortical infarction, and caudal displacement and 
Elongation o f  the rostral brainstem may result in brainstem 
haemorrhage and infarction, a com m on term inal event in 
raised intracranial pressure. Clinically a tentorial hernia
t may produce an ipsilateral fixed dilated pupil, due to 
I  ipsilateral ocu lom otor nerve damage, and ipsilateral 
t-j veakness due to  contralateral cerebral peduncle 
compression (Kernohan lesion -false localising sign). A 
f l  vvedge o f  necrosis in the parahippocampal gyrus provides 
h good evidence o f  raised intracranial pressure during life.
f D iffuse injury
T hree forms o f  diffuse brain injury are seen as a
■ consequence o f  trauma; diffuse ischaemic injury, which
involves grey matter, diffuse traum atic axonal injury 
(TAI), which involves white matter, and brain swelling 
w hich may be cytotoxic (grey m atter) or vasogenic 
(principally w hite matter).
In the absence o f a mass lesion, such as a subdural 
haematoma, persistent coma due to structural damage 
m ust be due to diffuse TAI, global hypoxia/ischaemia, or a 
com bination o f both.
W hile focal infarcts are com m only seen after fatal 
traumatic head injury (91% in one study6), usually as a 
consequence o f raised intracranial pressure (ICP) as 
detailed above, global cerebral ischaemia is less com mon. 
Global cerebral ischaemia may be related to hypotension, 
e.g. after multiple injuries, or secondary to raised ICP 
resulting in reduced cerebral b lood flow. Ischaemic 
neurons are widely distributed, initially following a pattern 
o f  selective vulnerability (Table 2).
Diffuse traumatic axonal injury (TAI) is a histological 
diagnosis, which requires examination o f multiple brain 
areas7 (Table 3). A pictorial representation o f the 
recom m ended blocks is provided (Figure 5). Three grades 
o f  diffuse TAI are recognised (Table 4).
D am aged axons are best identified using 
im m unocytochem istry for amyloid precursor protein (A(3- 
PP)8 (Figure 6a); using this technique damaged axons can 
be identified 2 hours after traumatic head injury,9 and are 
seen in all cases w ho survived 3 hours or more. Afl-PP acts 
purely as a marker for disrupted axonal flow and is not a 
specific indicator o f trauma. AJ3-PP positive axons are seen 
in  a variety  o f  conditions that include infarction, 
hypoglycaemia, and HIV infection.7 In the presence o f an 
appropriate history o f  traum a, im m unoreactve axons 
scattered throughout white m atter tracts allow a confident 
diagnosis o f  diffuse TAI. A(3-PP positive axons can be
tUla Publications Ltd.
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Figure 4a. Brain section demonstrating the complications o f raised 
intracranial pressure. There is a supracallosal hernia with infarction of 
the parasagittal tissue, and a tentorial hernia w ith associated 
infarction. In addition there is downward displacement o f the 
midline structures.
Figure 4b. Tonsillar hernia secondary to raised intracranial pressure. 
The tonsils are haemorrhagic and necrotic.
• Hippocampus- sector CA1 is most vulnerable, sector CA2 
least so.
• Cerebral cortex- neurons of layers 3, 5 and 6 are most 
vulnerable. Damage is most pronounced within the depths of 
sulci and is initially most severe posteriorly within the cerebral 
hemispheres (triple watershed zone).
• Basal ganglia (including thalamus)- variable.
• Cerebellum- Purkinje cells.
• Brainstem- brainstem nuclei tend to be relatively preserved in 
adults, but when they are affected sensory nuclei are more 
susceptible than motor nuclei.
• Ischaemic neurons have a time course and incontrovertible 
evidence of irreversible damage is the presence of 
incrustations.
Figure 4c. Brain stem haemorrhage is a common terminal event 
w hen the intracranial pressure is high.
identified up to between 1 and 3 m onths after traum atic 
b ra in  injury. W ith  longer survival C D  68 
im m unoreactivity (Figure 6b) can be useful in assessing 
the extent o f axonal pathology, microglial activation 
m irro ring  the distribution o f axonal pathology.10
Traum atic axonal injury is no t a static process. A small 
proportion  o f axons may be damaged at the tim e o f  head 
in ju ry  (primary axotomy), but animal experim ents suggest 
this is not the case for most o f the damaged axons, which 
degenerate over a period o f tim e after the head injury 
(secondary axotomy).11 C urren t evidence indicates that 
this process may proceed at different rates in  different 
brain areas and that axon size influences the rate o f 
damage. As a consequence, the size and m orphology o f 
axonal swellings after trauma do not convey inform ation 
relating to the tim ing or severity o f  the head injury.
Brain swelling can develop either locally, such as in 
relation to contusions, or can be diffuse involving one or 
b o th  hemispheres. In diffuse brain swelling 
hypoxia/ischaemia is the m ost com m on underlying 
pathology. As a consequence o f brain swelling there is raised 
IC P  producing ischaemic lesions in the distribution 
described above. The vascular complications o f raised ICP 
can produce a pattern o f AJ3-PP immunoreactivity that is 
difficult to distinguish from diffuse TAI, and in some cases 
the interpretation o f the underlying pathology is impossible.
T able 2. Selective vulnerability o f neurons after cerebral ischaemia.
The following survey is recom m ended as a minimum to make the 
diagnosis of diffuse traumatic axonal injury.
Bilateral blocks from a coronal brain slice at the level of the lateral 
geniculate bodies:
• Corpus callosum with adjacent parasagittal cortex and white 
matter.
• Deep grey matter including posterior limb of internal capsule
• Temporal lobe including hippocampus.
In addition the following areas require to be sampled:
• Genu (anterior sectionsjof corpus callosum.
• Cerebellar hemisphere including the dentate nucleus.
• Midbrain at the level of the decussation of the superior 
cerebellar peduncles.
• Pons at the level of the middle cerebellar peduncles.
• Medulla.
Table 3. Recommened block sampling for diagnosis o f diffuse TAI.
Grade 1- abnormalities limited to histological evidence of 
axonal damage throughout the white matter.
Grade 2- in addition to widely distributed axonal injury, there is 
a focal lesion in the corpus callosum.
Grade 3- represents the worst injuries within the spectrum, 
characterised by diffuse axonal damage in the 
presence of focal lesions in both corpus callosum and 
brainstem.
Table 4. Grades o f diffuse traumatic axonal injury
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Figure 6a. A ^-PP immunoreactive axons in a case of traumatic brain 
injury.
The Pathology of Head Injury
Figure 5a. The recommended sampling for diffuse traumatic axonal 
injury. The brain is sampled at the level o f the lateral geniculate body, 
and samples should include the corpus callosum and the internal 
capsule (arrows). Both hemispheres should be sampled.
Figure 5b. The rostral corpus callosum should be sampled at the 
level o f  the genu.
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Figure 6b. CD 68 immunoreactivity in the pons from a long term 
survivor o f traumatic brain injury. The macrophages are found 
predominandy within the corticospinal pathways, and are indicative 
o f Wallerian degeneration within these tracts. There is a relative 
paucity of immunoreactivity within the transverse pontine fibres.
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Tau Immunohistochemistry in acute brain injury
Epidemiological studies have identified a history of head 
injury as a risk factor for Alzheimer’s disease. However, the 
neuropathological mechanism underlying this relation­
ship is as yet unclear. Neuronal cytoskeletal changes in the 
form of neurofibrillary tangles and neuropil threads have 
recently been demonstrated in young men who had sus­
tained repetitive head injury and subsequently died in 
their 20s. In addition, recent experimental studies have 
found accumulation of tau within neuronal somata and 
damaged axons following diffuse brain injury. We hypoth­
esized that tau-immunoreactive tangles may be present in 
the brains of patients who died after a single acute blunt 
head injury. A total of 45 cases of fatal head injury were
Keywords: Alzheimer's disease, tau, traumatic brain injury
immunostained for tau. They comprised nine groups (n=5 
for each group) separated by age (0-19 years, 20- 
50years, 50+years) and survival time (<24h, 24 h - 
1 week, 1 week-1 month) and were compared with age- 
matched controls. Subtle alterations in tau immunoreac­
tivity, for example, in oligodendrocytes, were present in 
some head injury cases but not controls. However, neu­
rofibrillary tangles did not appear more prevalent after 
traumatic brain injury (TBI) when compared with age- 
matched controls. Although alterations in tau immunore­
activity may occur which warrant further study, neu­
rofibrillary tangles were not more prevalent after a single 
fatal episode of TBI.
Introduction
Alzheimer’s disease (AD) is a major cause of morbidity and 
mortality in the community. A number of risk factors have 
been identified, one of which is a previous history of head 
injury. There is a considerable epidemiological literature 
examining the relationship between traumatic brain 
injury (TBI) and the development of AD in later life. Many 
of these studies take the form of retrospective case-control 
studies and are therefore subject to recall bias. However,
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an association between TBI and AD has been reported by 
some [9,14,17,18] but not all authors [5,16,27]. Guo 
et al. [9] studied 2233 individuals who met the criteria for 
probable or definite AD, and compared them with 14 668 
controls (first-degree relatives or spouses) as part of the 
MIRAGE (Multi-Institutional Research in Alzheimer 
Genetic Epidemiology) project. They reported that TBI was 
a risk factor for AD and that the risk was proportional to 
the severity of the injury. For example, comparison of 
probands with unaffected spouses yielded odds ratios for 
AD of 9.9 for head injury with loss of consciousness and 
3.1 for head injury without loss of consciousness. Compar­
ison of probands with their parents and sibs yielded odds 
ratios of 4.0 for head injury with loss of consciousness and 
2.0 for head injury without loss of consciousness. At age
496 © 2003 Blackwell Publishing Ltd
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93 years the lifetime risk of developing AD was 77.2% for 
those with and 40.1% for those without a history of head 
injury. A number of prospective studies have been designed 
to try and address the problems of recall bias inherent in 
case-control studies. Again, however, there are conflicting 
data. Some studies [3,20,24] have reported between a 3 x 
and 4 x increased incidence of AD with a history of head 
injury. Against these data, however, there are a number of 
prospective studies which have failed to demonstrate an 
association between TBI and AD [13,15].
The mechanisms underlying a possible association 
between TBI and AD have not been determined. One of the 
principal features of AD is pathology in the form of neu­
rofibrillary tangles and neuropil threads within which 
abnormal forms of the microtubule-associated protein tau 
are found. Cytoskeletal pathology after TBI has been exam­
ined experimentally using a pig model with injury induced 
via controlled head rotational acceleration [25]. Head- 
injured pigs were examined at days 1, 3, 7 and 10 after 
injury, and compared to control animals without head 
injury. Within the experimental group tau and neurofila­
ment accumulations were identified immunohistochemi- 
cally in the white matter, colocalized with damaged axons 
(AJ3-PP immunoreactive), and within neuronal perikarya 
in the cerebral cortex.
Very little data exist on tau antibodies in man after a sin­
gle episode of TBI, although cleaved forms of tau protein 
are markedly elevated in the cerebrospinal fluid of brain- 
injured patients [28]. Newman et al. [19] assessed hyper- 
phosphorylated tau in man after fatal TBI using the Alz50 
antibody. They studied 27 cases of fatal TBI with 23 age- 
matched, nonhead-injured controls. A number of brain 
regions were examined including frontal and cingulate 
cortex, hippocampus, thalamus and pons. While eight 
trauma cases had tau-immunoreactive neurofibrillary 
pathology, the majority were older individuals (only one 
case was under the age of 51) and the distribution was 
comparable to controls. One case was a 16-year-old male 
who had tau-immunoreactive neurites in the pons only. In 
addition, tau immunoreactivity has been demonstrated in 
oligodendrocytes in patients dying after stroke and TBI 
[11].
However, cytoskeletal pathology is observed in cases of 
repetitive relatively mild head injury including, for exam­
ple, in boxing. Neurofibrillary tangles scattered through­
out the cerebral cortex and the brainstem, being most 
prominent in the medial temporal cortex, were reported in 
elderly ex-boxers by Corsellis et al. [4]. In some cases this
was associated with cognitive impairment, the condition 
being called dementia pugilistica. Geddes et al. [6 ] examined 
the brains of four young adults (age range: 23-28 years) 
with a history of repetitive head injury (two boxers, one 
footballer and one mentally subnormal patient with a his­
tory of self-inflicted head banging) and a frontal lobectomy 
specimen from an individual with intractable complex par­
tial seizures with recurrent minor head injury. They iden­
tified widespread neocortical neurofibrillary tangles and 
neuropil threads not seen in age-matched controls which 
in areas showed a perivascular distribution. Schmidt et al. 
[23] have compared the molecular profiles of the neu­
rofibrillary tangles in dementia pugilistica and AD. They 
found that dementia pugilistica and AD had a common tau 
isoform and phosphorylation profile. They concluded that 
the mechanisms underlying both these conditions might 
be similar.
In light of this background information the present 
study was designed to test the hypothesis that tau accumu­
lation in humans in the acute phase after TBI is similar to 
that seen in animal models.
M aterials and m ethods
Cases of TBI were selected from the archives of the Glasgow 
Neuropathology Department. For each case detailed 
clinico-neuropathological information was available, and 
a standardized protocol for tissue block sampling had been 
used. A total of 45 acute TBI cases with varying survival 
times ranging from < 24 h up to 1 month (Tables 1, 2 and 
3) were included in this study. In general, the acute TBI 
cases had all suffered a severe head injury [Glasgow Coma 
Scale (GCS): < 8 ] with only one case having a moderate 
injury (GCS: 9-12). Four cases had a mild head injury 
(GCS: 13-15) and died of pathology not directly related to 
the brain injury. In 12 cases GCS was not recorded as 
patients either died rapidly before hospital admission or 
were not formally assessed. In all of these cases the pathol­
ogy suggests a significant head injury. The mechanisms of 
injury varied with road traffic accidents (RTAs) being more 
common in the < 2 0 -year-old group, and falls more com­
mon in the > 50-year-old group. Fifteen cases with no sig­
nificant neurological impairment or neuropathological 
abnormality were used as controls (Table 4). The Research 
Ethics Committee of the Southern General Hospital 
approved the study.
The brains had been fixed in 10% formal saline for a 
minimum of 3 weeks before dissection after which a stan-
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Table 11. Details of traum atic brain injury cases aged < 20  years used in study
Survival Age
Documented
survival
Severity of headinjury 
(admission CCS)
Mechanism of 
head injury Main pathology
< 2 4 h 8 weeks 4 h Severe (NA) RTA DVI
1.5 years 22 h Severe (NA) FaU TAI
3 years 21 h Severe (5) RTA TAI, swelling
9 years 10 h Severe(3) RTA TAI, swelling
14 years 7 h Severe (3) RTA DVI
2 4 h - l  week 3 years 48  h Severe (NA) RTA Brain swelling
5 years 3 days Severe (NA) RTA TAI, swelling
7 years 48  h Severe (6) RTA Brain swelling
12 years 7 days Severe(5) RTA ICH, TAI
14 years 48  h Severe (3) RTA TAI, swelling
1 w eek-1  m onth 5 years 9 days Severe(5) RTA Acute LSDH
15 years 8 days Severe (4) RTA TAI, swelling
15 years 8 days Severe (4) RTA TAI, swelling
17  years 14 days Severe (5) RTA TAI
19 years 21 days Severe (3) RTA TAI
GCS, Glasgow Coma Scale; NA, not available; RTA, road traffic accident; DVI, diffuse vascular injury; TAI, diffuse traum atic axonal injury; ICH, 
intracerebral haem orrhage; LSDH, left subdural haem orrhage.
Table 2 . Details of traum atic brain injury cases aged 2 0 -5 0  years used in study
Survival
Age
(years) Documented survival
Severity of head injury 
(admission GCS)
Mechanism of 
head injury Main pathology
< 2 4 h 23 8h Severe(3) RTA TAI
25 20 h Severe (4) RTA Global ischaemia
30 1 6 h Severe (3) RTA Acute LSDH
34 23 h Severe (3) FaU Acute LSDH
39 12 h Severe (3) RTA DVI
2 4 h - l  week 23 3 days Mild (15) Assault Drug overdose
26 24 h Severe(3) Fall Contusions, swelling
26 4 days Severe(6) Fall Contusions, swelling
37 24 h Severe (3) Fall Acute RSDH
40 5 days Severe (4) Assault Acute LSDH
1 w eek-1 m onth 21 9 days Severe (NA) RTA TAI, acute LSDH
23 28 days Severe(3) Assault TAI
27 11 days Moderate (10) Fall TAI, R burst lobe
30 18 days Mild (15) Fall Extracranial pathol­
ogy
35 10 days Mild (15) Fall Exsanguination
GCS, Glasgow Coma Scale; RTA, road traffic accident; DVI, diffuse vascular injury; TAI, diffuse traum atic axonal injury; ICH, intracerebral haem ­
orrhage; R/LSDH, right/left subdural haem orrhage.
dardized brain cut and histological sampling were under­
taken. The tissue was processed in a VIP tissue processor 
(Bayer Diagnostics, Newbury, UK) using a 60-h cycle and 
embedded in paraffin wax. Eight-micrometre-thick sec­
tions; of temporal lobe including hippocampus were cut 
and stained with haematoxylin and eosin. In addition, 
immunohistochemistry was undertaken for tau (mono­
clonal antibody, Dako 1:15000). No pretreatment was
required and the primary antibody was applied overnight 
at 4°C. This antibody reacts with both the phosphorylated 
and nonphosphorylated forms of tau protein, and labels 
the tau protein of neurofibrillary tangles. The antibody 
was detected using the ABC kit (Vecta Stain, Vector Labo­
ratories, Peterborough, UK) and developed with diami- 
nobenzidine. Immunostained sections were assessed 
‘blind’ by C.S. and J.A.R.N.
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Table 3 . Details of traum atic brain injury cases aged > 5 0  years used in  study
Age Severity of head injury Mechanism of
Survival (years) Documented survival (admission GCS) head injury Main pathology
< 2 4 h 51 12 h Severe (3) Fall Acute RSDH
59 20 h Severe(3) Fall Bilateral acute SDH
66 21 h Severe (4) RTA Acute LSDH
71 12h Severe (NA) Fall Acute LSDH
88 7 h Severe (NA) Fall Acute LSDH
2 4 h - l  week 53 2.5 days Severe (NA) Fall Acute RSDH
56 4 days Severe(5) Fall Acute RSDH, TAI
60 8 days Severe (NA) Fall ICH
68 3 days Severe (4) RTA Acute LSDH, TAI
73 7 days Severe (NA) RTA Contusions, swelling
1 week-1  m onth 53 11 days Severe (3) Fall Acute LSDH
59 17 days Severe (6) Fall LSDH
60 10 days Mild (14) Fall ICH, TAI
79 8 days Severe (NA) RTA Acute LSDH
83 18 days Severe (NA) RTA ICH, TAI
GCS, Glasgow Coma Scale; NA, not available; RTA, road traffic accident; TAI, diffuse traum atic axonal injury; ICH, intracerebral haemorrhage; 
R/LSDH, right/left subdural haemorrhage.
Table 4. Details of control cases (non-head injured controls with no neurological disease) used in study
<20 years 2 0 -5 0  years >50 years
Age Cause of death Age Cause of death Age Cause of death
4 Congenital heart disease 20 Drug overdose 50 Metastatic carcinoma
8 Viral infection 21 Septic shock 59 Disseminated Langerhan’s histiocytosis
10 Burns 28 Drug overdose 68 Ruptured aortic aneurysm
18 Leukaemia 33 Ischaemic heart disease 69 Congestive cardiac failure
18 Systemic Hodgkin’s disease 38 Congestive cardiac failure 71 Pneumonia
)
Results
Four patterns of tau immunoreactivity were seen:
1 neuronal perikaryal immunoreactivity (Figure la);
2 neuropil threads (Figure la);
3  glial cell immunoreactivity with associated punctate 
staining in white matter (Figure lb); and
4 diffuse neuropil staining (Figure lc).
Neuronal perikaryal immunoreactivity (Table 5) was seen 
in the form of fibrillary structures (neurofibrillary tan­
gles). These were identified by anatomical region and anal­
ysed semiquantitatively as total number per x 1 0  fields. 
Neuronal perikaryal immunoreactivity was seen in both 
TBI and control cases and, in both groups, increased with 
age.
Neuropil threads (Table 5) were assessed as being either 
present or absent. Neuropil threads, like neuronal
perikaryal immunoreactivity, was seen in both TBI and 
control cases and, in both groups, increased with age.
Glial cell immunoreactivity (Table 5) was assessed as 
either present or absent. Glial tau immunoreactivity was 
seen in some TBI cases but, in general, was a not a feature 
of control cases.
Diffuse neuropil staining (Table 5) was assessed as either 
present or absent. This pattern of immunoreactivity was 
seen at all ages in both TBI and control cases.
Discussion
We have assessed tau immunoreactivity in the hippocam­
pus and adjacent temporal lobe in cases of fatal TBI with 
survival times ranging from < 24 h up to 1 month. We 
have shown that, unlike the previously reported animal 
studies, tau immunoreactivity is a feature of control 
brains, that is, brains with neither clinical nor gross neu-
© 2003 Blackwell Publishing Ltd, Neuropathology and Applied Neurobiology, 2 9 , 4 9 6 -5 0 2
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Figure 1. (a) Photomicrograph from the medial temporal cortex 
demonstrating both neuronal perikaryal immunoreactivity and 
neuropil threads. Tau-immunoreactive fibrillary structures 
(neurofibrillary tangles) are seen in four neuronal cell bodies, and 
neuropil threads are numerous. Tau immunostaining x 20. (b) 
Photomicrograph from cerebral white m atter showing tau 
immunoreactivity within glial cell bodies. In addition, there is a 
punctate pattern of staining within the white matter. Tau 
imm unostaining x 20. (c) Photomicrograph from the hippocampus 
showing diffuse tau immunoreactivity in the stratum  pyramidalis of 
the cornu ammonis. Tau immunostaining x 20
ropathological abnormalities. This was seen with the tau 
perikaryal, neuropil thread and diffuse neuropil immu­
noreactivity. Tau perikaryal and neuropil thread immu­
noreactivity increased with age, while diffuse tau neuropil
© 2003 Blackwell Publishing Ltd, Neuropathology and Applied Neurobiology, 2 9 , 4 9 6 -5 0 2
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immunoreactivity was seen at all ages. Tau glial immu­
noreactivity, however, did appear to be associated with 
acute TBI and immunoreactivity could be detected in cases 
with a survival of <24h. We could not demonstrate 
perikaryal accumulation of phosphorylated tau after 
acute TBI in these human studies, a finding reported in the 
pig model [25]. This experimental study used controlled 
head rotational acceleration to induce injury, resulting in 
diffuse traumatic axonal pathology. A range of antibodies 
(Tau-2, PHF-1, PHF- 6  and PHF-13.5) was used to assess 
tau pathology. The current study has examined human 
material derived from cases of fatal TBI with a variety of 
primary insults (RTA, fall and assault) producing mixed 
focal and diffuse pathologies, including diffuse traumatic 
axonal injury (TAI). It is probable that the loading condi­
tions determine the brain response, and that the highly 
controlled laboratory situation accentuates a specific 
brain response. The current study used only a single anti­
body to detect tau (Dako monoclonal antibody), and a 
wider panel of antibodies, such as that used by Smith et al, 
[2  5], may be required to detect specific cytoskeletal abnor­
malities. In addition, there may be species differences, 
such that cytoskeletal disruption, if present in man, may 
develop over a different time course. Smith et al. [25] dem­
onstrated axonal tau immunoreactivity at 3 days post­
trauma, and consistently found expression up to 1 0  days 
post-trauma (latest time point examined). Our study 
looked up to 1  month post-trauma, but longer survival 
times may need to be examined to fully assess the possibil­
ity of tau expression after TBI.
The study by Newman etal. [19], although looking at 
TBI in man, utilized a different antibody against tau from 
this study. While the current study utilized an antibody 
that reacts with both phosphorylated and nonphosphory- 
lated forms of tau, Newman et al. used Alz50, an antibody 
which selectively binds specific conformations of the tau 
protein [2]. The different antibodies may identify different 
stages in the temporal evolution of neurofibrillary 
pathology.
The cases of repetitive mild TBI reported by Geddes et al. 
[6 ] were all subjected to repetitive relatively mild blows to 
the head. These cases clearly differ from the mixed neuro­
pathologies seen in most cases of human TBI, but demon­
strate that in this rather specific type of insult TBI is 
associated with tau pathology. In cases of fatal TBI follow­
ing a single blow to the head structural cytoskeletal distur­
bances involving tau may be initiated. The pathological 
response to human TAI is known to develop over a period
of time [8 ], and the cytoskeletal response may be modified 
by coexistent primary and secondary pathologies. We may 
have to look at survival times beyond 1  month to fully 
assess the role of tau in the response to TBI, and the rela­
tionship between a single episode of TBI and the develop­
ment of Alzheimer type pathology. A second pathological 
feature associated with AD is the deposition of A(3 plaques 
within the neuropil. Diffuse A(3 plaques have been identi­
fied in approximately 30% of patients who die shortly after 
a single episode of severe TBI [21,22]. This is a higher pro­
portion than in non-head injury controls. Another group 
[1], however, has not confirmed this observation. Most of 
the deposit is in the form of A|542 [7,10], which is believed 
to be of pathological significance in AD.
In humans, genetic influences may play an important 
role in modifying the outcome after TBI. Possession of 
APOE e4 is associated with a worse outcome after TBI [2 6 ], 
and with an increased severity of chronic neurological def­
icits in high-exposure boxers [1 2 ], with ‘high-exposure’ 
being defined as participation in at least 1 2  professional 
bouts. The role of APOE polymorphisms in modifying 
cytoskeletal responses after TBI was not addressed in the 
current study but may be an area of future research.
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Introduction
Traum atic brain Injury rem ains a  significant cause of m o r­
bidity an d  m ortality throughout the world. In the United 
Kingdom m ore than  ISO 000 patien ts are adm itted  to  h o s ­
pital each  year with a  head injury. O f this group m ore th an  
80% are classified as having a mild head  injury, as defined 
by the Glasgow Coma Scale (GCS). T he GCS (Teas dale & 
lenne tt 1974, 1976) provides a m eans o f  quantifying the 
level of consciousness after traum atic bra in  injury based 
o n  the clinical features o f verbal perform ance, eye opening  
an d  m otor response. Using this scale th ree levels of sever 
Ity o fh ead  injury are defined; mild (score 13-15), m oderate 
(score 9-12), and  severe (score 3-8).
Approximately 1-2% o f patients adm itted  to hospital af­
te r traum atic brain injury die as a  consequence o f their in 
juries. The m ajority of fatalities are w ithin the severe head  
injury group, with 40% of the cases resulting in  death a t  6 
m onths (Murray e r a i ,  1999).
Among survivors of traum atic b ra in  injury o f all grades 
chronic disability may have a physical com ponent al 
though it is predom inantly  the cognitive and  behavioural 
problem s which provide the greatest challenge (lenne tt 
e t  a l ,  1981). O utcom e may be assessed by the Glasgow 
Outcom e Scale (GOS) (lenne tt & Bond 1975) which d e ­
fines four outcom e states; death/vegetative state, severe 
disability, m oderate disability, an d  good recovery. The 
GOS is based predom inantly  on assessm ent o f social re­
integration alter traum atic brain injury involving a s tru c ­
tured questionnaire-based interview. This has recently 
b ee n  m odified as the extended GOS (Teasdale et a l ,  1998). 
Predictors o f neurobehavloural ou tcom e in adults Include 
age (greater than  50 years is a  poor prognostic factor), the
ac u te  GCS, abnorm al brain stem  reflexes, subacute ventric­
ular enlargem ent, neurological deficit, and  the du ra tion  of 
post-traum atic am nesia (Capruso & Levin, 2000).
Som ew hat surprisingly, recent studies have indicated 
th a t the incidence of m oderate an d  severe disability In 
young p eop le  and  adults one year after m ild head  injury 
is sim ilar to  th a t seen  in survivors o f m oderate and  severe 
head  injury (Thornhill etaL , 2000). In addition there Is evi­
dence (discussed below) that traum atic brain injury may 
b e  associa ted  w ith continuing  cognitive decline in later 
years an d  with an  increased Incidence of Alzheimer's dis­
ease (AO). The m echanism s underlying the association b e ­
tw een head  in jury  and  AD are unknow n as yet, although, as 
w e shall d iscuss in this chapter, the response to traum atic 
bra in  injury and  the pathology of AD have som e features 
In  com m on  n o t only in  term s of a  cellular and  p ro tein  re ­
sponse b u t also striking parallels in the genetic influences.
In  order to  a ttem p t to clarify the m echanism s underlying 
post-traum atic cognitive deficit a  basic understanding of 
th e  pathology o f traum atic brain injury is helpful.
Blunt force head  injury results in b o th  focal and  diffuse 
pathologies involving the skull an d  the underlying brain 
a n d  its coverings. Focal lesions can  take th e  form  o f skull 
fractures, cerebral contusions (Fig. 20.1), focal ischaem ic 
lesions secondary to  raised intracranial pressure, and  in­
tracranial haem atom as. Diffuse lesions m ay take the form 
o f  cerebral Ischaem ia or cerebral swelling, or m ay develop 
a s  a  consequence o f rotational forces (diffuse traum atic ax­
onal Injury) (Graham et a l ,  1995b). The prim ary injury is 
re la ted  to m echanical dam age, and  can  be focal o r diffuse, 
o r  a  com bination  of both. It is related to the effects o f bo th  
th e  im pact an d  inertial forces on the skull and brain. D e­
layed secondary  events such  as diffuse traum atic axonal
TV Neuropathology of Dtmm da Second Bdttion, ed. Margaret M. Esirt John Q. Thrjanowaki and Virginia M.-Y. Lae 
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fty. 10.1. Healed cerebral contusions. There are orange-brovm scars on the under aspect of the frontal and temporal lobes.
injury and  cerebral ischaem ia develop over a  period of 
hours, days, o r weeks after the traum atic episode. The sec­
ondary  events m ay be related to  neurochem ical alterations 
and  the associated cellular and  m olecular alterations in ­
duced  by traum a (Graham et a l ,  2000).
Effects of h e a d  injury o n  cogn itive  function
Concussion refers to  an  im m ediate, usually reversible 
episode o f brain dysfunction after traum atic b ra in  injury. 
A clinical spec trum  is recognized ranging from mild c o n ­
cussion, in  which consciousness is o ften  preserved, to  se­
vere diffuse axonal injury resulting in  the vegetative state 
(Gennarelli, 1993). The anatom ical basis of concussion syn­
drom es is currently  considered to  be diffuse axonal pa th o l­
ogy and, in  particular; axonal d isrup tion  resulting in  d is­
connection  betw een areas involved In consciousness; cere­
bral cortex, bra instem  reticular activating areas, thalam us
an d  hypothalam us (Gennarelli, 1993). The vegetative state 
refers to a  group of pa tien ts  w ho have loss o f m eaningful 
cognitive function  an d  aw areness, bu t retain spontaneous 
breathing and  periods of w akefulness. The neuropatho- 
logical basis of the vegetadve sta te  has been  defined in  a 
s tudy  tha t exam ined 49 patien ts  in  the vegetative state, 35 
o f w hom  h ad  experienced traum atic b ra in  Injury (Adams 
e t a l ,  2000) (Fig. 20.2). In  the  traum a-re la ted  cases diffuse 
traum atic axonal injury o f grade 2 o r 3 w as found in 71% 
o f cases, and  thalam ic pathology in 80% o f cases. In cases 
w ith  m inim al b ra instem  an d  cerebral cortical pathology, 
thalam ic pathology w as always present. Therefore, d a m ­
age to  the thalam ic nuclei a n d /o r  the afferent an d  efferent 
w hite  m atter pathw ays o f  th e  thalam us appear to  play a 
m ajor ro le in  the genesis o f  the vegetative state  after head 
Injury. W hite m atter (W alierian) degenera tion  is a  conse­
quence of severe diffuse traum atic  axonal injury (Fig. 20.3). 
The axonal loss results in  gliosis an d  m acrophage activation 
(Fig. 20.4), w hich m ay b e underg en etic  control as discussed
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Fif. 24.2. Corona] slice-vegetalive. 21 month survival post RTA- Note the thinning of the corpus callosum, ventricular enlargement and 
small rather granular lhalami due to diffuse traumatic atonal injury.
latex In contrast, the structural basis o f  m odera te  disabfl 
Ity after traum atic bra in  injury is m ore likely to  be a  local 
lesion rather th an  diffuse brain pathology, usually  an  evac­
uated  Intracranial haem atom a (Adams e t aL, 2001). In a  
study  o f 30 severely disabled patients 50% h a d  focal b ra in  
pathology only. Some severely disabled patien ts  did  show  
diffuse brain pathology similar to  vegetative state  patien ts, 
an d  It m ay be th a t there is a  greater quantitative a m o u n t of 
dam age In the vegetative cases (len n e tt e t a l ,  2001).
Long-term  o utcom e from  h e a d  in jury  a n d  c h ro n k  
n e u ro d eg en era tio n
Clinical studies
Mild head  Injury (acute GCS 13-15) is associated w ith  a 
higher than  expected incidence of disability  (GOS m oder 
a te o r  severe disability) a t 1 year post-in jury  (Thornhill e ta l ,
2000). Of maj or Interest In the context o f  this discussion  are 
th e  longer-term  effects o n  cognition m any  years after the
injury, and  the relationship betw een traum atic brain injury 
an d  AO.
There is a  considerable epidem iological literature ex­
am ining the relationship betw een traum atic b ra in  injury 
and  the developm ent of AD In later life. M any o f these 
studies take the form  o f retrospective case-control studies 
and  are therefore subject to  recall bias. A n u m ber o f  these 
studies have reported  a n  association betw een traum atic 
b ra in  injury and AD (French e ta l ,  1985; Graves e ta l ,  1990; 
M ortim er e ta l ,  1991; van Duijn et a l ,  1992; Mayeux e t o f , 
1993; Rasm ussen e ta l ,  1995; Salib & Hilliec, 1997; O 'M eara 
e ta l ,  1997; Nemetz e f o i ,  1999; Guo e ta l ,  2000), although 
som e do n o t reach statistical significance (C handra et a l ,  
1987, Amaduccl et a l ,  1986). In  particular, the s tudy  by 
Mayeux e t  aL In 1993 reported  an  a lm ost four fold in­
creased risk o f developing AD after traum atic b ra in  injury 
w hen com pared to  age m atched  controls. Guo e ta l  (2000) 
stud ied  2233 individuals w ho m et th e  crite ria  for probable 
o r definite AD, and  com pared them  w ith 14668 controls 
(first-degree relatives or spouses) as p a rt o f the MIRAGE 
(M ulti-Institutional Research in Alzheimer G enetic
IpiMRM
05218191SSC20 October I t . 2003 9:30 CharGounuO
458 C. Smith et al.
(b)
Rg. 20.3. Watkrian degeneration. Same caae as Fig. 20.1. (a) 
Normal corticospinal tract, (h) Pallor oi  staining with increased 
cellularity. AAR Luxol fast bhie/Cmyt violet (a ISO).
Epidemiology) project. They reported  tha t traum atic brain 
injury was a  risk factor for AD an d  th a t the risk w as p ropor­
tional to  the severity of the Injury For exam ple, com parison  
o f probands with unaffected spouses yielded odds ratios 
for AD o f 9 9  for head in jury  with loss of consciousness 
and 3.1 for head injury w ithout loss o f consciousness. 
Com parison of probands with their paren ts an d  sibs were 
4.0 for bead injury with loss of consciousness an d  2.0 for 
head injury w ithout loss o f  consciousness. At age 93 years 
the lifetime risk of developing AD w as 77.2% for those with 
and 40.1% for those w ithout a  history of head  injury. O ther 
retrospective case-control studies, however, have n o t c o n ­
firmed tha t there is an  association betw een traum atic bra in  
injury and AD (B roeeraL, 1990; Ferinl Stram bi e ta l ,  1990; 
Li e ta l ,  1992; M ender e ta l ,  1992; Fratiglioni e ta l ,  1993).
To try  an d  address th e  problem s of recall bias Inherent 
in  case-contro l stud ies a  n u m b er o f prospective studies 
have been  designed. Again, however; there is conflicting 
data . Cortdn e t  a l  (1989) perform ed neuropsychological 
assessm en t o f  57 W orld War 2 veterans with a  penetrating 
head  injury at two tim e poin ts 30 years apart, and  co m ­
pared  the ir perfo rm ance with 27 veterans who suffered a 
periphera l nerve Injury only and w ho were assessed over 
th e  sam e 30 year period. They found tha t a  penetrating 
h ea d  Injury exacerbated  the decline in cognitive perfor­
m ance over tim e w hen  com pared  with the peripheral in ­
jury  group. Schofield et a l  (1997) reported  a com m unity- 
based  longitudinal s tudy  of ageing in north M anhattan. 
271 partic ipants w ithou t significant cognitive im pairm ent 
a t th e  tim e of en ro lm en t were interview ed in relation to 
previous head  injury an d  associated loss of consciousness. 
Patients w ere th en  followed up  for 5 years with annual eval - 
uations. They reported  tha t previous traum atic brain injury 
was a  risk factor for AD w ith a  th ree fold increased risk. 
Plassm an et al. (2000) exam ined 1776 World War 2 navy 
an d  m arine veterans, w ith military m edical records. 548 
had  a history of non-penetra ting  traum atic brain injury, 
1228 did n o t  All individuals were assessed for AD. They 
found  tha t in  this g roup m oderate head  injury (Frankowski 
scale, Frankowski e t a l ,  1985) resulted In 2.3 x  Increased 
risk o f AD, while severe head  injury resulted In a  four-fold 
increased  risk. Against this data, however, there are a  n u m ­
b er o f prospective stud ies which have failed to  d em o n ­
stra te  an  association betw een traum atic brain injury and  
AD (K atzman et a l ,  1989; Aronson et a l ,  1990; Williams 
e t  a l ,  1991; B re te le re ta i, 1995). Launer e ta l  (1999), as part 
o f the  E uropean S tudies o f D em entia (EURODEM), ana l­
ysed four E uropean popu lation  based  prospective studies, 
w ith  individuals aged 65 years o r older a t  time of recru it­
m ent. This large study  did  not find an  association betw een 
traum atic b ra in  injury an d  AD. M ehta et a l  (1999) re­
po rted  the prospective popu lation  based Rotterdam study, 
w hich  looked a t  6645 individuals aged 55 years o r older 
an d  w ho did  n o t have dem entia w hen recruited. This study 
found  th a t m ild traum atic b ra in  injury was not associ­
a ted  with an  increased risk o f  AD, although the follow-up 
period  w as sh o rt being on  average 2.1 years after initial 
asse ssm e n t
There are m any difficulties in  assessing the  relationship 
betw een traum atic b ra in  Injury an d  AD as the conflict­
ing  results presen ted  above d ea rly  Illustrate. Retrospective 
case-control stud ies have both  recall and  selection bias. 
The prospective stud ies retain  a  lesser degree of recall bias 
an d  do  n o t rely o n  th e  recollections of cognitively Impaired 
individuals. H ow ever som e o f  the prospective studies have 
only a sho rt follow up  period , 5 years in m any cases, and
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tills m ay bias the outcom e. C om parisons betw een studies 
are difficult due to differences in  definitions o f severity of 
bra in  injury, post injury o u tcom e status, an d  clinical d e f­
initions o f AD. Also the age a t  the tim e o f th e  injury an d  
the age a t  the tim e of assessm ent are likely to  b e  im portan t 
variables.
Boxers and dementia pagUstka
While the d ata  relating to  long term  associa tions betw een 
traum atic brain Injury an d  AD is cu rren tly  conflic ting  the 
association betw een relatively m ild repetitive head  injury 
and  cognitive Im pairm ent has been  estab lished  in the lit­
erature for marry yean . The ‘pu n ch  d runk ' s ta te  was first 
described by Marti an d  In 1928 and  w as renam ed dem en­
tia pugilistica  by Milispaugh in  1937. D em entia pugilis- 
tica was fully reviewed In the previous ed ition  of this book 
(Bruton 1997) and  asum m arized  account will be presented 
here. This condition Is described in  boxers w ho  have co m ­
peted  in m any bouts over a  long period  of time. Clinically, 
they develop a  degree of intellectual de te rioration  o ften  
with an  associated m ovem ent disorder, usually parklnson 
ism b u t in  som e cases predom inan tly  ataxia. The largest 
study o f this disorder clinically (Roberts. 1969) exam ined 
224 ex boxers using neurological exam ination , electroen 
cephalogram , an d  sim ple psychom etric testing. He found 
tha t 17% had varying degrees o f m ovem ent disorderinvolv- 
ing the cerebellar, pyram idal an d  extra pyram idal systems. 
M inor degrees of intellectual function  w ere seen in  sev­
eral o f  the  ex boxers, although only  tw o required  long term  
care as a  result of their cognitive im pairm en t. Roberts con 
eluded th a t the occurrence o f encepha lopa thy  Increased 
significantly with the num ber o f bou ts  an d  the length o f 
the boxer's career. He also concluded , however; th a t the 
rate of cognitive decline was n o t g reater th an  that as s o d  
ated with ageing alone. M ore recent stud ies (Casson e t a l ,  
1984; McLatchie e ta l ,  1987; Brooks e ta l .  1987; M urelius & 
H aglund, 1991; H eilbranner e ta l ,  1991) suggest tha t full­
blown dem entia pugilistica  is now rarely seen, although 
m ild cognitive and m ovem ent d isorders are still associated 
w ith boxing.
W hile dem entia pugilistica  was initially described  in  re­
lation to  boxing, cases have been described  in National 
H unt jockeys (Foster et a t ,  1976). l a  addition , there is 
a  considerable literature relating to  th e  risks of repeti­
tive m ild traum atic head  Injury an d  o th e r sports such  as 
soccer (Matser et a l ,  1999, Ktrkendall e t a l ,  2001), rugby 
union  an d  Australian rules football (M cIntosh e ta l ,  2000), 
A m erican football (M aroon et a l ,  2000), an d  ice hockey 
(Biasca e t al., 1993). In th e  absence o f large prospective 
studies the risk o f cognitive im pairm en t an d  m ovem ent
disorders secondary to  repetitive m ild traum atic brain 
Injury in  relation to  these co n ta c t sports, rem ains 
uncertain.
The largest pathological assessm ent of dem entia  pugilis 
tica was the exam ination o f the b ra ins o f  IS boxers, 11 
o f  w hom  w ere diagnosed w ith dem entia  pugilistica  in  Ufe 
(Corsetlis e ta l ,  1973). This followed o n  from  previous case 
reports (Brandenburg & H allervorden 1954; G rahm ann 
& Ule, 1957; C onstantinidis & Tlssot. 1967) an d  the
(b)
Fig. 16.4. Walkman degeneration. Same case a» Fig 20.1.
(a) Corticospinal tract in pons (bottom right} showing an 
astrocytosia compared with normal transverse fibres of pons (top 
left). GFAP (xi80). <M Corticospinal tract (right) in pons. There are 
many macrophages compared with normal transverse fibres of 
pons (left). CD 68 (x 180).
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Hg. M.S. High powered view of a boxer* teptum. The septal leaves are widely separated forming a large 
cavum. Only a few strands of tissue remain (x 3LS).
descriptions by Mawdsley an d  Ferguson (M awdstey & 
Ferguson, 1963; Ferguson & Mawdsley, 1965) o f  th e  b ra ins 
o f  four ex-boxers. Corsellis e ta l  (1973) reported  four p r in ­
cipal features of the brain in  dem entia  pugilistica-
(i) abnorm alities o f the sep tum  pellucidum , (ii) cerebellar 
damage, (iii) degeneration o f the substan tia  nigra, a n d  (iv) 
cerebral cortex pathology.
(0 A fenestrated cavum  9eptum  pellucidum  was see n  in 
77% of ex-boxers bu t in  only 3% o f non-boxers. O ne th ird  of 
the non-boxers w ho had a  fenestrated cavum  sep tum  p e l­
lucidum  had evidence of a  previous head injury (Fig. 20.5). 
The degree o f separation of the two leaflets o f the sep tum  
pellucidum  m ay be related to  repetitive injury being  m ost 
pronounced in  the ex- boxers.
(ii) Ataxia m ay be a  feature o f  dem entia pugilistica. 
Corsellis e ta l  (1973) described cortical scarring o f  th e  in fe ­
rior aspects o f the lateral cerebellar hem ispheres ad jacen t 
to  the tonsils in  10 of the 15 ex-boxers bra ins stud ied . His 
tologically there was gliosis and  loss of bo th  Purklnje cells 
and granule cells (Fig. 20.6).
(iii) Parkinsonism  is a  co m m o n  feature o f d em entia  
pugilistica an d  substan tia nigra pathology appears to  be 
the underlying ca u se  Pigm ented cell loss is o ften  m arked, 
bo th  w ithin the  substantia nigra and  the locus coeruleus, 
and neurofibrillary tangles can  be seen in  som e o f the
rem aining neurons (Fig 20.7). Lewy bodies are no t a  feature 
(Corsellis et a l ,  1973).
(tv) Gross cortical pathology, a  com m on feature o f acute 
traum atic b ra in  injury in  the form  of contusions, does no t 
appear to be a significant feature of dem entia pugilistica  
(Corsellis e ta l ,  1973; Adams & B ruton, 1989). However, d if­
fuse m icroscopic cortical pathology is a  feature o f dem entia  
pugilistica (see below).
Pathological mechanisms which may underlie long 
term  neurodegeneiation after head injury
O ver-representation of late cognitive decline in  survivors o f 
traum atic brain injury m ay sim ply reflect the additive ef­
fects of the acute dam age and  later age-related functional 
com prom ise. From  this view point th e  acute Injury acts to 
decrease the ‘functional reserve' o f  the b ra in  an d  su b se ­
q u en t age related neurodegeneration is m ore likely a t an  
earlier age to  result in  traverse of the threshold of im p air­
m en t required to  m anifest as dem entia. Hcavever, there are 
rem arkable parallels in  the pathological processes involved 
bo th  in  th e  response to  traum atic b ra in  in jury  an d  AD 
(see below). It is possible th a t a  com ponen t o f the acute re ­
sponse to  traum atic brain injury ac ts a sa 'tr ig g er’ re in itiate  
a  positive feedback loop tha t sm oulders away to becom e
P1MRM
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20.6. Low power view of cerebellar folia In the tonsillar region of a boxer's cerebellum. The mojec ular 
layer of the scarred cortex is narrowed and tnten&ely glrosed.
m an ifest in  later years as frank neurodegenerative pathol­
ogy and  d em en tia  (Nlcoll et a t ,  1995; Griffin et a l ,  1998) 
(Fig. 20.8).
D etailed classical neuropathological descrip tions of co­
h o rts  o f  long term  survivors o f traum atic brain injury In­
c luding  lm m unohlstochem ical studies are lack ing  How­
ever, som e of th e  processes th a t are believed to  be involved 
in  chronic neurode generation, Including AD, have been  ex­
p lored  in the context o f both acute injury an d  long-term  
survival after tra u m a
(a) Cytoakdetal neurodegenerative pathology
Cytoskeletal pathology after diffuse traum atic b ra in  injury 
h as  b een  exam ined experim entally using a pig m odel with 
Injury induced  via controlled head  rotational acceleration 
(Sm ith ef a t ,  1999). H ead-injured pigs w ere exam ined a t 
days 1 ,3 ,7  an d  10 post-injury, and  com pared  to control a n ­
im als w ithout head  injury. W ithin the experim ental group 
tau  an d  neurofilam ent accum ulations were identified im- 
m unohistochem icaily  w ith in  the w hite matter, co-localised 
w ith  dam aged axons (A(3-PP im munoreactive), a n d  within 
n eu ro n al perikarya In the cerebral cortex. To d a te  a  sim i­
lar observation has n o t been  m ade in  hum ans following a 
single episode of traum atic brain Injury although cleaved 
form s o f  tau  p ro te in  a re  elevated markedly in  th e  CSF of 
bra in-in jured  patien ts (Zemlan et aL, 1999). However, in
fig. 26.7. [a) Transverse cut through the raidbrain of an ddedy 
male non-boxer to show the normal pigmentation of the 
substantia nigra (x 0.75). (b) (c) and (rf). The substantia nigra of 
three punch drunk boxers. Some pigment is stfll visible In (b) but 
(0) and (tf) are almost totally devoid of pipnentadon tx 0.75).
cases of repetitive m ild head  Injury cytoskeletal pathology 
Is observed. Neurofibrillary tangles were reported  in  ex- 
boxers by Corselils e t  aL (1973) sca ttered  th roughout the 
cerebral cortex an d  the  bra instem , being  m ost p rom inent 
in  the m edial tem poral cortex  (Fig. 20.9). Recently, Geddes 
et al. (1999) exam ined th e  brains o f four young individuals
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»»• 20.1 Graphical illustration of potential mechanisms operating after head injury. See text for further explanation.
(b)
R}. 20.9. Neurofibrillary tangles affecting roost neurons In the 
parahJppocainpal gyrus in a case of dementia pugilistica. Note the 
absence of senile plaques, von Braunmuhl's silver stain (x 1001.
(age range from  23-28 years) w ith  a  h is to ry  o f repetitive 
head Injury (two boxers, one footballer, an d  one m entally 
subnorm al pa tien t with ah isto ry  o f self inflicted head  bang 
lng) an d  a frontal lobectom y spec im en  from  a n  Individual 
with intractable com plex partial seizures with recurrent 
m inor head  Injury. They Identified w idespread  neocorti 
cal neurofibrillary tangles and neuropil th reads no t seen In 
age m atched  controls which in  areas show ed a perivascular 
distribu tion  (Fig. 20.10). Schm idt e t aL (2001) have co m ­
pared th e  m olecular profiles o f the neurofibrillary tangles 
in  dem entia pugilistica  an d  AD. They found th a t dem entia  
pugilistica  an d  AD had  a  com m on tau  iso form  an d  p h o s­
phorylation profile. They concluded  tha t th e  m echanism s 
underlying bo th  these conditions m ight be similar.
(b) Amyloid deposition
Diffuse Aji p laques have been  identified in approxim ately 
30% o f individuals w ho d ie shortly  after a  single ep isode of 
severe traum atic brain injury (Roberts ef a l ,  1991, 1994; 
G raham  et a l ,  1995a). This is a  higher proportion  th an  
In non-head  injury controls. O ther groups (Adle-Blassette 
t t a l ,  1996), however, have n o t confirm ed th is observation. 
Most o f this la in  the form o f  Afi42 (G en tie m an  et a l , 1997; 
Horsburgh eta l., 2000), w hich Is believed to  b e  o f pathologi - 
cal significance in  AD The d istribu tion  of the plaques does
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(b)
Hf. 24.10. Neurofibrillary (angles h  the oeocoslex from a case at 
repetitive- head Injury (a) Neurofibrillary tangles showing a 
perivascular dLstributioo Tau U 100). (fit Infraneororuti tau 
immunoreactivity In a oeococtical neuron. Tau (x 180).
n o t correlate w ith local traum atic lesions such  as co n tu ­
sions bu t m ay be an  expression o f a  diffuse acute phase 
response (eg. hypoxia, acidosis, oedem a, reduced  cere­
bral blood Sow) (G raham  et a l ,  1995). For exam ple, the 
A(3 deposits m ay be the result o f increased p roduction  or 
altered  distribu tion  o f A0-PP, Increased deavage o f  A0-PP 
in  a  proteolytic environm ent to produce A0, an  alteration 
in  the balance o f production ofA fi^iA f)^ extracellular co n ­
ditions which favour the precipitation o f amyloid fibrils, o r 
decreased removal o r drainage ofA0.
In  th e  study by Corsellls et a l  (1973) neurofibrillary ta n ­
gles were found In the  alm ost com plete absence of senile 
p laques w hen exam ined using silver (Bieischowsky) and 
Congo red stains. However, when this w as re-exam ined us 
ing im m unohistochem istryw ith  formic acid pre- trea tm ent 
for the 0 -amyloid p ro tein  (A0), extensive Im m unoreactive
plaque-llke s tructures were seen  in  m ost cases of dem entia  
pugilistica  (Roberts e t  a l ,  1990) although the neuritic 
p laques characteristic o f AD were absent. In  the s tudy  by 
G eddes e ta l  (1999) A0 plaques were no t seen  despite using 
b o th  a  m odified Bieischowsky silver stain  and  A0 im m uno 
h istochem istry  w ith  formic a d d  p re -trea tm en t They co n ­
cluded  th a t neurofibrillary tangle form ation in  the absence 
o f A 0 deposition  is an  early consequence o f repetitive head 
in ju ry  an d  that, because of the ir striking perivascular dis­
tribu tion , neurofibrillary tangle form ation m ay be related 
to  dam age to  blood  vessels.
T he re la tionship  betw een A0 deposition and genetic 
po lym orphism s is discussed in  a later section.
(c) N euronal loss
N euronal loss after traum atic b ra in  Injury has been  re­
p o rted  in  the neocortex, the h ippocam pus, the cerebellum  
an d  th e  thalam us (Adams et aL, 1985; Kotapka e ta l ,  1992; 
Ross e t  a l ,  1993). In  the acute phase, neuronal loss is re­
lated to  con tusions o r as a  consequence o f cerebral hy- 
poxia/ischacm ia , and  bilateral hippocam pal neuronal loss 
has been  do cu m e n te d  in  85% of cases in one study  (Adams 
e t  a l ,  1985). The m echanism s of cell death  have b een  ex­
tensively studied and  the processes of necrosis and  p ro ­
gram m ed cell d ea th  have been  considered to  be separate 
m echanism s, a lthough this view is being increasingly chal 
lenged an d  shared  m olecular pathways have been  iden ti­
fied In both  processes. The role o f program m ed cell d eath  
afte r trau m atic  b ra in  injury has been  reviewed by Raghu 
path l et a l  (2000). Ceil death  has been  Identified in  s itu  
after traum atic b ra in  Injury In both  anim al m odels and  
in  h u m an  m aterial using the term inal deaxynudeotidyl 
transferase m ed iated  dUTP nick end-labelling (TUNEL) 
techn ique (Rink et a l ,  1995, Smith e t a l ,  1997). This tech ­
n ique Identifies DNA fragm entation, a  feature com m on 
to bo th  necrosis an d  program m ed cell death . D ifferenti­
ation  betw een necrosis and program m ed cell death  Is pos 
stole by assessing o ther m echanism s seen  in program m ed 
cell d ea th  such  as  caspase activation, and identification of 
th e  m orphological expression o f program m ed cell death, 
apoptosis. TUNEL positive neurons an d  oligodendrogtial 
cells have b een  reported  in h u m an  traum atic bra in  Injury; 
Clark e ta l  (1999) dem onstra ted  elevated levels o f b d - 2 and  
caspase 3, increased  cleavage of bo th  caspases 1 and  3, and  
cells w ith  the  m orphological appearances o f apoptosis in  8 
patien ts  w ho  h ad  contusions removed surgically betw een 1 
an d  9 days after a n  ep isode o f traum atic bra in  Injury. Smith 
e ta l  (2000) an d  ShaweroL (2001) studied a  num ber ofbrain  
areas In h u m a n  p ost-m ortem  tissue o f 18 patien ts w ho su r­
vived betw een 6 hours an d  10 days after traum atic b ra in
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injury. TUNEL-positive ceils were seen  in  both grey and  
w hite m atter, peaking  betw een 25 an d  48 hours although 
still identifiable a t 10 days po st injury. There was a  m ixture 
o f bo th  ap op todc and  necrotic m orphology in  neurons, al­
though w hite m atter TUNEL-posltive cells m ote consis­
tently show ed an  apop todc m orphology. They concluded 
tha t in  hum an  frontal lobe contusions bo th  apoptosis and  
necrosis con trib u ted  to  post- traum atic pathology, an d  that 
m ultiple cefl types, including neurons, w ere involved.
R ecent experim ental stud ies suggest that the cellular 
pathology Initiated by an  ep isode of acu te  traum atic brain 
Injury m ay Indeed  be progressive. Rats subjected to  severe 
lateral fluid percussion  b ra in  Injury w ere studied for u p  to 
12 m onths an d  show ed long te rm  cognitive and neurologi­
cal m otor dysfunction (Pierce e ta l ,  1998) accom panied by 
continuing  cell loss (Smith er a l,  1997). Recent studies in 
hum an  cases have dem onstra ted  TUNEL-posidve cells up 
to 12 m on ths  a lter traum atic brain injury (Williams et a l ,
2001). Again, the m ajority  of the cells were present In the 
white m atter a n d  were considered to  b e  closely associated 
with W alterian degeneration . Long-term  DNA fragm ents 
don  therefore appears to  be a feature o f traum atic brain 
injury in  hum ans.
(d)Cholinerg(c brain pathways
The nucleus basalts of M eynert within th e  basal forebrain 
provides cholinergic innervation  of the  cerebral cortex and 
the hippocam pus, an d  dam age to th is pathw ay ca n  result 
Ina tten tion , m em ory  and  em otional dysfunction (Everitt A 
Robbins, 1997). A bnorm alldes within th e  cholinergic p ro ­
jection system  have been postu la ted  to  contribu te both  to 
the altered m en tal state  In AD (Geula & Mesulam, 1994) 
and to  the  neurobehavioural sequelae w hich persist after a 
head  Injury (Cardenas e ta l ,  1994).
In rats there is a  reduction in the nu m b er o f  choline 
acetyltransferaselChATI positive neu rons after experim en 
tally induced  traum atic brain Injury (Schmidt & Grady, 
1995), an d  alterations o f cholinergic innervation o f the 
cerebral cortex an d  h ippocam pus have been detected  
(Dixon e ta l ,  1995,1997).
P atients w ho die acutely as a  consequence of traum atic 
brain in jury  have reduced  levels o f cortical ChAT when 
com pared  to  age-m atched  controls (Dewar & Graham . 
1996; M urdoch e ta l ,  1998). Recently, neuronal dam age has 
been  dem onstra ted  w ithin the nucleus basalis o f M eynert 
in eight o f twelve fatally h ead  injured patien ts, w ith a  m e­
dian survival tim e o f 27 h ours  (Murdoch etaL, 2001). N eu­
ronal dam age was a  result o f  both m echanical distortion  
(tissue hern ia tion) an d  focal ischaem ia. The au thors c o n ­
cluded tha t dam age to  cholinergic neu rons m ay con tribu te 
to  the dysfunction o f m em ory  and  cognition in survivors
o f traum atic b ra in  injury, although studies of the nucleus 
basalis of M eynert in  lo n g te rm  survivors has no t been  u n ­
dertaken.
(e) N eu to ln flam m ation
Recent studies have focussed a tten tio n  o n  'neuroinflam  
m atio ri as a  potential cu lprit bo th  in  AD a n d  in  the response 
to  brain Injury (Engel e ta l ,  2000; Nicoil e ta l ,  2000; Griffin 
e t a l ,  1998). T he principal m ediator of inflam m atory p ro ­
cesses In the central nervous system  Is the microglial celL 
M icroglia have a variety o f  functions including an tigen  pre - 
sen tation , synthesis an d  secretion  o f  cytokines and phago­
cytosis. These cells a re  a  source of several o f the proteins 
upreguia ted  bo th  in  AD an d  after traum atic b ra in  Injury, 
including apoE. and pro-inflam m atory  cytokines such as 
interleukin 1 (IL-1). This raises the question th a t patients 
w ho sustain  a  head  injury m ay have a  microglial response 
w hich plays a  role bo th  in influencing the ir ou tcom e foi 
lowing injury and the ir increased susceptibility to  AD later 
In life.
I H  is th ough t to  orchestrate  the inflam m atory re­
sponses w ithin the b ra in  after a n  insult, resulting in  a  
num ber o f responses including: (a) m icroglial proliferation 
(G anter e ta l ,  1992), (b) induction  o f  neuronal production 
o f A0-PP (G oklgaber e t a l ,  1989), and (c) astrocytic a c ­
tivation with upregulation o f astrocytic-derived proteins 
(Das & Potter, 1995).
IL-1 is expressed in Increased quantities in the cerebral 
cortex w ithin hours o f traum atic b ra in  Injury (Griffin e ta l ,  
1994), an d  chronic overexpression o f IL-1 Is found In AD 
(Griffin e t a l ,  1989). Griffin et a l  (1998) have proposed a 
‘Cytokine Cycle' in  w hich traum atic b ra in  injury, o r o ther 
b rain insults, can. In susceptib le Individuals, initiate an  
overexuberant susta ined  Inflam m atory response which 
can  result in neurodegenera tion . A 0 P P  and  the astrocyte 
produced  m olecule S-1000 are upreguia ted  in  response to 
increased IL-1 levels, an d  are know n to be upreguiated 
in  AD (Griffin e t  aL, 1989; M rak e t  a l ,  1996). A0-PP is 
n o t only upreguia ted  in  acu te traum atic b ra in  injury, b u t 
there is increased In traneuronal processing o f the molecule 
(Buxbaum  et aL, 1992) potentially resulting in A0 p roduc­
tion an d  deposition. T he relation betvreen ID  1 and  A0-PP 
in  the  acute p hase is uncertain , bu t Increased levels o f IL-1 
m ay result In susta ined  A0-PP, and  therefore A0, p roduc­
tion. Positive feedback o f this in teraction  m ay  be provided 
by soluble fragm ents of A0-PP (sAPP) w hich are produced 
by the processing o f A0 PP. sAPP prom otes microglial a c ­
tivation by a  m echan ism  th at is m odulated  by apoE in an  
isoform  specific fashion (Barger & H arm on, 1997).
I H  positive m icroglial cells lie in  close relation to 
A0-PP positive n eu rons and dystrophic neurites in the
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brains of bead-injured patien ts (Griffin et aL, 1994) an d  
are also found in  d o se  apposition to neurofibrillary tangle - 
contain ing  neurons InAD (Sheng e ta l ,  1997). ID  1 is know n 
to be trophic to neurons in  lew concentra tions, b u t at higher 
concentrations ID  1 has a  neurotoxic effect, Inducing over­
expression an d  phosphorylation of bo th  neurofilam ents 
an d  tau  (Sheng e ta l ,  2000).
T here is a  considerable experim ental lite rature relating to  
neuroinQ am m ation and neuronal death . A recen t study o f 
mixed cultures of activated glia and  neurons suggested that 
Inflam matory neurodegeneration m aybe m ediated  by ghal 
nitric oxide (NO) (Bal-Price *t Brown, 2001). They proposed 
tha t NO produced by activated m ic ro tia  or astrocytes in ­
hibits th e  m itochondrial function o f su rround ing  neurons, 
causing glutam ate release from  neurons (and possibly from 
astrocytes). Activation o f NMDA receptors by g lutam ate 
triggers massive Influx o f Ca2* into neurons, leading to  cell 
death. O ther potential m echanism s o f NO m ed iated  n eu ­
ronal dea th  include m itochondrial dam age (Heales e ta l ,  
1999) and  poty(ADPribose) synthetase activation (Zhang 
e ta l ,  1994).
Evidence for g ene tic  influences o n  o u tcom e 
a fte r  h e a d  Injury
The response to  brain injury and  AO have in  com m on not 
only a  cellular and  protein response b u t there are strik­
ing parallels in the genetic influences. There is a  poiym or 
ph ism o f the apolipoprotein E gene (APOE, gene; apoE, p ro ­
tein) of which there are 3 com m on alleles (e2, e3 and  s4). 
Possession of APOE e4 allele is the m ajor genedc suscep­
tibility factor for sporadic AD (Saunders e t  aL, 1993). In 
addition, the APOEpolymorphism influences neu ropatho  
logical findings In patients who d ie from head  Injuries 
(Nicoll et a l ,  199S). This study exam ined the brains of 90 
individuals who died w ithin 2 weeks o fa h e a d  injury. A0 d e ­
posits were found In 23 cases and  the frequency o f the APOE 
e 4 allele w ithin this group was significantly greater than  
th a t seen  in  either control populations w ithou t neurologi­
cal disease or in  AD. In addition all individuals hom ozygous 
for the APOE e4 allele had A0 deposition. Furtherm ore, 
the  density  of these plaques is related to  APOE  genotype, 
with greater num bers o f plaques being  associated with 
the APOE s4 allele in  an  allele dose d ep e n d an t m an n er 
(Le. hom ozygotes having greater num bers o f plaques th an  
heterozygotes) (Horsburgh e t  a l ,  2000). The Initial in te r­
p re ta tion  of these findings by Nicoll e t a l  w as tha t in  gene t­
ically susceptible individuals (i.e. those  with an  APOE e4 
allele) traum atic brain injury appears to  act as a  trigger for 
A0 deposition. However, there are alternative explanations
for these observations (Roses A Saunders, 1995); A0 d e ­
posits  m ay pre-date the Injury, an d  patients with e4, who 
are m ore likely to  have age-related deposits, m ay have a 
higher m ortality from  traum atic bra in  injury an d  there­
fore be selected for an  autopsy-based s tu d y  Until it  Is 
possible to  image A0 plaques during life it m ay n o t be 
possible to  resolve this uncertainty. Subsequent clinical 
stud ies have indeed shown that head-injured patien ts (and 
patien ts  with spontaneous intracerebral haem orrhage) 
w ho possess APOE  e4 have poorer ou tcom e than  non  
carriers o f APOE *4 (Alberts e ro i, 1995; Tteasdaie e t a l , 1997; 
M cC arro n eraf, 1998). Iordan e ta i ,  1997 studied 30 profes­
sional boxers and  assessed their cognitive status in relation 
to  APOE  genotype and  num ber of professional bouts. They 
concluded that possession of an  APOE s4 allele is associ­
a te d  with Increased severity of chronic neurological deficits 
In high exposure boxers. A recent neuropathological study 
com pared  A0 deposits in  long term  survivors o f traum atic 
b ra in  injury (survival tim e up  to  20 years) with age-m atched  
an d  APOE  genotype-m atched controls (M acFarlane et a l ,  
1999). They (bund A0 deposits were m ore com m on In e4 
patien ts In both  the long term  survivors an d  the control 
groups, bu t were n o t m ore com m on am ong long term  su r­
vivors th an  controls.
A fu rther genedc polym orphism  has recently been  sug­
gested to  confer susceptibility to  AD and this further im 
pli cates neuroinflam m atory processes. Interleukin 1 (ID 1) 
exists In two distinct forms (ID la  an d  ID  10 w ith IL-IA  
an d  /D IB  genes respectively). Polymorphisms have been  
identified in  each o f these genes (both have an allele 1 an d  
a n  allele 2) and a n  association has been dem onstra ted  b e ­
tw een  the Hr LA 2,2 genotype and  AD (Nicoll et a l ,  2000; 
Grim aldi e ta l ,  2000). Nicoll et a l ,  studied 232 pathologi 
catty confirm ed cases of Alzheimer's disease an d  found the 
IL -IA  genotype in  alm ost 13% o f cases as com pared  to  
6.6% of age-m atched and  APOE- m atched controls. In ad d i­
tio n  they found tha t hom ozygosity for allele 2 o f bo th  IL- 1A 
an d  LL-1B conferred an  even greater risk, although hom ozy­
gosity for allele 2 o tIL -lB  alone was not significant.
In  AD there, is evidence tha t patients with APOE  «4 have 
increased microglial activity com pared  to  patien ts w ith­
o u t APOE e4 (Egensperger e t  a l ,  1998). Although there is 
curren tly  a  lack o f definitive inform ation relating to APOE  
genotype, IL-1 genotype and microglial activation in  trau ­
m atic brain Injury these observations raise the possibility 
th a t microglial activation Cneurotnflamm ation’) m ay be 
u n d er genetic influence. Specifically, they raise the q u es­
tio n  th a t individuals with the relevant alleles (APOE »4 or 
IL -IA  allele 2) w ho sustain a head injury m ay have a  re la­
tively overexuberant microglial response w hich is assoc i­
a ted  bo th  w ith a  poorer outcom e from  injury an d  greater
465
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Abstract
Epidemiological and pathological studies suggest that head injury is a significant risk factor for subsequent neurodegenera­
tion and cognitive decline in later life. The precise mechanisms for the development of post-traumatic neurodegenerative change 
are unclear but we hypothesize that persistence of inflammatory processes in the brain may play a key role and that some 
individuals are more susceptible to such changes based on their genetic make-up. In support of this hypothesis we present 
evidence of persistent elevated microglial activity in long-term survivors of head injury and the suggestion of an association 
between the extent of this activity and interleukin-1 genotype.
© 2004 Elsevier Ireland Ltd. All rights reserved.
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1. Introduction
Head injury is a significant risk factor for neurodegen­
eration and cognitive decline in later life. This observation is 
based largely on the results of long-term outcome studies of 
patients with head injury and epidemiological studies of the 
environmental risk factors for Alzheimer’s disease (AD). 
One of the largest epidemiological studies, part of the 
MIRAGE (multi-institutional research in Alzheimer genetic
* Corresponding author. Tel.: +44 20 8846 7680; 
fax: +44 20 8846 7680.
E-mail address: s.gentleman@imperiaLac.uk (S.M. Gentleman).
epidemiology) project, involved nearly 17,000 individuals 
[1]. Within this cohort there were 2233 probands who met 
the criteria for probable or definite AD, while the rest were 
first-degree relatives or spouses with no signs of dementia. 
When the histories of the probands were compared with 
those of their relatives the authors confirmed that traumatic 
brain injury was a risk factor for AD and, furthermore, that 
the risk was proportional to the severity of the injury. To 
illustrate this, a comparison of probands with unaffected 
spouses yielded odds ratios for AD of 9.9 for head injury 
with loss of consciousness and 3.1 for head injury without 
loss of consciousness. In another study a large cohort of 
people who served in the armed forces in World War II were
0379-0738/$ -  see front matter ©  2004 Elsevier Ireland Ltd. All rights reserved, 
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assessed for AD and their military medical records checked 
for evidence of a non-penetrating traumatic brain injury [2], 
In this population a moderate head injury resulted in a 
2.3-fold increased risk of AD, while for severe injuries this 
rose to a 4-fold increased risk. While these large cohort 
studies provide strong support for the link between head 
trauma and AD it must be realised that such retrospective 
studies can suffer from recall and selection bias and there 
are other studies that have not been able to find an 
association [3].
Further insight into a potential link between head injury 
and neurodegenerative change has come from the study of 
boxers with dementia pugilistica or ‘punch-drunk’ syn­
drome. In this case the association is between repetitive 
sub-clinical head injury experienced during the course of a 
boxing career and the emergence of a presenile dementing 
syndrome in later life. At the pathological level it has been 
known for some time that neurofibrillary tangles, similar to 
those seen in AD, can be found in the brains of boxers with 
this syndrome [4] and more recently the molecular composi­
tion of the tangles has been shown to be the same as that seen 
in AD [5]. In addition, Geddes et al [6] examined the brains 
of four young individuals (age range from 23 to 28 years) 
with a history of repetitive head injury (two boxers, one 
footballer, and one mentally subnormal patient with a history 
of self inflicted head banging) and a frontal lobectomy 
specimen from an individual with intractable complex par­
tial seizures with recurrent minor head injury. They identi­
fied widespread neocortical neurofibrillary tangles and 
neuropil threads not seen in age-matched controls, which 
in areas showed a peri-vascular distribution. In the original 
study by Corsellis [4] and colleagues, using standard silver 
staining techniques, no amyloid plaques were seen. How­
ever, with the advent of specific antibodies raised against the 
(3-amyloid peptide (A(3) re-examination of the sections 
revealed widespread diffuse plaques with no neuritic com­
ponents [7],
Surprisingly, the link between head injury and Alzhei­
mer-type pathology is not restricted to long-term survivors. 
In a large cohort of patients who died within weeks of a 
severe head injury just under a third were found to have some 
degree of A(3 deposition in their brains at post mortem [8,9]. 
The patients in this cohort covered a large age range and 
undoubtedly some of these deposits will have been there 
before the injury and reflect the normal ageing process. 
However, in the younger patients it is unlikely that there 
would have been any age-related deposits, supporting the 
suggestion that they were produced as a result of the head 
trauma. Not all groups have been able to confirm this 
phenomenon [10] but further studies have added weight 
to this interpretation by showing that, after acute brain injury 
in man and in experimental models, there is an upregulation 
of many of the proteins thought to be involved in the 
pathogenesis of AD [11,12]. Upregulation of the (3-amyloid 
precursor protein (APP), in particular, may favour an 
increase in processing and production of A(3.
2. Neuroinflammation
The precise mechanisms involved in the development of 
neurodegenerative pathology in survivors of traumatic 
brain injury are unclear, but they are likely to include a 
combination of disrupted calcium homeostasis, free radical 
mediated damage and inflammatory changes. The last of 
these is the object of increasing interest in that many key 
inflammatory proteins have been found associated with the 
A(3 plaques in AD and are thought to play an important 
role in the evolution of the plaques and the progression of 
the disease [13]. There are some key differences between 
the inflammatory components of AD pathology and the 
changes seen in the brain in the immediate aftermath of a 
brain injury. While there is no evidence for a classical cell 
mediated immune response in AD, after brain injury one 
can observe infiltration and accumulation of T-lymphocytes 
and macrophages during the acute post-traumatic period 
when the blood brain barrier is compromised [14]. How­
ever, we have observed that the T-lymphocyte numbers 
decline relatively rapidly towards control levels after 48 h 
and do not persist in the tissue suggesting that they are 
unlikely to play a direct role in any chronic neurodegen­
erative process. By contrast CD68 positive macrophages 
were observed even at the longest survival times and were 
not restricted to areas of focal damage [15]. It therefore 
seems that resident microglial cells and/or invading macro­
phages are the key cells mediating the inflammatory pro­
cesses in both AD and in long-term survivors of head 
injury. Taking this one stage further one might expect that 
the microglial response of an individual may affect both the 
immediate outcome following injury and the increased 
susceptibility to AD later in life.
When they are activated, microglial cells have a number 
of actions including phagocytosis of cell debris and the 
secretion of pro-inflammatory cytokines such as interleu­
kin-1 (IL-1). IL-1 promotes microglial proliferation, acti­
vation of astrocytes resulting in the increased production of 
proteins such as apolipoprotein E (apoE) and it can also 
induce the neuronal production of APP [16,17]. EL-1 is 
chronically over-expressed in AD [18] and can be found in 
microglial cells close to APP-immunoreactive cells and 
neurites in head-injured patients [11]. These observations 
have given rise to the so called cytokine cycle in which 
AD, epilepsy, trauma or indeed any brain insult may 
initiate an inflammatory response in the brain, which is 
initially protective but in some susceptible individuals is 
self-perpetuating and goes on to cause neurodegenerative 
changes [19]. Precisely how this sustained glial response 
results in the death of neurons is not clear but, based on 
recent in vitro studies, one theory is that microglial derived 
nitric oxide may cause impairment of mitochondrial func­
tion in neighbouring neurons and release of glutamate, 
which acts on NMDA receptors to promote an influx of 
Ca2+ ions into the cell, eventually leading to cell death 
[20].
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3. Genotype effects
One of the key aspects of the processes outlined in the 
cytokine cycle is that they may be influenced by the genetic 
make-up of an individual. Possession of the e4 allele of the 
gene for apolipoprotein E (APOE) has been firmly estab­
lished as a genetic risk factor for the development of AD 
(Saunders et al., 1993). Significantly, patients with this allele 
who die from a head injury are four times as likely to have 
evidence of cortical A3 deposition than those without [21]. 
Furthermore the numerical density of the deposits appears to 
correlate with the e4 allele dosage, with homozygotes having 
more than heterozygotes [22]. There are at least two differ­
ent possible interpretations of this data. The first is that 
individuals with an e4 allele are more likely to trigger A3 
deposition in their brains after a head injury. The second is 
that the A3 deposits are age-related, pre-dating the injury, 
and that those with an c4 allele have a higher mortality from 
head injury thereby biasing their selection in autopsy studies 
[23]. Deciding which of these interpretations is correct will 
require the development of in vivo imaging techniques for 
A^ deposits.
An effect of genotype on outcome after head injury has 
been observed in a prospectively acquired patient series [24]. 
Around 57% of the patients with an e4 allele had an 
unfavourable outcome 6 months after injury, compared with 
27% in those patients without an e4 allele. Subsequent 
studies have reinforced this with the observations that 
possession of an e4 allele is an indicator of poor prognosis 
in patients with post-traumatic coma [25] and is a predictor 
of poor functional outcome in general after head injury 
[26].
Polymorphisms in the APOE gene are not the only 
genetic influences associated with AD. Single nucleotide 
polymorphisms in the promotor region (—889 C —* T) of the 
ILIA gene and the coding region (+3953 C —► T) of the IL-1B 
gene, which encode the two isoforms of IL-1, have pre­
viously been shown to modify the risk for certain inflam­
matory diseases [27,28]. The well-documented involvement 
of inflammation and IL-1 in the development of AD pathol- 
ogy prompted a number of studies to determine if the 
polymorphisms would modulate risk for AD [29-32]. Nicoll 
et al studied 232 neuropathologically confirmed cases of AD 
and found the ILIA —889 TT risk genotype in 12.9% of late 
onset AD (LOAD) cases as compared to 6.6% of 167 age- 
matched and APOE-matched controls from four centres in 
the UK and US. This yielded an odds ratio of 2.97 (P = 
0.011) after controlling for age, for possession of the e4 
allele, and without regard to centre of origin. In addition they 
found that homozygosity for allele T of both ILIA and IL-1B 
conferred an even greater risk (odds ratio = 10.8, P < 0.005), 
although homozygosity for IL-1B +3953T allele alone was 
not significant. Others report that the ILIA —889 TT geno­
type can modulate the course of AD course by reducing the 
age of onset These authors found more ILIA —889 CT and 
TT in early onset AD than in LOAD [33-36].
These findings strongly support the importance of IL-1 in 
the pathogenesis of AD. Demographic differences may 
contribute to some of the negative findings as most studies 
on Chinese/Korean populations failed to find any difference 
between the frequencies of ILIA —889 TT genotypes in AD 
and controls. In their population studies, TT genotypes were 
extremely rare to absent [37-39]. Other studies on white 
Americans [40] and European [35,41,42] populations failed 
to show ILIA —889 T allele as a risk factor for AD.
4. A hypothesis
Much of the evidence outlined above points to a central 
role for microglial cells in the pathology of AD and the 
development of neurodegenerative changes in the brains of 
long-term survivors of head injury. Taken with the findings 
that the genotype of an individual can affect outcome after a 
head injury we hypothesize that the genotype of an indivi­
dual will affect the nature of their microglial response to 
head injury. Some of the possible ways in which one might 
envisage this genotype phenotype interaction are illustrated 
in a modified version of the cytokine cycle (Fig. 1). The 
simplest scenario might be that a rapid microglial response 
in the acute phase after an injury might be expected to be 
beneficial but that if this response is maintained over a long 
survival time it may lead to the later cognitive decline 
reported in the clinical studies. There is already some 
evidence to support this idea in AD, where it has been 
reported that patients with the e4 allele of APOE have 
increased microglial activity in their brains at post mortem 
compared to patients without the risk allele [43].
5. Microglia and contusions
In a preliminary study designed to test the hypothesis that 
genotype might affect the microglial response we studied a 
series of 15 surgically removed contusions from patients 
with head injury. Controls comprised cerebral cortical tissue 
without specific neuropathological abnormality from 14 
biopsies and 14 autopsies. APOE and IL-1 genotypes were 
determined by PCR from paraffin sections as previously 
described [29]. Sections were immunostained with anti- 
CD68 to identify microglia (mouse monoclonal antibody 
to a macrophage-specific llOkDa glycoprotein-Dako, 
1:1,000) and CR3/43 which labels activated microglia 
(mouse monoclonal antibody to class II MHC: HLA-DR, 
-DQ and -DP 3 chains-Dako, 1:800). Immunoreactivity was 
assessed quantitatively by taking the mean number of cells 
stained in 5 x 20 objective fields from each case.
As might be expected, more immunoreactive microglia 
were seen in the contusion group than in either set of controls 
and this was true for both antibodies (Fig. 2). There was a 
trend towards an increase in microglial number with age but 
this didn’t reach significance, possibly because of the rela­
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Fig. 1. A possible model for the influence of gene polymorphisms in the cytokine cycle and resultant amyloid cascade following head injury.
tively small numbers in the study. Likewise there was no 
association between survival time (in this case defined as the 
time between the trauma and the surgical excision of the 
contusion) and number of activated microglia. However, 
analysis of the cases in terms of their genotype revealed 
some interesting patterns. A simple analysis based on the 
presence or absence AFOEe4 revealed no difference in terms 
of microglial activation, but a similar subdivision in terms of 
the possession of none, 1 or 2 ILIA — 889T alleles showed 
that those with the risk allele had greater microglial activa-
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tion than those without (Fig. 3). Furthermore a plot of the 
time between head injury and surgery shows some stratifica­
tion in terms of genotype (Fig. 4).
6. M icrog lia  a n d  h ead  in ju ry
Encouraged by the possibility that there might be geno­
type-based effects on pathological phenotype the studies 
were expanded to look at a large cohort of 81 consecutive
OCD68 
a  CR3/43
Biopsy Contusion
Fig. 2. A bar chart illustrating the extent of microglial immunoreactivity in three different groups: autopsy controls, biopsy controls and 
contusion biopsy samples. The contusion biopsy group shows an overall increase in the amount of immunoreactivity with both microglial 
markers CD68 (dotted) and CR3/43 (dashed) as compared to the two control groups.
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Fig. 4. A scatterplot illustrating the association of microglial acti­
vation and survival time in relation to IL-IA genotype.
cases of blunt head injury managed by the Department of 
Neuropathology, Institute of Neurological Sciences in Glas­
gow (60 males, 21 females; age range 0.15-79 years; 
survival times ranging from <11 to 334 h). CD68 immunor­
eactivity expressed by microglia and macrophages was 
quantified in contusion, grey and white matter using image 
analysis (Image-Pro Plus, Datacell) (Fig. 5).
As with the previous study, independent of patient gen­
otype, CD68 loads were highest in the contusions and lowest 
in the grey matter regions remote from the site of contusion. 
When data were analyzed in terms of presence or absence of 
risk alleles (i.e. e4 or allele T), there was no significant 
difference in the CD68 load between patients with or without 
the risk alleles in contusion and white matter. Subjects 
without e4 allele had significantly higher CD68 loads in 
the grey matter than those with one or two e4 allele (P -  
0.049 using a Mann-Whitney test). There was a significant 
relationship between survival time and CD68 load in the
contusion area (P = 0.002) and in the white matter (P = 
0.038) of head-injured patients (one-way ANOVA on ranks). 
Spearman Rank Tests revealed no effect of age or post­
mortem interval on CD68 loads.
The results of this study suggest that there is not a simple 
relationship between the extent of the microglial response 
after head injury, in terms of CD68 load, and patient IL-1 
genotype. Paradoxically, the absence of an e4 risk allele was 
associated with an increased CD68 load in non-contused 
grey matter. However, for a number of reasons, these results 
should be interpreted with caution. First, the initial traumatic 
insult in these patients was very heterogeneous and this may 
mask any genotype variations. This is very difficult to 
control for, although in all cases, the injury was severe 
enough to cause death. Secondly, there were only relatively 
few cases homozygous for the risk alleles APOEe4 (4), ILIA 
—889T allele (8) and 1L-1B +3953 T allele (4). To reduce the 
risk of any bias in the statistical analysis it will be necessary 
to look at more cases with these genotypes. In terms of 
survival time there was a significant increase in the CD68 
load in contusions and white matter 2-3 days after injury. 
However, again the results need careful interpretation 
because there was a skewed distribution in the survival 
times of the patients, with the majority dying within the 
first 48 h after head injury. Further studies are needed on 
cases with longer survival times.
7. L o n g -te rm  m ic ro g lia l response
To address this, a new cohort of head-injured cases was 
identified from the archive in Glasgow. Cases were separated 
into two groups; the first with survival times of less than 12 
months and the second with survival times from 12 months 
up to 22 years. In addition age-matched controls (n = 15),
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Fig. 5. Two examples illustrating the image analysis procedure in a non-contused (A-C) and a contused tissue area (D-F). Images of CD68 
immunoreactive cells were captured using a X20 microscope objective (A,D). The images were thresholded on the basis of hue and intensity 
(B,E) and measurements expressed as area of immunostaining divided by area of interest sampled.
without significant neurological disease were identified. 
Sections of parasagittal cortex including underlying white 
matter, and hippocampus were immunostained for CD68 and 
CR3/43 to identify microglia and MHC class II activated 
cells, respectively.
Both CD68 and CR3/43 immunoreactivity increased 
with ageing in the controls, reflecting both hypertrophy 
and hyperplasia of microglia. In head-injured cases there
was, however, a greater increase in CD68 immunoreactivity 
in both parasagittal and hippocampal white matter than was 
seen up to 4 years after the injury and this appeared not to be 
influenced by age. CR3/43 immunoreactivity had a greater 
load in both parasagittal and hippocampal white matter and 
was seen up to 16 years after the injury (Fig. 6).
In summary, we have described microglial hyperplasia 
and hypertrophy with both MHC class II upregulation and
Fig. 6. White matter from the frontal lobe of a long term head injury survivor immunostained for the microglial markers CD68 (A) and CR3/43 
(B). Note the disparity in the number and size of microglia stained with the lysosomal marker (A) as compared to the MHC class II marker (B). 
Bars = 50 pm.
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increased phagocytosis in the white matter of cases of fatal 
head injury, and continued neuroinflammation for many 
years in survivors. This may be due to the consequences 
of both focal and diffuse pathologies after traumatic brain 
injury and may form the basis for the cognitive deficits seen 
in long-term survivors.
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Abstract
Previous studies have found the e4  allele of the apolipoprotein E gene {APOE s4) is 
associated with an unfavourable outcome after head injury. In order to clarify the 
mechanisms involved, in this study association was Sought between carriage of APOE e4 
and specific pathological features of traumatic brain injury (TBI). Included in the study 
were 239 fatal cases of TBI (1987-1999) for which APOE genotypes were determined 
from archival tissue. For each case specific pathological features of trauma were recorded 
blind to the APOE e4  status. Of the 238 cases examined, there were 83 APOE e4  carriers 
(35 %) and 156 non-carriers (65 %).
Possession of APOE e4  was associated with a greater incidence of moderate or severe 
contusions ( e4 carriers 42% versus e4  non-carriers 30%; p= 0.05) and a greater incidence 
of severe ischaemic brain damage ( e4  carriers 54% versus e4  non-carriers 42%; p= 0.08). 
Significant differences were not noted between the other pathological features examined 
Possession of APOE e4  is associated with a greater incidence of moderate/severe 
contusional injury and severe ischaemic brain damage in fatal cases of TBI. This may be 
relevant to the relatively poor outcome from traumatic brain injury in patients with APOE 
e4 identified in clinical studies.
Keywords: APOE, polymorphisms, head injury, contusions, ischaemic damage
Introduction
Clinical studies of traumatic brain injury (TBI) have shown that possession of 
the e4  allele of the apolipoprotein E gene {APOE e4 )  is associated with a relatively 
poor outcome (1,2). In one such study 57% of APOE e4  carriers had an unfavourable 
outcome (defined as dead, in the vegetative state or with severe disability) compared 
with 27% of non-carriers o f APOE e4  (1). There is evidence that APOE e4  carriers 
also have worse outcome after spontaneous intracerebral haemorrhage (3,4), cardiac 
bypass surgery (5,6), cerebral ischaemia after cardiopulmonary resuscitation (7) and 
in boxing (8); in subarachnoid haemorrhage the evidence is conflicting (9-11) and the 
effect appears not to influence outcome from ischaemic stroke (12).
The specific mechanisms by which APOE genotype influences outcome after 
brain injury in humans are largely unclear. Much of the work relating to mechanisms 
involving apoE has been undertaken using in-vitro cell cultures and animal models, 
and the direct relevance of these studies to man is uncertain (13). Relevant 
mechanisms postulated range from basic cellular functions such as maintenance of 
cytoskeletal integrity (14), and protection from oxidative stress (15) and 
excitotoxcicity (16), to general systemic dysfunction such as increased risk of 
atherosclerosis (17), and altered blood coagulation (18).
The pathology of traumatic brain injury (TBI) can be classified as either focal 
or diffuse (19). Focal injuries include contusions, intracranial haemorrhages, and the 
vascular complications of raised intracranial pressure. Diffuse injuries include diffuse 
traumatic axonal injury (TAI), cerebral swelling, and ischaemic brain damage. 
Multiple factors influence the type and severity of the resulting brain injury and 
include the mechanism, location and magnitude of the primary injury, and host factors 
such as age and nutritional status.
We postulate that head-injured patients with APOE e4 , amounting to 
approximately a third of the population, are selectively predisposed to one or more of 
the different pathological features that constitute the response to TBI, and that this 
underlies the association o f APOE e4  with poor clinical outcome. We sought to test 
this hypothesis by identifying the prevalence of specific pathological features in 
APOE e4  carriers, compared with non-carriers of APOE e4 , in a large tissue and data 
archive of fatal cases of head injury.
Materials and methods 
Case selection
The study was approved by the Research Ethics Committee of the Southern 
General Hospital, Glasgow, Scotland. Cases were selected from the paraffin- 
embedded tissue archive o f the Glasgow Neuropathology department. Initially all 
cases that died from TBI during the 13 year period, 1987-1999 within the archive and 
examined by the authors were selected. While many of the cases had been managed 
by the Department of Neurosurgery, Institute of Neurological Sciences, some patients 
had died at District General Hospitals or at the scene of the incident. A total of 259 
cases were identified (are-range; 2 months-89 years). A prerequisite for inclusion in 
this study was successful APOE genotyping from the formalin-fixed paraffin 
embedded post mortem brain tissue.
APOE genotyping
APOE genotype was determined using a previously described PCR method 
(20). Of the initial 259 cases, 239 were successfully genotyped (92% success rate). 
Cases were discarded after four unsuccessful attempts at genotyping.
Pathological data
A
Archival data which had been gathered prospectively during the years 1987- 
1999 inclusive according to a uniform protocol was logged into a database and 
included the following information for each case: age, length of survival after episode 
of TBI, skull fractures, intracranial haemorrhages, diffuse traumatic axonal injury 
(TAI), ischaemic brain damage, raised intracranial pressure and associated infarcts, 
and contusions.
Skull fractures were documented as being either present or absent, and 
intracranial haemorrhages were recorded in relation to the anatomical compartment 
involved (extradural, subdural, intracerebral).
Traumatic axonal injury (TAI) was documented as being absent or present, 
and if present was graded as grade 1,2 or 3 (21). Grade 1 lesions had widespread 
axonal damage in the corpus callosum, the cerebral hemispheres, and the brainstem. 
Grade 2 lesions, in addition, had focal haemorrhagic lesions in the corpus callosum, 
and in grade 3 there was in addition a haemorrhagic lesion in the rostral brain stem. 
The term diffuse axonal injury (DAI) was originally applied to traumatic damage 
exclusively. However, as immunohistochemical studies using p-APP as a marker of 
axonal damage have demonstrated, many brain insults can result in axonal damage. 
Therefore, it has been proposed that that the aetiology of any axonal damage should 
always be indicated, and that DAI (as originally defined) now be referred to as TAI 
(22).
Ischaemic brain damage was assessed using a grading system in which severe 
comprised those cases in which the lesions were diffuse, multifocal and large within 
arterial territories; moderate when the lesions were limited to the arterial boundary 
zones, singly or in combination with subtotal infarction in the distribution of the
cerebral arteries, or if  there were 6-10 subcortical lesions; and mild if there were five 
or less subcortical lesions in the brain (23).
Raised intracranial pressure was considered to be present if there were 
tentorial hernias (either macroscopic or microscopic) (24), and associated vascular 
complications within the distributions of the anterior cerebral artery, the posterior 
cerebral artery, and in the cerebellum and brainstem.
Contusions were graded using the total contusion index (TCI) developed by 
Adams et al (25), and subsequently modified (26). This assesses the extent (0-3) and 
depth (0-4) o f contusions in a variety of anatomical locators, producing a numerical 
score for each hemisphere which is then combined and interpreted as absent, mild, 
moderate, or severe. The anatomical locators are the frontal, temporal, parietal and 
occipital lobes, the cortex above and below the Sylvian fissure, and the cerebellum. 
The maximum score for an anatomical locator is 12 (4x3=12), and the TCI has a 
maximum value of 144 (each side 6x12=72,2x72=144). For this study contusional 
injury was mild if  the TCI was less than 20, moderate if the TCI was between 20 and 
37, and severe if  the TCI was greater than 37. These values were based on those used 
in previous studies (27).
Data analysis
The pathological features for each case documented on the database were then 
assessed in relation to APOE e4 allele carriage presence or absence (see table 1). 
Comparison of the prevalence of the features was made using confidence intervals 
(Cl) for the differences in proportions. Calculations were performed using Minitab 
(Version 12).
Results
Of the total number of 239 cases of fatal TBI examined there were 83 APOE e4  
carriers (35%) and 156 were non-carriers of APOE e4 (65%). Differences were noted 
between APOE e4 carriers and non-carriers of APOE e4  in relation to contusions and 
ischaemic brain damage (table 1). 42% of e4  carriers (35/83) had moderate or severe 
contusions (i.e. a total contusion index of >20) compared with 29% of non-carriers of 
e4  (46/156, p=0.05). With regard to ischaemic brain damage a trend was noted 
between the possession of APOE e4  and severe ischaemic brain damage which was 
present in 54% of APOE e4  carriers and 42% of non-carriers of e4  (p=0.08). No 
significant associations were demonstrated between possession of APOE e4  and the 
presence of extradural haematoma, subdural haematoma, intracerebral haematoma, 
skull fracture, traumatic axonal injury or evidence of raised intracranial pressure. 
Discussion
Among the pathological features which are present in fatal cases of TBI this 
study has identified an association between possession of APOE e4  and contusion 
severity and a trend for an association with severe ischaemic brain damage. These 
findings suggest that cerebrovascular and haematological mechanisms may underlie, 
at least in part, the association of APOE e4  with poor outcome after TBI. A limitation 
of this study relates to the fact that the pathology of only the most severe outcome 
from TBI group could be assessed (i.e. a fatal outcome). In addition this study is 
purely observational, based only on pathological assessment of injuries and does not 
take into account any possible changes in neurosurgical referral and treatment practice 
which may have occurred over the 13 year period. The cases studied had variable 
mechanisms of injury (RTA, fall, assault) which would result in variable forces being
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applied to the head, and a wide range of ages; however, APOE e4  was distributed 
across all the various types of injury and ages.
A fatal outcome occurs in only 5-10% of the total hospitalised TBI population, 
although approximately 50% of TBI related deaths occur before the patient can be 
transferred to hospital (28). An important question is whether the association 
identified in this study is of relevance to survivors of TBI. A recent study, performed 
in the same institute, of CT scans of survivors of TBI (29) showed that although 
patients with APOE e4 were no more likely to have intracranial haemorrhages than- 
non carriers o f APOE e4, if  haemorrhages were present then they were of greater 
volume in those patients with APOE e4. This study, therefore, provides a degree of 
clinical correlation with our autopsy based work, and suggests that our findings may 
well be relevant to survivors of TBI.
Although prospective clinical studies of outcome after TBI have identified 
APOE e4  carriers as more likely to fall into poor outcome or poor recovery groups (1 ,  
2 ) , they have not yet specifically addressed the question of whether APOE e4  carriers 
are more likely to have a fatal outcome. The previous clinical studies have looked at 
the prevalence e4  carriers in poor outcome (severe, vegetative, or fatal) after TBI (1 )  
or in vegetative state patients only (2 ) . The present study, looking at only the fatal 
outcome group, did not find an over-representation of e4  carriers, the APOE e4  
carriage rate (35%) being similar to that of all head-injured patients admitted to the 
same institution (33%, n=984, Teasdale et al, unpublished observations). Therefore, 
although APOE ^-associated vascular pathology may influence the outcome in 
survivors it seems unlikely to significantly increase the probability of a fatal outcome 
after TBI. However, the situation after spontaneous intracerebral haemorrhage 
appears to be different; there is evidence that among patients with stroke due to
a
spontaneous intracerebral haemorrhage APOE e4 carriers are substantially more likely 
to die in hospital (40% versus 25%) (30).
These findings point towards an important role for apoE in cerebrovascular 
and haematological mechanisms which are of relevance in the response to an episode 
of brain injury. More specifically, existing evidence indicates that apoE may play an 
important role in relation to both blood vessel wall integrity and coagulation of blood.
One role of apoE is as a lipid transport protein and apoE is therefore involved 
in the transport of the fat soluble vitamins together with lipids, from the small 
intestine to the liver. This mechanism is suggested to underlie the relatively low 
levels of plasma vitamin K in APOE s4 carriers (31). Vitamin K is required by the 
liver for the synthesis of clotting factors and prothrombin times have been reported to 
vary with APOE genotype (32). Prolonged clotting times were also identified in 
APOE e4  carriers after stroke ( 1 8 )  providing further evidence that APOE genotype is 
of relevance to the coagulation cascade. The possibility that contusions in head- 
injured patients with APOE e4  are more severe as a result of relatively deficient 
clotting mechanisms provides the basis for a testable hypothesis.
A further mechanism of possible relevance to the findings of this study relates 
to the increased prevalence o f atherosclerosis and cerebral amyloid angiopathy in 
carriers o f APOE e4  (1 3 ) . Such vascular pathology might pre-date the head injury 
and promote contusional haemorrhage by increasing vascular fragility and decreasing 
the capacity for reactive vasoconstriction. Post mortem studies have confirmed the 
association of APOE e4  with cerebral amyloid angiopathy in patients who died from 
TBI and have suggested that this is associated with increased severity of contusions 
(3 3 )  although the number o f cases in this study was small.
Animal models, using APOE knockout and transgenic mice, have provided 
further information about apoE mechanisms and the response of the brain to injury 
(13). ApoE deficient mice were found to have larger infarcts than wild-type mice (34) 
and a greater extent of neuronal damage after controlled ischaemia (35), which can be 
ameliorated by continuous intracerebral infusion of apoE (36). Using transgenic mice 
differences have been demonstrated between the response to ischaemia and 
excitotoxicity in mice with human APOEzS and APOEz4 genes, such that the 
APOEz4 mice have larger lesions (37,38) than APOEz3 mice (39).
Further elucidation of potential vascular and haematological mechanisms 
which may underlie the role of apoE in response to brain injury could result in the 
development of new therapeutic interventions which may modify the outcome after 
TBI.
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Table 1
Pathological Feature APOE e4 carriers 
n=83 (35%)
APOE e4 
non-carriers 
n=156 (65%)
95% Confidence 
Interval for difference
p-value
Moderate/severe contusions 35 (42%) 46(29%) 0 to25% 0.05
Severe ischaemic brain 
damage
45 (54%) 66(42%) -1 to25% 0.08
Skull fracture 61 (73%) 105 (67%) - 6 tol8% 0.31
Traumatic axonal injury 31 (37%) 68(44%) -19 to 7% 0.35
Extradural haemorrhage 13 (16%) 13 (8%) -4 to 14% 0.31
Subdural haemorrhage 52 (60%) 98(63%) -13 tol3% 0.98
Intracerebral haemorrhage 31 (37%) 47(30%) -5 to 20% 0.26
Raised intracranial pressure 58(70%) 98(63%) -5 to 20% 0.27
